GLP-1 receptor agonists and their medical use

Abstract

The present disclosure relates to improved GLP-1 receptor agonist polypeptides and molecules comprising these improved GLP-1 receptor agonist polypeptides, such as molecules comprising one or more GLP-1 receptor agonist polypeptides conjugated to an anti- gastric inhibitory peptide receptor (GIPR) antibody. The present disclosure is also directed to the use of these improved GLP-1 receptor agonist polypeptides and conjugate molecules comprising these polypeptides for treating or preventing obesity, an obesity related condition, type 2 diabetes, and / or a type 2 diabetes related condition.

Description

 COMPOSITIONS AND METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS [1] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 63 / 566,857, filed March 18, 2024. INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY[2] Incorporated by reference in its entirety is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: 1.51 MB (XML) file named “10889-WO01-SEC_Sequence_Listing.xml”; created on March 13, 2025.FIELD OF THE INVENTION[3] The present disclosure relates to improved Glucagon-like peptide-1 (GLP-1) receptor agonist polypeptides and molecules comprising these improved GLP-1 receptor agonist polypeptides, such as conjugate molecules comprising one or more GLP-1 receptor agonist polypeptides conjugated to an anti-gastric inhibitory peptide receptor (GIPR) antibody. The present disclosure is also directed to the use of these improved GLP-1 receptor agonist polypeptides and conjugate molecules comprising these polypeptides for treating or ameliorating a metabolic disorder, such as obesity and type 2 diabetes. These improved GLP-1 receptor agonist polypeptides and conjugate molecules comprising these polypeptides are also useful for treating or ameliorating obesity related conditions and type 2 diabetes related conditions.BACKGROUND OF THE INVENTION[4] Glucose-dependent insulinotropic polypeptide (GIP) is a single 42-amino acid peptide secreted from K-cells in the small intestine (duodenum and jejunum). Human GIP is derived from the processing of proGIP, a 153-amino acid precursor that is encoded by a gene localized to chromosome 17q (Inagaki et al., Mol Endocrinol 1989; 3:1014-1021; Fehmann et al. Endocr Rev. 1995; 16:390-410). GIP was formerly called gastric inhibitory polypeptide.[5] GIP secretion is induced by food ingestion. GIP has a number of physiological effects in tissues, including promotion of fat storage in adipocytes and promotion of pancreatic islet β-cell function and glucose-dependent insulin secretion. GIP and glucagon like polypeptide-1 (GLP-1) are known insulinotropic factors (“incretins”). Intact GIP is rapidly degraded by DPPIV to an inactive form. The insulinotropic effect of GIP is lost in type 2 diabetic subjects while GLP-1’s incretin effect remains intact (Nauck et al. J. Clinc. Invest. 1993; 91:301-307).[6] The GIP receptor (GIPR) is a member of the secretin-glucagon family of G-protein coupled receptors (GPCRs) having an extracellular N-terminus, seven transmembrane domains and an intracellular C-terminus. The N-terminal extracellular domains of this family of receptors are usually glycosylated and form the recognition and binding domain of the receptor. GIPR is highly expressed in a number of tissues, including the pancreas, gut, adipose tissue, heart, pituitary, adrenal cortex, and brain (Usdin et al., Endocrinology 1993, 133:2861-2870). Human GIPR comprises 466 amino acids and is encoded by a gene located on chromosome 19q13.3 (Gremlich et al., Diabetes 1995; 44:1202-8; Volz et al., FEBS Lett. 1995, 373:23-29). Studies have suggested that alternative mRNA splicing results in the production of GIP receptor variants of differing lengths in human, rat and mouse. [7] GIPR knockout mice (GIPR - / -) are resistant to high fat diet-induced weight gain and have improved insulin sensitivity and lipid profiles (Yamada et al., Diabètes. 2006, 55:S86; Miyawaki et al. Nature Med. 2002, 8:738-742). In addition, a novel small molecule GIPR antagonist SKL-14959 prevents obesity and insulin resistance (Diabetologia 2008, 51:S373, 44th EASD Annual meeting poster).[8] Collectively, these links to obesity and insulin resistance imply GIPR inhibition is a useful approach for therapeutic intervention.[9] Glucagon-like peptide-1 is a 31-amino acid peptide derived from the proglucagon gene. It is secreted by intestinal L-cells and released in response to food ingestion to induce insulin secretion from pancreatic β–cells (Diabetes 2004, 53:S3, 205-214). In addition to the incretin effects, GLP-1 also decreases glucagon secretion, delays gastric emptying and reduces caloric intake (Diabetes Care, 2003, 26(10): 2929-2940). GLP-1 exerts its effects by activation of the GLP-1 receptor, which belongs to a class B G-protein-coupled receptor (Endocrinology 1993, 133(4):1907-10). The function of GLP-1 is limited by rapid degradation by the DPP-IV enzyme, resulting in a half-life of approximately 2 minutes. Recently, long-lasting GLP-1 receptor agonists (GLP-1 RAs) such as exenatide, liraglutide, dulaglutide have been developed and are now being used clinically to improve glycemic control in subjects with type 2 diabetes. Furthermore, GLP-1 receptor agonists also promote body weight reduction as well as reduction in blood pressure and plasma cholesterol levels in subjects (Bioorg. Med. Chem.Lett 2013, 23:4011-4018).  SUMMARY OF THE INVENTION

[10] The present disclosure relates to improved GLP-1 receptor agonist polypeptides. The present disclosure also relates to molecules comprising these improved GLP-1 receptor agonist polypeptides, such as molecules comprising one or more GLP-1 receptor agonist polypeptides conjugated to an antagonist anti-gastric inhibitory peptide receptor (GIPR) antibody.

[11] Accordingly, a first aspect of the present disclosure is directed to a human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide comprising the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), wherein Aib at position 2 is α-amino-isobutyric acid (also referred to as 2-amino-isobutyric acid),X17 is Q, K, E, or R; X20 is K, R, Q, or homoarginine (hArg); X24 is A, E, Q, D, d-Ala, G, N, K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), T, S, or Y; X27 is V, K, Aib, N, S, T, Y, Q, or R; and X28 is K, E, R, Q, D, N, G, S, or T; and wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG (SEQ ID NO: 1574).

[12] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1576), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R, wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG (SEQ ID NO: 1574).

[13] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAREFIX24WLX27X28GGG (SEQ ID NO: 1577) wherein X17 is Q or K; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R.

[14] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLKX28GGG (SEQ ID NO: 1578), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; and X28 is K, E, or R.

[15] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence of any one of SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1582, or SEQ ID NO: 1583 as provided herein.

[16] In another aspect, the GLP-1 receptor agonist polypeptide of the present disclosure comprises 31 amino acids, comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1580, and comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16, 24, and 28; an arginine at position 20; a lysine at positions 17 and 27; and a glycine at position 30.

[17] In another aspect, the GLP-1 receptor agonist polypeptide of the present disclosure comprises 31 amino acids, comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1579, and comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 27; and a glycine at position 30.

[18] In another aspect, the GLP-1 receptor agonist polypeptide of the present disclosure comprises 31 amino acids, comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1581, and comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 17, 27; and a glycine at position 30.

[19] In another aspect, the GLP-1 receptor agonist polypeptide of the present disclosure comprises 31 amino acids, comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1583, and comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 28; an arginine at position 20; a lysine at positions 17, 27; a glutamine at position 24; and a glycine at position 30.

[20] In another aspect, the GLP-1 receptor agonist polypeptide of the present disclosure comprises 31 amino acids, comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1582, and comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at positions 20 and 28; a lysine at positions 27; and a glycine at position 30.

[21] Another aspect of the present disclosure is directed to a molecule comprising a first human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide as described herein and a half-life extending moiety.

[22] In one embodiment, the first GLP-1 receptor agonist polypeptide of the molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereinX17 is Q, K, E, or R; X20 is K, R, Q, or homoarginine (hArg); X24 is A, E, Q, D, d-Ala, G, N, K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), T, S, or Y; X27 is V, K, Aib, N, S, T, Y, Q, or R; and X28 is K, E, R, Q, D, N, G, S, or T; and wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1574.

[23] In one embodiment, the first GLP-1 receptor agonist polypeptide of the molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1576), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R, wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1574.

[24] In one embodiment, the first GLP-1 receptor agonist polypeptide of the molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAREFIX24WLX27X28GGG (SEQ ID NO: 1577) wherein X17 is Q or K; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R.

[25] In one embodiment, the first GLP-1 receptor agonist polypeptide of the molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLKX28GGG (SEQ ID NO: 1578), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; and X28 is K, E, or R.

[26] In one embodiment, the first GLP-1 receptor agonist polypeptide of the molecule comprises the amino acid sequence of any one of SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1582, or SEQ ID NO: 1583.

[27] In one embodiment, the half-life extending moiety of the molecule is an antibody.

[28] Another aspect of the present disclosure is directed to a conjugate molecule comprising a first human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide as described herein conjugated to an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody.

[29] In one embodiment, the conjugate molecule comprises a first GLP-1 receptor agonist polypeptide comprising an amino acid sequence of any one of SEQ ID NO: 1575–1583 conjugated to an antagonist anti-GIPR antibody. The anti-GIPR antibody of the conjugate molecule comprises a first cysteine conjugation site within a light chain or heavy chain of the antibody, and the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody. In one embodiment, the first cysteine conjugation site of the anti-GIPR antibody is at position 88 of the light chain, position 384 of the heavy chain, or position 487 of the heavy chain according to AHo numbering.

[30] In one embodiment, the first GLP-1 receptor agonist polypeptide of the conjugate molecule is conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody via a first linker moiety. In one embodiment, the first linker moiety is a peptide linker and the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 1585–1593. In one embodiment, the first linker moiety is a PEG linker.

[31] In one embodiment, the conjugate molecule further comprises a second GLP-1 receptor agonist polypeptide. The second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to a second cysteine conjugation site of the anti-GIPR antibody.

[32] In one embodiment, the second GLP-1 receptor agonist polypeptide comprises any of the GLP-1 receptor agonist polypeptides disclosed herein. In one embodiment, the second GLP-1 receptor agonist polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 1575-1583. In one embodiment, the second GLP-1 receptor agonist polypeptide comprises the same amino acid sequence as the first GLP-1 receptor agonist polypeptide.

[33] In one embodiment of this aspect of the disclosure, the second GLP-1 receptor agonist polypeptide of the conjugate molecule is conjugated, at its C-terminus, to the second cysteine conjugation site of the anti-GIPR antibody via a second linker moiety. In one embodiment, the second linker moiety is a peptide linker and the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 1585–1593. In one embodiment, the second peptide linker comprises the same amino acid sequence as the first peptide linker. In one embodiment, the second linker moiety is a PEG linker.

[34] In one embodiment, the first and second conjugation sites of the anti-GIPR antibody of the conjugate molecule are at position 88 of each light chain, position 384 of each heavy chain, or position 487 of each heavy chain according to AHo numbering.

[35] In one embodiment, the anti-GIPR antibody of the conjugate molecule comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise the amino acid sequences of SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively.

[36] In one embodiment, the anti-GIPR antibody of the conjugate molecule comprises a VL and VH comprising the amino acid sequence of SEQ ID NO: 74 and SEQ ID NO: 231, respectively.

[37] In one embodiment, the anti-GIPR antibody of the conjugate molecule comprises a light chain and a heavy chain comprising the amino acid sequence of SEQ ID NO: 388 and SEQ ID NO: 545, respectively, with a cysteine substitution at position 88 of each light chain, position 384 of each heavy chain, or position 487 of each heavy chain according to AHo numbering.

[38] Another aspect of the present disclosure is directed to a molecule, where the molecule comprises an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein said antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. The molecule further comprises a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1579; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1592. The first GLP-1 receptor agonist polypeptide of the molecule is conjugated, at its C-terminus, via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571), and the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571). In one embodiment, each light chain of the antibody comprises a VL of SEQ ID NO: 74, and each heavy chain of the antibody comprises a VH of SEQ ID NO: 231. In one embodiment, each light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO: 1571.

[39] Another aspect of the present disclosure is directed to a molecule, where the molecule comprises an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein said antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. The molecule further comprises a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1580; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1591. The first GLP-1 receptor agonist polypeptide of the molecule is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571), and the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571). In one embodiment, each light chain of the antibody comprises a VL of SEQ ID NO: 74, and each heavy chain of the antibody comprises a VH of SEQ ID NO: 231. In one embodiment, each light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO: 1571.

[40] Another aspect of the present disclosure is directed to a molecule, where the molecule comprises an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein said antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. The molecule further comprises a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1586. The first GLP-1 receptor agonist polypeptide of the molecule is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571), and the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571). In one embodiment, each light chain of the antibody comprises a VL of SEQ ID NO: 74, and each heavy chain of the antibody comprises a VH of SEQ ID NO: 231. In one embodiment, each light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO: 1571.

[41] Another aspect of the present disclosure is directed to a molecule, where the molecule comprises an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein said antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. The molecule further comprises a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1585. The first GLP-1 receptor agonist polypeptide of the molecule is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571), and the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering (which corresponds to position 275 of SEQ ID NO: 1571). In one embodiment, each light chain of the antibody comprises a VL of SEQ ID NO: 74, and each heavy chain of the antibody comprises a VH of SEQ ID NO: 231. In one embodiment, each light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO: 1571.

[42] Another aspect of the present disclosure is directed to a pharmaceutical composition comprising a GLP-1 receptor agonist polypeptide as disclosed herein, or a GLP-1 receptor agonist polypeptide containing molecule as disclosed herein, and a pharmaceutically acceptable excipient.

[43] Another aspect of the present disclosure is directed to a method of reducing body weight and / or food intake in a subject in need thereof. This method comprises administering, to the subject in need thereof, a GLP-1 receptor agonist polypeptide as disclosed herein, a GLP-1 receptor agonist polypeptide containing molecule as disclosed herein, or a pharmaceutical composition as disclosed herein.

[44] Another aspect of the present disclosure is directed to a method of treating obesity or an obesity related condition in a subject in need thereof. This method comprises administering, to the subject in need thereof, a GLP-1 receptor agonist polypeptide as disclosed herein, a GLP-1 receptor agonist polypeptide containing molecule as disclosed herein, or a pharmaceutical composition as disclosed herein.

[45] Another aspect of the present disclosure is directed to a method of treating type 2 diabetes or type 2 related condition in a subject in need thereof. This method comprises administering, to the subject in need thereof, a GLP-1 receptor agonist polypeptide as disclosed herein, a GLP-1 receptor agonist polypeptide containing molecule as disclosed herein, or a pharmaceutical composition as disclosed herein.

[46] Described herein are novel GLP-1 receptor agonist polypeptides and molecules comprising an antagonist anti-GIPR antibody conjugated to one or more of the novel GLP-1 receptor agonist polypeptides. The GLP-receptor agonist polypeptides described herein comprise one or more defined amino acid substitutions that enhance stability and / or efficacy of the agonist polypeptides and molecules containing the peptides.  BRIEF DESCRIPTION OF THE DRAWINGS

[47] FIG. 1 shows the reaction scheme for the generation of an anti-GIPR antibody / GLP-1 receptor agonist conjugate molecule of the present disclosure.

[48] FIG. 2 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a peptide linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1579. The C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1592. The C-terminus of the polypeptide linker has been bromoacetylated (at the ε-amino group on the side chain of the lysine residue) to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue.

[49] FIG. 3 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a peptide linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1580. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the α-amino group of the lysine residue of the linker peptide of SEQ ID NO: 1591. The N-terminus of the polypeptide linker has been bromoacetylated to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue.

[50] FIG. 4 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a peptide linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1585. The C-terminal lysine residue of the polypeptide linker has been bromoacetylated (at the ε-amino group on the side chain of the lysine residue) to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue

[51] FIG. 5 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a peptide linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1586. The C-terminal lysine residue of the polypeptide linker has been bromoacetylated (at the ε-amino group on the side chain of the lysine residue) to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue

[52] FIG. 6 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a peptide linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1593. The C-terminal lysine residue of the polypeptide linker has been bromoacetylated (at the ε-amino group on the side chain of the lysine residue) to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue.

[53] FIG. 7 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a PEG linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the PEG20 linker via the α-amino group of the lysine residue of the PEG20 linker. The PEG20 is covalently linked to the ε-amino group on the side chain of the lysine. The glycine residue at the opposing terminal end of the PEG linker has been bromoacetylated to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue.

[54] FIG. 8 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a PEG linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1582. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the PEG20 linker via the α-amino group of the lysine residue of the PEG20 linker. The PEG20 is covalently linked to the ε-amino group on the side chain of the lysine. The glycine residue at the opposing terminal end of the PEG linker has been bromoacetylated to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue.

[55] FIG. 9 shows the structure of a GLP-1 receptor agonist polypeptide of the present disclosure covalently linked to a PEG linker. The GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1583. As shown, the C-terminal amino acid residue of the GLP-1 receptor agonist polypeptide is covalently linked to the PEG20 linker via the α-amino group of the lysine residue of the PEG20 linker. The PEG20 is covalently linked to the ε-amino group on the side chain of the lysine. The glycine residue at the opposing terminal end of the PEG linker has been bromoacetylated to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue.

[56] FIG. 10 shows body weight loss over a 12-day period in diet-induced obese C57BL6 mice administered, on day 0, a single dose of 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecule 62207 of the present disclosure, or vehicle (A52Su).

[57] FIG. 11 shows body weight loss over an 18-day period in diet-induced obese C57BL6 mice administered, on day 0, a single dose of 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecule 65296 of the present disclosure, or vehicle (A52Su).

[58] FIG. 12 shows body weight loss over an 18-day period in diet-induced obese C57BL6 mice administered, on day 0, a single dose of 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecules 69730 and 69850 of the present disclosure, or vehicle (A52Su).

[59] FIG. 13 shows body weight loss over a 16-day period in diet-induced obese C57BL6 mice administered, on day 0, a single dose of 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecules 59112 and 59117 of the present disclosure, or vehicle (A52Su).

[60] FIG. 14 shows body weight loss over a 20-day period in diet-induced obese C57BL6 mice administered, on day 0, a single dose of 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecule 65300 of the present disclosure, or vehicle (A52Su).

[61] FIG. 15 shows body weight loss over a 24-day period in diet-induced obese C57BL6 mice administered, on day 0 and day 10, 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecule 59112 of the present disclosure, or vehicle.

[62] FIG. 16 shows body weight loss over a 24-day period in diet-induced obese C57BL6 mice administered, on day 0 and day 10, 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecules 62207, 65296, 65300 of the present disclosure, or vehicle.

[63] FIG. 17 shows body weight loss over a 24-day period in diet-induced obese C57BL6 mice administered, on day 0 and day 10, 0.5 mg / kg surrogate anti-GIPR / GLP-1 agonist conjugates, i.e., reference conjugate molecule 1238 and conjugate molecules 59117, 69730, 69850, 73313 of the present disclosure, or vehicle.  DETAILED DESCRIPTION OF THE INVENTION

[64] The present disclosure relates to improved GLP-1 receptor agonists and molecules comprising the improved GLP-1 receptor agonists. The present disclosure further relates to the utility of these improved protein therapeutics for treating or ameliorating metabolic disorders, such as obesity, type 2 diabetes, elevated glucose levels, elevated insulin levels, non-alcoholic fatty liver disease, cardiovascular diseases, and diabetic nephropathy. Iand type 2 diabetes related conditions as described herein. The present disclosure also relates to the utility of these improved protein therapeutics for treating or ameliorating obesity related conditions and type 2 diabetes related conditions.

[65] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[66] Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[67] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages means ±1%.

[68] Following convention, as used herein “a” and “an” mean “one or more” unless specifically indicated otherwise.

[69] As used herein, the terms “amino acid” and “residue” are interchangeable and, when used in the context of a peptide or polypeptide, refer to both naturally occurring and synthetic amino acids, as well as amino acid analogs, amino acid mimetics and non-naturally occurring amino acids that are chemically similar to the naturally occurring amino acids.

[70] A “naturally occurring amino acid” is an amino acid that is encoded by the human genetic code, as well as those amino acids that are encoded by the genetic code that are modified after synthesis, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. An amino acid analog is a compound that has the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs can have modified R groups (e.g., norleucine) or modified peptide backbones, but will retain the same basic chemical structure as a naturally occurring amino acid.

[71] An “amino acid mimetic” is a chemical compound that has a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Examples include a methacryloyl or acryloyl derivative of an amide, β-, γ-, δ-imino acids (such as piperidine-4-carboxylic acid) and the like.

[72] A “non-naturally occurring amino acid” is a compound that has the same basic chemical structure as a naturally occurring amino acid, but is not incorporated into a growing polypeptide chain by the translation complex. A non-naturally occurring amino acid also includes, but is not limited to, amino acids that occur by modification (e.g., posttranslational modifications) of a naturally encoded amino acid (including but not limited to, the 20 common amino acids) but are not themselves naturally incorporated into a growing polypeptide chain by the translation complex. A non-limiting list of examples of non-naturally occurring amino acids that can be inserted into a polypeptide sequence or substituted for a wild-type residue in polypeptide sequence include β-amino acids, homoamino acids, cyclic amino acids and amino acids with derivatized side chains. Examples include (in the L-form or D-form; abbreviated as in parentheses): citrulline (Cit), homocitrulline (hCit), Nα-methylcitrulline (NMeCit), Nαmethylhomocitrulline (Nα-MeHoCit), ornithine (Orn), Nα-Methylornithine (Nα-MeOrn or NMeOrn), sarcosine (Sar), homolysine (hLys or hK), homoarginine (hArg or hR), homoglutamine (hQ), Nαmethylarginine (NMeR), Nα-methylleucine (Nα-MeL or NMeL), N-methylhomolysine (NMeHoK), Nα-methylglutamine (NMeQ), norleucine (Nle), norvaline (Nva), 1,2,3,4-tetrahydroisoquinoline (Tic), Octahydroindole-2-carboxylic acid (Oic), 3-(1-naphthyl)alanine (1-Nal), 3-(2-naphthyl)alanine (2Nal), 1,2,3,4-tetrahydroisoquinoline (Tic), 2-indanylglycine (IgI), para-iodophenylalanine (pIPhe), para-aminophenylalanine (4AmP or 4-Amino-Phe), 4-guanidino phenylalanine (Guf), glycyllysine (abbreviated “K(Nε-glycyl)” or “K(glycyl)” or “K(gly)”), nitrophenylalanine (nitrophe), aminophenylalanine (aminophe or Amino-Phe), benzylphenylalanine (benzylphe), γcarboxyglutamic acid (γ-carboxyglu), hydroxyproline (hydroxypro), p-carboxyl-phenylalanine (Cpa), α-aminoadipic acid (Aad), Nα-methyl valine (NMeVal), N-α-methyl leucine (NMeLeu), Nαmethylnorleucine (NMeNle), cyclopentylglycine (Cpg), cyclohexylglycine (Chg), acetylarginine (acetylarg), α, β-diaminopropionoic acid (Dpr), α, γ-diaminobutyric acid (Dab), diaminopropionic acid (Dap), cyclohexylalanine (Cha), 4-methyl-phenylalanine (MePhe), β, β-diphenyl-alanine (BiPhA), aminobutyric acid (Abu), 4-phenyl-phenylalanine (or biphenylalanine; 4Bip), α-amino-isobutyric acid (Aib), beta-alanine, beta-aminopropionic acid, piperidinic acid, aminocaprioic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N-ethylglycine, Nethylaspargine, hydroxylysine, allo-hydroxylysine, isodesmosine, allo-isoleucine, Nmethylglycine, Nmethylisoleucine, N-methylvaline, 4-hydroxyproline (Hyp), g-carboxyglutamate, e-N,N,N-trimethyllysine, e-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3methylhistidine, 5-hydroxylysine, ω-methylarginine, 4-Amino-O-Phthalic Acid (4APA), and other similar amino acids, and derivatized forms of any of those specifically listed.

[73] As used herein, the term “polypeptide” refers to a polymer of amino acid residues. Polypeptides comprising between two and fifty amino acids may also be referred to as “peptides” herein. “Polypeptide” further encompasses an amino acid polymer in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as naturally occurring amino acid polymers. The term can also encompass an amino acid polymer that has been modified, e.g., by the addition of carbohydrate residues to form a glycoprotein, or by the addition of a phosphate group to form a phosphorylated polypeptide. Polypeptides can be produced by a naturally-occurring and non-recombinant cell, or polypeptides can be produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of a native protein, or molecules having deletions from, additions to, and / or substitutions of one or more amino acids of a native sequence. Polypeptide can also be produced synthetically.

[74] As used herein, a “variant” of a polypeptide comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and / or substituted into the amino acid sequence relative to a reference polypeptide sequence.

[75] As used herein, a “derivative” of a polypeptide is a polypeptide that has been chemically modified in some manner distinct from insertion, deletion, or substitution variants, such as, e.g., via conjugation to another chemical moiety.

[76] A composition of the present invention that includes a GLP-1 receptor agonist polypeptide as described herein covalently linked, attached, or bound either directly or indirectly through a linker moiety, to an anti-GIPR antibody of the invention is referred to herein as a “conjugate”, conjugate molecule”, “conjugate protein”, or “antibody conjugate”.

[77] As used herein, the term “linker moiety” refers to a biologically acceptable (i.e., safe and non-toxic) peptidyl or nonpeptidyl organic group that is covalently bound to a first molecule (e.g., a first polypeptide) and covalently joins or conjugates the molecule to a second molecule (e.g., a second polypeptide). Where the linker moiety consists of a polypeptide or a polypeptide derivative (e.g., a polypeptide that has been chemically modified at one or both of the N-terminus and C-terminus to incorporate a functional group that permits conjugation to the first or second molecule), it may be referred to as a “linker polypeptide” herein. For example, in one embodiment, a linker polypeptide may comprise an acetylated terminus (e.g., when a thiol-bromoacetyl reaction is used to conjugate the derivatized terminus of the linker polypeptide to a cysteine residue of a polypeptide by forming a thioether linkage that comprises a sulfur atom of the cysteine residue).

[78] The phrase “percent sequence identity,” in the context of two or more polypeptide sequences, refers to the ratio of the number of identical amino acid residues between two or more aligned amino acid (polypeptide or protein) sequences over the aligned length of the sequences, expressed as a percentage. To calculate the percent sequence identity of two sequences, the sequences are aligned along their length. A sequence alignment algorithm, e.g., BLAST (Myers et al., J. Mol. Biol. 215(3):403-10 (1990)), can be utilized to align two sequences to ensure the corresponding amino acids are positioned correctly against each other. The number of identical amino acids at each position in the alignment is divided by the number of total number of aligned positions and multiplied by 100.

[79] The terms “GIPR polypeptide” and “GIPR protein” are used interchangeably to refer to the naturally-occurring glucose-dependent insulinotropic polypeptide receptor protein that is expressed in a mammal, such as a human or a mouse, and includes naturally occurring alleles (e.g., naturally occurring allelic forms of human GIPR protein). For purposes of this disclosure, the term “GIPR polypeptide” can be used interchangeably to refer to any full-length GIPR polypeptide (UniProt Accession No. P48546-1), e.g., SEQ ID NO: 1572, which consists of 466 amino acid residues and which is encoded by the nucleotide sequence SEQ ID NO: 1573. The term also encompasses known isoforms of the GIPR protein (see e.g., UniProt Accession Nos. P48546-2 and P48546-3).

[80] The term “GIPR polypeptide” also encompasses naturally occurring GIPR polypeptide variants. Such variants may include modifications to the naturally occurring GIPR sequence (SEQ ID NO: 1572) that include, but are not limited to, one or more amino acid substitutions, deletions, and / or insertions. A GIPR polypeptide encompasses an amino acid sequence that is at least about 85 percent identical to a naturally-occurring GIPR polypeptide (e.g., SEQ ID NO: 1572). In other embodiments, a GIPR polypeptide comprises an amino acid sequence that is at least about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to a naturally-occurring GIPR polypeptide amino acid sequence (e.g., SEQ ID NO: 1572). Such GIPR polypeptides preferably, but need not, possess at least one activity of a wild-type GIPR polypeptide, such as the ability to bind GIP. The present invention also encompasses nucleic acid molecules encoding such GIPR polypeptide sequences.

[81] The terms “GIP”, “Gastric inhibitory polypeptide”, “glucose-dependent insulinotropic peptide” and “GIP ligand” are used interchangeably and mean a naturally-occurring wild-type polypeptide expressed in a mammal, such as a human or a mouse, and includes naturally occurring alleles (e.g., naturally occurring allelic forms of human GIP protein). GIP is a natural ligand for GIPR. For purposes of this disclosure, the term “GIP” can be used interchangeably to refer to any mature GIP polypeptide.

[82] As used herein, the term “antibody” refers to an intact immunoglobulin. An antibody comprises two full-length heavy chains and two full-length light chains. Antibodies may be derived solely from a single source, or may be “chimeric,” that is, different portions of the antibody may be derived from two different antibodies as described further below.

[83] As used herein, the term “light chain” or “immunoglobulin light chain” refers to a polypeptide comprising, from amino terminus (N-terminus) to carboxyl terminus (C-terminus), a single immunoglobulin light chain variable region (VL) and a single immunoglobulin light chain constant domain (CL). The immunoglobulin light chain constant domain (CL) can be a human kappa (κ) or human lambda (λ) constant domain.

[84] As used herein, the term “heavy chain” or “immunoglobulin heavy chain” refers to a polypeptide comprising, from amino terminus (N-terminus) to carboxyl terminus (C-terminus), a single immunoglobulin heavy chain variable region (VH), an immunoglobulin heavy chain constant domain 1 (CH1), an immunoglobulin hinge region, an immunoglobulin heavy chain constant domain 2 (CH2), an immunoglobulin heavy chain constant domain 3 (CH3), and optionally an immunoglobulin heavy chain constant domain 4 (CH4). Heavy chains are classified as mu (μ), delta (Δ), gamma (γ), alpha (α), and epsilon (ε), and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. In accordance with the present disclosure, an antibody is of the IgG isotype. IgG has several subclasses, including, but not limited to IgG1, IgG2, IgG3, and IgG4.

[85] Variable regions of immunoglobulin chains generally exhibit the same overall structure, comprising relatively conserved framework regions (FR) joined by three hypervariable regions, more often called “complementarity determining regions” or CDRs. The CDRs from the two chains of each heavy chain and light chain pair typically are aligned by the framework regions to form a structure that binds specifically to a specific epitope on the target antigen or protein. From N-terminus to C-terminus, naturally-occurring light and heavy chain variable regions of an antibody both typically conform with the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. Numbering systems have been devised for assigning numbers to amino acids that occupy positions in each of these domains. Exemplary numbering systems are defined in Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, MD), and Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989). Other numbering systems for identifying amino acids in immunoglobulin chains include IMGT® (the international ImMunoGeneTics information system; Lefranc et al., Dev. Comp. Immunol. 29:185-203; 2005) and AHo (Honegger and Pluckthun, J. Mol. Biol. 309(3):657-670; 2001).

[86] As used herein, an “antagonist anti-GIPR antibody” and “anti-GIPR antibody” refer to an intact immunoglobulin of the IgG isotype that partially or fully blocks, inhibits, or neutralizes a biological activity of the GIPR protein. Antagonist activity of the anti-GIPR antibody of the present disclosure is determined using the GIPR activity assay and GIPR binding assay defined herein.

[87] As used herein, an “antibody fragment” is a portion (regardless of how that portion is obtained or synthesized) of an antibody that lacks at least some of the amino acids present in a full-length chain but which is capable of binding to the same antigen at the same epitope as the corresponding full-length antibody. Exemplary antibody fragments include, but are not limited to, Fab, Fab', and F(ab')2 fragments.

[88] As used herein, a “Fc domain” refers to the portion of an antibody comprising the second and third constant domains of the heavy chain (i.e., CH2 and CH3), and can optionally comprise the CH4 domain. The Fc domain may be an Fc domain from an IgG1, IgG2, IgG3, or IgG4 immunoglobulin. In some embodiments, the Fc region comprises CH2 and CH3 domains from a human IgG1 or human IgG2 immunoglobulin. The Fc region may retain effector function, such as C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), and phagocytosis. In other embodiments, the Fc region may be modified to reduce or eliminate effector function. A “Fc-containing polypeptide” refers to a polypeptide comprising an Fc domain as defined herein.

[89] As used herein, the terms “GLP1 receptor agonist” and “GLP-1 receptor agonist polypeptide” are used interchangeably and refer to a molecule that mimics a biological activity of the naturally occurring glucagon-like peptide (GLP-1) molecule with respect to a GLP1 receptor.

[90] As used herein, the term “pharmaceutically acceptable” refers to a species or component that is generally safe, non-toxic, and neither biologically nor otherwise undesirable for use in a subject.

[91] As used herein, the term “pharmaceutically acceptable excipient” refers to a broad range of ingredients that may be combined with a polypeptide or conjugate molecule disclosed herein to prepare a pharmaceutically acceptable composition or formulation. Excipients include, for example, vehicles (e.g., solvents, dispersion media), coatings, isotonic and absorption delaying agents, diluents, colorants, glidants, disintegrants, flavoring agents, coatings, binders, sweeteners, lubricants, sorbents, and preservatives (e.g., antibacterial and antifungal agents).

[92] As used herein, the term “therapeutically effective amount” refers to that amount of a polypeptide or conjugate molecule disclosed herein that elicits a desired biological or medical response in a cell, a tissue, a system, or a subject. The desired biological or medical response does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations.

[93] As used herein, the term “subject” or “subjects” refers to humans and other mammals. The term “mammal” as used herein includes, for example, humans, non-human primates, cattle, sheep, goats, pigs, horses, cats, dog, rabbits, rodents (e.g., rats or mice), and monkeys. Human subjects include neonates, infants, juveniles, adults, and geriatric subjects. In one embodiment, the subject is a human. In one embodiment, the subject is an adult human.

[94] It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the disclosed, which is defined solely by the claims.GLP-1 RECEPTOR AGONIST POLYPEPTIDES

[95] The present disclosure is directed to GLP-1 receptor agonist polypeptides and molecules, e.g., protein conjugates, comprising these GLP-1 receptor agonist polypeptides. These GLP-1 receptor agonist polypeptides, which are also referred to herein as GLP-1 receptor agonists and GLP-1R agonist polypeptides, encompass molecules that mimic one or more biological activities of the native human GLP-1 polypeptide with respect to its binding to the human GLP-1 receptor. In addition, these GLP-1 receptor agonist polypeptides possess one or more advantageous properties relative to the native GLP-1 protein and / or other GLP-1 receptor agonist polypeptides known in the art.

[96] The native human GLP-1 polypeptide is produced from post-translational processing of proglucagon within intestinal cells. Proglucagon cleavage by PCSK1 / PC1 generates a peptide comprising the proglucagon residues 71-108 or a C-terminally amidated form comprising residues 71-107 amide. Additional N-terminal truncation of this proglucagon derived peptide fragment within the intestinal cells is required to form the active GLP-1 peptide. Thus, the active human GLP-1 peptide, which is referred to as GLP-1(7-37), comprises the amino acid sequence of HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 1584). A C-terminally amidated version of this peptide is known as GLP-1(7-36)amide.

[97] In one embodiment of the present disclosure, the GLP-1 receptor agonist polypeptide is an analog of the native human GLP-1(7-37) peptide, i.e., an analog of the amino acid sequence of SEQ ID NO: 1584. As used herein, a “GLP-1 analog” refers to a molecule which possesses improved biological activity, e.g., improved stability or agonist potency, relative to the corresponding biological activity of GLP-1(7–37), when evaluated by the GLP-1 receptor agonist activity assay as described in Example 3 herein or using other art-known measures such as receptor binding assays or in vivo blood glucose assays as described, e.g., by Hargrove et al., Regulatory Peptides, 141:113-119 (2007), the disclosure of which is incorporated by reference herein. In one embodiment, a GLP-1 analog refers to a peptide comprising an amino acid sequence with at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 amino acid substitutions, insertions, deletions (or a combination of two or more of substitutions, insertions, deletions), when compared to the amino acid sequence of a GLP-1(7-37). In one embodiment, the GLP-1 analog of the present disclosure comprises an amino acid sequence with 5, 6, 7, 8, or 9 amino acid substitutions, insertions, deletions (or a combination of two or more of substitutions, insertions, deletions), when compared to the amino acid sequence of a GLP-1(7-37) (SEQ ID NO: 1584). In one embodiment, the GLP-1 analog of the present disclosure comprises an amino acid sequence with 5, 6, 7, 8, or 9 amino acid substitutions in the amino acid sequence of the GLP-1(7-37) polypeptide of SEQ ID NO: 1584. In one embodiment, these 5, 6, 7, 8, or 9 amino acid substitutions comprise a substitution at any 5 or more positions selected from A2, V10, G16, Q17, K20, A24, V27, K28, and R30 of the GLP-1(7-37) peptide of SEQ ID NO: 1584. In one embodiment, the GLP-1 analog comprises substitutions at A2, V10, G16, and R30, plus one or more additional amino acid substitutions at residues selected from Q17, K20, A24, V27, and K28 of SEQ ID NO: 1584. In one embodiment, the GLP-1 analog comprises substitutions at A2, V10, G16, and R30, plus two additional amino acid substitutions as residues selected from Q17, K20, A24, V27, and K28 of SEQ ID NO: 1584. In one embodiment, the GLP-1 analog comprises substitutions at A2, V10, G16, and R30, plus three additional amino acid substitutions as residues selected from Q17, K20, A24, V27, and K28 of SEQ ID NO: 1584. In one embodiment, the GLP-1 analog comprises substitutions at A2, V10, G16, and R30, plus four additional amino acid substitutions as residues selected from Q17, K20, A24, V27, and K28 of SEQ ID NO: 1584. In one embodiment, the GLP-1 analog comprises substitutions at A2, V10, G16, R30, Q17, K20, A24, V27, and K28 of the GLP-1(7-37) peptide of SEQ ID NO: 1584. GLP-1 analogs of the present disclosure include any of the aforementioned analogs in an amidated form, acid form, pharmaceutically acceptable salt form, and any other physiologically active forms of the molecule.

[98] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereAib at position 2 is α-amino-isobutyric acid; X17 is selected from glutamine (Q), lysine (K), glutamic acid (E), or arginine (R), X20is selected from K, R, Q, or homoarginine (hArg), X24is selected from alanine (A), E, Q, aspartic acid (D), d-Ala, glycine (G), asparagine (N), K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), threonine (T), serine (S), or tyrosine (Y); X27 is selected from valine (V), K, α-amino-isobutyric acid (Aib), N, S, T, Y, Q, or R; and X28 is selected from K, E, R, Q, D, N, G, S, orT. In accordance with this, and all embodiments of the present disclosure, the GLP-1 receptor agonist of the present disclosure does not comprise the amino acid sequence of SEQ ID NO: 1574 (H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG).

[99] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1576), where X17 is Q or K; X20 is K or R; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R. As noted above, the GLP-1 receptor agonist of the present disclosure does not comprise the amino acid sequence of SEQ ID NO: 1574.

[100] In one embodiment, the GLP-1 receptor agonist polypeptide of the present disclosure comprises the amino acid sequence H[Aib]EGTFTSDYSSYLEEX17AAREFIX24WLX27X28GGG (SEQ ID NO: 1577), where X17 is Q or K; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R. Alternatively, the GLP-1 receptor agonist of the present disclosure comprises the amino acid sequence of (H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLKX28GGG (SEQ ID NO: 1578), where X17 is Q or K; X20 is K or R; X24 is A, E, or Q; and X28 is K, E, or R.

[101] Non-limiting examples of GLP-1 receptor agonists of the present disclosure are presented in the Table 1 below. The description column of Table 1 provides the amino acid substitution (relative to GLP-1(7-37)) that are present at the identified position in the particular GLP-1 receptor agonist polypeptide sequence.Table 1. GLP-1 Receptor Agonist Polypeptide SequencesDescription SequenceSEQ ID NO:Aib2;Y10;E16;E24;R20;K27;G30H[Aib]EGTFTSDYSSYLEEQAAREFIEWLKKGGG1579Aib2;Y10;E16;E24;E28;R20;K17;K27;G30H[Aib]EGTFTSDYSSYLEEKAAREFIEWLKEGGG1580Aib2;Y10;E16;E24;R20;K17,K27;G30H[Aib]EGTFTSDYSSYLEEKAAREFIEWLKKGGG1581Aib2;Y10;E16;E24;R20;R28;K27;G30H[Aib]EGTFTSDYSSYLEEQAAREFIEWLKRGGG1582Aib2;Y10;E16;E28;K17;K27;R20;Q24;G30H[Aib]EGTFTSDYSSYLEEKAAREFIQWLKEGGG1583Aib is α-amino-isobutyric acid

[102] In one embodiment, the human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide of the present disclosure comprises 31 amino acids and comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1580. This GLP-1 receptor agonist polypeptide also comprises an α-amino-isobutyric acid (Aib) at position 2; a tyrosine at position 10; a glutamic acid at positions 16, 24, and 28; an arginine at position 20; a lysine at positions 17 and 27; and a glycine at position 30. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1580. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1580. In one embodiment, this GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1580.

[103] In one embodiment, the human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide of the present disclosure comprises 31 amino acids and comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1579. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 27; and a glycine at position 30. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1579. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1579. In one embodiment, this GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1579.

[104] In one embodiment, the human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide of the present disclosure comprises 31 amino acids and comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1581. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 17, 27; and a glycine at position 30. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1581. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1581. In one embodiment, this GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581.

[105] In one embodiment, the human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide of the present disclosure comprises 31 amino acids and comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1583. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 28; an arginine at position 20; a lysine at positions 17, 27; a glutamine at position 24; and a glycine at position 30. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1583. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1583. In one embodiment, this GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1583.

[106] In one embodiment, the human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide of the present disclosure comprises 31 amino acids and comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1582. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at positions 20 and 28; a lysine at positions 27; and a glycine at position 30. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1582. In one embodiment, this GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1582. In one embodiment, this GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1582.

[107] In one embodiment, the GLP-1 receptor agonist consists of the amino acid sequence of SEQ ID NO: 1579. In one embodiment, the GLP-1 receptor agonist consists of the amino acid sequence of SEQ ID NO: 1580. In one embodiment, the GLP-1 receptor agonist consists of the amino acid sequence of SEQ ID NO: 1581. In one embodiment, the GLP-1 receptor agonist consists of the amino acid sequence of SEQ ID NO: 1582. In one embodiment, the GLP-1 receptor agonist consists of the amino acid sequence of SEQ ID NO: 1583.

[108] In one embodiment, the GLP-1 receptor agonist agonizes the human GLP-1 receptor. In one embodiment, the GLP-1 receptor agonist polypeptide has an EC50of less than or equal to 50 pM for agonizing the human GLP-1 receptor as measured using the GLP-1 receptor agonist activity assay described herein in Example 3. For example, the GLP-1 receptor agonist polypeptide has an EC50 of less than or equal to 45 pM, less than or equal to 40 pM, less than or equal to 35 pM, less than or equal to 30 pM, less than or equal to 25 pM, less than or equal to 20 pM, less than or equal to 15 pM. In one embodiment, the GLP-1 EC50 is measured in the GLP-1 receptor agonist activity assay described in Example 3 herein.

[109] In one embodiment, the GLP-1 receptor agonist polypeptide has an EC50 of about 10 pM for agonizing the human GLP-1 receptor as measured using the GLP-1 receptor agonist activity assay described herein in Example 3. In one embodiment, the GLP-1 receptor agonist polypeptide has an EC50 of about 15 pM, about 20 pM, about 25 pM, about 30 pM, about 35 pM, about 40 pM, about 45 pM, about 50 pM, about 55 pM, about 60 pM, about 65 pM, about 70 pM, about 75 pM for agonizing the human GLP-1 receptor as measured using the GLP-1 receptor agonist activity assay described herein in Example 3.

[110] In one embodiment, the GLP-1 receptor agonists disclosed herein are chemically derivatized at one or more amino acid residues by known organic chemistry techniques. In accordance with this and all embodiments of the disclosure “chemical derivative” or “chemically derivatized” refers to a peptide (e.g., peptide linker as described herein), polypeptide (e.g., GLP-1 receptor agonist polypeptide), or other protein (e.g., anti-GIPR antibody as described herein) having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those polypeptides which contain one or more naturally occurring amino acid derivatives of the twenty canonical amino acids, whether in L- or D-form. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.

[111] Useful derivatizations include, in one embodiment, those in which the amino terminal of the polypeptide is chemically blocked so that conjugation to an Fc-containing peptide or an antibody will be prevented from taking place at an N-terminal free amino group of the GLP-1 receptor agonist polypeptide. There may be other beneficial effects of such as modification, for example, a reduction in the polypeptide agonist’s susceptibility to enzymatic proteolysis. The N-terminus can be acylated or modified to a substituted amine, or derivatized with another functional group, such as an aromatic moiety (e.g., an indole acid, benzyl (Bzl or Bn), dibenzyl (DiBzl or Bn2), or benzyloxycarbonyl (Cbz or Z)), N,N-dimethylglycine or creatine. For example, in one embodiment, an acyl moiety, such as, but not limited to, a formyl, acetyl (Ac), propanoyl, butanyl, heptanyl, hexanoyl, octanoyl, or nonanoyl, are covalently linked to the N-terminal end of the peptide, which can prevent undesired side reactions during conjugation of the peptide to an Fc-containing peptide or antibody. Other exemplary N-terminal derivative groups include —NRR1 (other than —NH2), —NRC(O)R1, —NRC(O)OR1, —NRS(O)2R1, —NHC(O)NH1, succinimide, or benzyloxycarbonyl-NH— (Cbz-NH—), wherein R and R1 are each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from C1-C4 alkyl, C1-C4 alkoxy, chloro, and bromo.

[112] In one embodiment, one or more individual amino acid residues of the GLP-1 receptor agonist polypeptide as described herein is derivatized. Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below by way of example.

[113] Lysinyl residues and amino terminal residues of the GLP-1 receptor agonist polypeptides described herein may be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

[114] Arginyl residues may be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group

[115] Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

[116] Carboxyl sidechain groups (aspartyl or glutamyl) of the GLP-1 receptor agonist polypeptides described herein may be selectively modified by reaction with carbodiimides (R′—N═C═N—R′) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

[117] Glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions.

[118] Cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking.

[119] In one embodiment, one or more peptidyl [—C(O)NR—] linkages (bonds) between amino acid residues of the GLP-1 receptor agonist polypeptide are replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages are —CH2-carbamate [—CH2—OC(O)NR—], phosphonate, —CH2-sulfonamide [—CH2—S(O)2NR—], urea [—NHC(O)NH—], —CH2-secondary amine, and alkylated peptide [—C(O)NR6— wherein R6 is lower alkyl].

[120] Other possible modifications to the GLP-1 receptor agonist polypeptide include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. CONJUGATE MOLECULES COMPRISING THE GLP-1 RECEPTOR AGONIST POLYPEPTIDES

[121] Another aspect of the present disclosure is directed to molecules comprising a GLP-1 receptor agonist polypeptide as described supra.

[122] In one embodiment, the molecule comprises a first GLP-1 receptor agonist polypeptide, where the first GLP-1 receptor agonist polypeptide is conjugated to a half-life extending domain. The half-life extending domain may be conjugated directly or via a linker moiety to the GLP-1 receptor agonist polypeptide.

[123] In one embodiment, the half-life extending domain is a polypeptide (e.g., an antibody, antibody fragment, or peptide) that alters the pharmacodynamics and pharmacokinetics of the GLP-1 receptor agonist polypeptide relative to the unconjugated polypeptide. For example, in one embodiment, a half-life extending domain extends elimination half-time relative to the unconjugated polypeptide. In addition, in one embodiment, a half-life extending domain alters one or more pharmacodynamic properties of the polypeptide, such as, e.g., tissue distribution, penetration, or diffusion.

[124] In one embodiment, the half-life extending domain is a molecule that specifically binds to a circulating plasma protein.

[125] In one embodiment, the half-life extending domain is a molecule that specifically binds to an albumin. In one embodiment, the half-life extending domain is a polypeptide (e.g., an antibody, antibody fragment, or peptide) that specifically binds to an albumin.

[126] In one embodiment, the half-life extending domain is a molecule that specifically binds to human serum albumin (HSA). In one embodiment, the half-life extending domain is a polypeptide (e.g., an antibody, antibody fragment, or peptide) that specifically binds to HSA.

[127] In one embodiment, the half-life extending domain is HSA or a variant thereof.

[128] In one embodiment, the half-life extending domain is a molecule that specifically binds to the neonatal Fc receptor (FcRn). In one embodiment, the half-life extending domain is a polypeptide (e.g., an antibody, antibody fragment, or peptide) that specifically binds to FcRn.

[129] In one embodiment, the half-life extending domain is an Fc domain.

[130] In one embodiment, the half-life extending domain is an Fc-containing polypeptide. In one embodiment, the half-life extending domain is an antibody. In one embodiment, the half-life extending domain is an antibody fragment.

[131] In one embodiment, the half-life extending domain is an antibody.

[132] Another aspect of the disclosure is directed to a conjugate molecule comprising a GLP-1 receptor agonist polypeptide as disclosed herein and an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody. In one embodiment, the conjugate molecule comprises a first GLP-1 receptor agonist polypeptide comprising the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereinX17 is Q, K, E, or R; X20 is K, R, Q, or homoarginine (hArg); X24 is A, E, Q, D, d-Ala, G, N, K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), T, S, or Y; X27 is V, K, Aib, N, S, T, Y, Q, or R; and X28 is K, E, R, Q, D, N, G, S, or T, and wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1574; and an antagonist anti-GIPR human antibody.

[133] An exemplary molecule of the present disclosure comprises a first GLP-1 receptor agonist polypeptide conjugated to an antagonist anti-GIPR human antibody. This molecule is referred to herein as an “anti-GIPR antibody / GLP-1 receptor agonist conjugate molecule”, a “conjugate molecule”, or an “anti-GIPR / GLP-1 conjugate molecule”. Exemplary antagonist anti-GIPR antibodies are disclosed infra.

[134] According to this embodiment of the disclosure, the antagonist anti-GIPR antibody of this anti-GIPR / GLP-1 conjugate molecule comprises a first cysteine conjugation site within a light chain or a heavy chain of the anti-GIPR antibody. The first GLP-1 receptor agonist polypeptide of the molecule is conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody.

[135] In one embodiment, this anti-GIPR / GLP-1 conjugate molecule further comprises a second GLP-1 receptor agonist polypeptide. The second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to a second cysteine conjugation site of the anti-GIPR antibody. The second cysteine conjugation site of the anti-GIPR antibody is also located within a light chain or heavy chain of the anti-GIPR antibody. Preferably the first and second cysteine conjugations sites of the anti-GIPR antibody are located at corresponding positions within each light chain or within each heavy chain.

[136] In one embodiment, the first and second GLP-1 receptor agonist polypeptides of this conjugate molecule that are conjugated to the anti-GIPR antibody comprise the same amino acid sequence. In one embodiment, the first and second GLP-1 receptor agonist polypeptides of the conjugate molecule comprise different amino acid sequences.

[137] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of this anti-GIPR / GLP-1 receptor agonist conjugate molecule (or any conjugate molecule of the present disclosure) comprise the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereAib at position 2 is α-amino-isobutyric acid; X17 is selected from glutamine (Q), lysine (K), glutamic acid (E), or arginine (R), X20 is selected from K, R, Q, or homoarginine (hArg), X24 is selected from alanine (A), E, Q, aspartic acid (D), d-Ala, glycine (G), asparagine (N), K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), threonine (T), serine (S), or tyrosine (Y); X27 is selected from valine (V), K, α-amino-isobutyric acid (Aib), N, S, T, Y, Q, R; and X28 is selected from K, E, R, Q, D, N, G, S, T. In accordance with this, and all embodiments of the present disclosure, the GLP-1 receptor agonist of the anti-GIPR / GLP-1 conjugate molecule of the present disclosure does not comprise the amino acid sequence of H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG (SEQ ID NO: 1574).

[138] In one embodiment, incorporation of the amino acid substitutions at the identified positions, in particular at residues 17, 20, 24, 27, and 28 (SEQ ID NO: 1575), improves in vivo stability of the conjugate molecule. For example, the identified amino acid substitutions render the GLP-1 polypeptide resistant to in vivo clipping from the conjugate as measured by a high ratio (≥ 0.65) of intact to total GIPR-GLP-1 molecule AUC0-t(see Example 5). In one embodiment, the incorporation of the amino acid substitutions at the identified positions of the GLP-1 receptor agonist polypeptide, in particular at positions 17, 20, 24, 27, and 28, improves the potency of the conjugate molecule. For example, the identified amino acid substitutions render the conjugate molecule more therapeutically potent as measured by body weight loss following in vivo administration (see Example 4).

[139] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the anti-GIPR / GLP-1 receptor agonist conjugate molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1576), where X17 is Q or K; X20 is K or R; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R. As noted above, the GLP-1 receptor agonist of the anti-GIPR antibody / GLP-1 receptor agonist conjugate molecule does not comprise the amino acid sequence of SEQ ID NO: 1574.

[140] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the anti-GIPR / GLP-1 receptor agonist conjugate molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAREFIX24WLX27X28GGG (SEQ ID NO: 1577), where X17 is Q or K; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R. Alternatively, the first and / or second GLP-1 receptor agonist of the anti-GIPR antibody / GLP-1 receptor agonist conjugate molecule comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLKX28GGG (SEQ ID NO: 1578), where X17 is Q or K; X20 is K or R; X24 is A, E, or Q; and X28 is K, E, or R.

[141] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the conjugate molecule comprise 31 amino acids and comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1580. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16, 24, and 28; an arginine at position 20; a lysine at positions 17 and 27; and a glycine at position 30. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1580. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide of the conjugate molecule comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1580. In one embodiment, the first and / or second GLP-1 receptor agonist of the anti-GIPR / GLP-1 conjugate molecule comprises the amino acid sequence of SEQ ID NO: 1580.

[142] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the conjugate molecule comprise 31 amino acids and comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1579. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 27; and a glycine at position 30. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1579. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1579. In one embodiment, the first and / or second GLP-1 receptor agonist of the anti-GIPR / GLP-1 conjugate molecule comprises the amino acid sequence of SEQ ID NO: 1579.

[143] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the conjugate molecule comprise 31 amino acids and comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1581. The first and / or second GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 17, 27; and a glycine at position 30. In one embodiment, first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1581. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1581. In one embodiment, the first and / or second GLP-1 receptor agonist of the anti-GIPR / GLP-1 conjugate molecule comprises the amino acid sequence of SEQ ID NO: 1581.

[144] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the conjugate molecule comprise 31 amino acids and comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 1583. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 28; an arginine at position 20; a lysine at positions 17, 27; a glutamine at position 24; and a glycine at position 30. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1583. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1583. In one embodiment, the first and / or second GLP-1 receptor agonist of the anti-GIPR / GLP-1 conjugate molecule comprises the amino acid sequence of SEQ ID NO: 1583.

[145] In one embodiment, the first and / or second GLP-1 receptor agonist polypeptides of the conjugate molecule comprise 31 amino acids and comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:1582. This GLP-1 receptor agonist polypeptide also comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at positions 20 and 28; a lysine at positions 27; and a glycine at position 30. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1582. In one embodiment, the first and / or second GLP-1 receptor agonist polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1582. In one embodiment, the first and / or second GLP-1 receptor agonist of the anti-GIPR / GLP-1 conjugate molecule comprises the amino acid sequence of SEQ ID NO: 1582.

[146] In one embodiment, the first GLP-1 receptor agonist polypeptide of the conjugate molecule is directly conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody. In one embodiment, each of the first and second GLP-1 receptor agonist polypeptides of the molecule is directly conjugated, at its C-terminus, to the first and second cysteine conjugations sites of the anti-GIPR antibody, respectively. The position of the first and second cysteine conjugation sites within the anti-GIPR antibody are described in more detail infra.

[147] In one embodiment, the first GLP-1 receptor agonist polypeptide of the conjugate molecule is conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody via a linker moiety. In one embodiment, each of the first and second GLP-1 receptor agonist polypeptides of the conjugate molecule are conjugated, at their C-terminus, to the first and second cysteine conjugation sites of the anti-GIPR antibody, respectively, via first and second linker moieties, respectively.

[148] In one embodiment a linker moiety couples the C-terminal end of a GLP-1 receptor agonist polypeptide to a conjugation site on an anti-GIPR antibody. The presence of any linker moiety in the GLP-1 receptor agonist conjugate molecules as described herein is optional. In one embodiment, the linker moiety serves primarily as a spacer to position, join, connect, or optimize presentation or position of the functional moieties of the molecule (e.g., the GLP-1 receptor agonist polypeptide and / or the anti-GIPR antibody). In another embodiment, a linker moiety is utilized to optimize pharmacological activity or stability of the GLP-1 receptor agonist containing molecules disclosed herein. In a preferred embodiment, the linker moiety of the anti-GIPR antibody / GLP-1 receptor agonist polypeptide conjugate molecule described herein contributes to the enhanced the stability of the molecule in terms of resistance to cleavage upon in vivo administration.

[149] In one embodiment, the linker moiety is a peptide linker moiety. Peptide linkers are made up of amino acids that are typically linked together by peptide bonds and are a length of from 1 to about 40 amino acid residues, preferably, a length of from 10 to about 30 amino acid residues, and more preferably, a length of from 10 to about 20 amino acid residues. In some embodiments, the peptide linker may comprise amino acid residues where one or more of the amino acid residues are not linked via a peptide bond (i.e., The amino acid residues of the linker are chosen from among the twenty canonical amino acids. More preferably, the amino acid residues of the linker are chosen from among glycine, alanine, proline, asparagine, glutamine, and / or serine. Even more preferably, a peptidyl linker is made up of a majority of amino acids that are sterically unhindered, such as glycine, serine, and alanine linked by a peptide bond. It is also desirable that, if present, the peptidyl linker is one that is not subject to rapid proteolytic turnover in circulation.

[150] Exemplary linker moieties of the anti-GIPR antibody / GLP-1 receptor agonist conjugate molecules described herein include the linker peptide of SEQ ID NO: 1585, the linker peptide of SEQ ID NO: 1586, the linker peptide of SEQ ID NO: 1587, the linker peptide of SEQ ID NO: 1588, the linker peptide of SEQ ID NO: 1589, the linker peptide of SEQ ID NO: 1590, the linker peptide of SEQ ID NO: 1591, the linker peptide of SEQ ID NO: 1592, and the linker peptide of SEQ ID NO: 1593. Additional peptide linkers suitable for inclusion in the anti-GIPR antibody / GLP-1 receptor agonist conjugate molecules described herein are provided in Table 2 herein.

[151] In one embodiment, the linkage between a GLP-1 receptor polypeptide and a peptide linker is a peptide bond between the C-terminal amino acid residue of the GLP-1 agonist polypeptide and N-terminal amino acid residue of the peptide linker. In one embodiment, the linkage between a GLP-1 receptor polypeptide and a peptide linker is an amide bond between the C-terminal amino acid residue of the GLP-1 agonist polypeptide and the side chain of a lysine residue (i.e., at the ε amino group of the lysine) on the peptide linker. In one embodiment, the linkage between a GLP-1 receptor polypeptide and a peptide linker is an amide bond between the C-terminal amino acid residue of the GLP-1 agonist polypeptide and the α amino group of a C-terminal lysine residue on the peptide linker.

[152] In one embodiment, exemplary linker peptides comprise a sequence of amino acid residues coupled via standard peptide bonds (e.g., the peptide linkers of SEQ ID NOs: 1585-1587 and 1592-1654). In one embodiment, exemplary linker peptides comprise at least on non-standard peptide bond. In this embodiment, the linker peptide comprises a sequence of amino acid residues coupled via standard peptide bonds, where the C-terminal residue of this sequence is coupled, via an amide bond, to the epsilon amino group of a lysine residue. For example, the exemplary linker peptides of SEQ ID NOs: 1588-1591 comprise a non-standard amino acid linkage at the lysine residue. In particular, for the linker peptides of SEQ ID NOs: 1588 and 1590, the glutamine residue at position 15 of these peptides is linked via an amide bond to the epsilon amino group of the adjacent lysine. This unique linkage is represented in the linker peptide as provided in Table 2 by the lysine residue outside the parenthesis enclosing the remainder of the linker sequence. Similarly, for the linker peptides of SEQ ID NOs: 1589 and 1591, the serine residue at position 15 of these peptides is linked via an amide bond to the epsilon amino group of the adjacent lysine residue. The linkage between a GLP-1 receptor polypeptide and a peptide linker of SEQ ID NO: 1588, SEQ ID NO: 1589, SEQ ID NO: 1590, or SEQ ID NO: 1591 occurs via an amide bond between the C-terminal amino acid residue of the GLP-1 agonist polypeptide and the α amino group of the lysine residue of the linker. In these embodiments, the N-terminal amino acid residue of the linker peptide is coupled to the cysteine conjugation site on the anti-GIPR antibody residue. The N-terminal amino acid residue of the linker peptide may be modified, e.g., bromoacetylated, to facility the coupling to the cysteine conjugation site on the anti-GIPR antibody.

[153] In one embodiment, the molecule disclosed herein comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1579 covalently linked to the linker peptide of SEQ ID NO: 1585, the linker peptide of SEQ ID NO: 1586, the linker peptide of SEQ ID NO: 1587, the linker peptide of SEQ ID NO: 1588, the linker peptide of SEQ ID NO: 1589, the linker peptide of SEQ ID NO: 1590, the linker peptide of SEQ ID NO: 1591, the linker peptide of SEQ ID NO: 1592, or the linker peptide of SEQ ID NO: 1593. In one embodiment, the molecule disclosed herein comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1579, where the C-terminal amino acid residue of the polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1592 as depicted in FIG. 2. In one embodiment, the C-terminal lysine of the linker peptide is modified, e.g.,bromoacetylated, for coupling to the cysteine residue of the conjugation site on the anti-GIPR antibody.

[154] In one embodiment, the molecule disclosed herein comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1580 covalently linked to the linker peptide of SEQ ID NO: 1585, the linker peptide of SEQ ID NO: 1586, the linker peptide of SEQ ID NO: 1587, the linker peptide of SEQ ID NO: 1588, the linker peptide of SEQ ID NO: 1589, the linker peptide of SEQ ID NO: 1590, the linker peptide of SEQ ID NO: 1591, the linker peptide of SEQ ID NO: 1592, or the linker peptide of SEQ ID NO: 1593. In one embodiment, the molecule disclosed herein comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1580, where the C-terminal amino acid residue of the polypeptide is covalently linked to the αamino group of the lysine residue of the linker peptide of SEQ ID NO: 1591 as depicted in FIG. 3. As noted above, the adjacent serine residue of the linker, i.e., the serine at position 15 of the linker peptide of SEQ ID NO: 1591, is linked via an amide bond to the epsilon amino group of the lysine residue as shown in FIG. 3. In this embodiment, the N-terminal glycine residue of the linker peptide is modified, i.e., bromoacetylated, for coupling to the cysteine residue of the conjugation site on the anti-GIPR antibody.

[155] In one embodiment, the molecule disclosed herein comprise a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1581 covalently linked to the linker peptide of SEQ ID NO: 1585, the linker peptide of SEQ ID NO: 1586, the linker peptide of SEQ ID NO: 1587, the linker peptide of SEQ ID NO: 1588, the linker peptide of SEQ ID NO: 1589, the linker peptide of SEQ ID NO: 1590, the linker peptide of SEQ ID NO: 1591, the linker peptide of SEQ ID NO: 1592, or the linker peptide of SEQ ID NO: 1593. In one embodiment, the molecule disclosed here comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1581, where the C-terminal amino acid residue of the polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1585 as depicted in FIG. 4. In one embodiment, the C-terminal lysine of the linker peptide is modified, e.g.,bromoacetylated as shown in FIG. 4, for coupling to the cysteine residue of the conjugation site on the anti-GIPR antibody.

[156] In one embodiment, the molecule disclosed here comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1581, where the C-terminal amino acid residue of the polypeptide is covalently linked to the N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1586 as depicted in FIG. 5. In one embodiment, the C-terminal lysine of the linker peptide is modified, e.g.,bromoacetylated as shown in FIG. 5, for coupling to the cysteine residue of the conjugation site on the anti-GIPR antibody.

[157] In one embodiment, the molecule disclosed here comprises a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1581, where the C-terminal amino acid residue of the polypeptide is covalently linked to N-terminal amino acid residue of the linker peptide of SEQ ID NO: 1593 as depicted in FIG. 6. In one embodiment, the C-terminal lysine of the linker peptide is modified, e.g.,bromoacetylated on the sidechain, as shown in FIG. 6, for coupling to the cysteine residue of the conjugation site on the anti-GIPR antibody.

[158] In one embodiment, the molecule disclosed herein comprise a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1582 covalently linked to the linker peptide of SEQ ID NO: 1585, the linker peptide of SEQ ID NO: 1586, the linker peptide of SEQ ID NO: 1587, the linker peptide of SEQ ID NO: 1588, the linker peptide of SEQ ID NO: 1589, the linker peptide of SEQ ID NO: 1590, the linker peptide of SEQ ID NO: 1591, the linker peptide of SEQ ID NO: 1592, or the linker peptide of SEQ ID NO: 1593.

[159] In one embodiment, the molecule disclosed herein comprise a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1583 covalently linked to the linker peptide of SEQ ID NO: 1585, the linker peptide of SEQ ID NO: 1586, the linker peptide of SEQ ID NO: 1587, the linker peptide of SEQ ID NO: 1588, the linker peptide of SEQ ID NO: 1589, the linker peptide of SEQ ID NO: 1590, the linker peptide of SEQ ID NO: 1591, the linker peptide of SEQ ID NO: 1592, or the linker peptide of SEQ ID NO: 1593.

[160] Other peptide linkers that are suitable for inclusion in the molecules as described herein are provided in Table 2.Table 2. Linker Peptide Sequences Linker SequenceSEQ ID NO:GGQGGQGGQGGQGGQK1585GGGGQGGGGQGGGGQK1586SGGGGSGGGGSGGGGK1587GGQGGQGGQGGQGGQK1588GGSGGSGGSGGSGGSK1589GGGGQGGGGQGGGGQK1590GGGGSGGGGSGGGGSK1591GGSGGSGGSGGSGGSK1592GGGGSGGGGSGGGGSK1593GGGGS GGGGS PAPAP APAPA PASGG1598GSPAP APAPA PAPAP APAPA PASGG1599GGGGS GGGGS GGGGS GGGGS GGGGS1600GSPAP APAPA PAPAP APAPA PASG1601GSPAP APAPA PAPAG GGGSG GGGS1602GSPAP APAPA PASGG GG1603GSPAP APAPA PASGG1604GSPAP APAPA SGG1605GGGGS GGGGS GGGGS GGGGS1606GSGGG GSGGG GSGGG GSGGG G1607GGGGS GGGGS GGGGS1608GSGGG GSGGG GSGGG G1609GAKAA AEKAA AEKAA AEKAA AEA1610GAKAQ ADAKA QADAK AQADA KAQAD SGG1611GGGSG GGS1612GGGSG GGSGG GS1613GGGSG GGSGG GSGGG S1614GGGSG GGSGG GSGGG SGGGS1615GGGSG GGSGG GSGGG SGGGS GGGS1616GGGGS GGGGS1617GGGGS GGGGS GGGGS GGGGS GGGGS GGGGS1618GGG1619GGGG1620GGGGG1621GGGGG GG1622GGGGG K1623GGGGG KR1624GGGKG GGG1625GGGNG SGG1626GGGCG GGG1627GPNGG1628GGGGS1629GGEGG G1630GGEEE GGG1631GEEEG1632GEEE1633GGDGG G1634GGDDD GG1635GDDDG1636GDDD1637GGGGS DDSDE GSDGE DGGGG S1638WEWEW1639FEFEF1640EEEWW W1641EEEFF F1642WWEEE WW1643FFEEE FF1644GSGSA TGGSG STASS GSGSA TH1645HGSGS ATGGS GSTAS SGSGS AT1646AEAAA KEAAA KEAAA KAGG1647GSPAP APAPA PAPAP APAPA PASGG 1648A PAPAP APAPA PAGGG GSGGG GSK1649A PAPAP APAPA PAPAP APAPA K1650G GGGSG GGGSG GGGSG GGGSK1651G GGGSG GGGSG GGGSK1652G GSAPA PAPAP APAPA PAPAP APSGK1653GG GGSGG GGSGG GGSK1654 

[161] In one embodiment, the linker moiety, if present, is a non-peptidyl linker moiety. One non-limiting example class of suitable non-peptidyl linkers is polyethylene glycol (PEG) linkers, such as, e.g.,wherein n is such that the linker has a molecular weight of about 100 Daltons (Da) to about 5000 Da, preferably about 100 Da to about 500 Da. Additional non-peptidyl linker moieties that are suitable for incorporation into the GLP-1 agonist polypeptide containing molecules are disclosed infra. In one embodiment, the PEG linker is a PEG20 linker comprising K-(G-PEG20), K-(PEG20) or (G-PEG20)-K.

[162] In one embodiment, the molecule disclosed herein comprise a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1581 covalently linked to the αamino group of the lysine residue of the PEG20 linker (G-PEG20)-K as shown in FIG. 7. At the opposite end of the PEG20 molecule is a bromoacetylated glycine residue that facilitates conjugation to the cysteine conjugation site on the anti-GIPR antibody.

[163] In one embodiment, the molecule disclosed herein comprise a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1582 covalently linked to the αamino group of the lysine residue of the PEG20 linker (G-PEG20)-K as shown in FIG. 8. At the opposite end of the PEG20 molecule is a bromoacetylated glycine residue that facilitates conjugation to the cysteine conjugation site on the anti-GIPR antibody.

[164] In one embodiment, the molecule disclosed herein comprise a GLP-1 receptor agonist polypeptide of SEQ ID NO: 1583 covalently linked to the αamino group of the lysine residue of the PEG20 linker (G-PEG20)-K as shown in FIG. 9. At the opposite end of the PEG20 molecule is a bromoacetylated glycine residue that facilitates conjugation to the cysteine conjugation site on the anti-GIPR antibody.

[165] Additional non-peptidyl linker moieties that are suitable for incorporation into the GLP-1 agonist polypeptide containing molecules include alkyl linkers such as -NH-(CH2)s-C(O), wherein s = 2-20. These alkyl linkers may further be substituted by any non-sterically hindering group such as lower alkyl (e.g., C1-C6) lower acyl, halogen (e.g., Cl, Br), CN, NH2, phenyl, etc.

[166] Other suitable non-peptidyl linkers comprise a rigid polyheterocyclic core of controlled length. Such linkers may be chemically differentiated on either end to accommodate orthogonal coupling chemistries (i.e., azide “click”, amide coupling, thioether formation by alkylation with maleimide or haloacetamide, oxime formation, reductive amination, etc.).

[167] Non-peptidyl linkers can be synthesized by conventional organic chemistry reactions.

[168] The above is merely illustrative and not an exhaustive treatment of the kinds of nonpeptidyl linkers that can optionally be employed in accordance with the present disclosure.

[169] In one embodiment, the antagonist anti-GIPR antibodies of the conjugate molecules disclosed herein comprise at least one conjugation site. In one embodiment, the anti-GIPR antibodies of the conjugate molecule disclosed herein comprise at least two conjugation sites (e.g., a first and second conjugation site). The one or more conjugation sites of the anti-GIPR antibody are amenable to conjugation of the GLP-1 receptor agonist polypeptides as disclosed herein by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. GLP-1 receptor agonist polypeptides can be conjugated or coupled to the selected conjugation site of the anti-GIPR antibody through an assortment of different conjugation chemistries known in the art. For example, in one embodiment, a maleimide-activated conjugation partner targeting an accessible cysteine thiol on the anti-GIPR antibody can be used. In one embodiment, conjugation or coupling chemistries targeting the side chains of either canonical or non-canonical, e.g., unnatural, amino acids in the anti-GIPR antibody sequence can be used.

[170] Chemistries for chemoselective conjugation of the anti-GIPR antibody to the GLP-1 receptor agonist polypeptide include, but are not limited to, copper(I)catalyzed azide–alkyne [3+2] dipolar cycloadditions, Staudinger ligation, other acyl transfers processes, oximations, hydrazone bonding formation, and other suitable organic chemistry reactions such as cross-couplings using water-soluble palladium catalysts (see e.g., Bong et al., Organic Letters 3(16):2509-11 (2001); Dibowski et al., Angew. Chem. Int. Ed. 37(4):476-78 (1998); DeVasher et al., J. Org. Chem. 69:7919-27 (2004); Shaugnessy et al., J.Org. Chem, 68, 6767-6774 (2003); Prescher et al., Nature Chemical Biology 1(1); 13-21 (2005)).

[171] In one embodiment, conjugation (or covalent binding) to the anti-GIPR antibody is through the side chain of an amino acid residue at the conjugation site, for example, but not limited to, a cysteinyl residue. The amino acid residue, for example, a cysteinyl residue, at the internal conjugation site that is selected can be one that occupies the same amino acid residue position in a native Fc domain sequence, or the amino acid residue can be engineered into the Fc domain sequence by substitution or insertion.

[172] Non-limiting examples of unnatural amino acid residues that can be useful as a conjugation site include: azido-containing amino acid residues, e.g., azidohomoalanine, p-azido-phenylalanine; keto-containing amino acid residues, e.g., p-acetyl-phenylalanine; alkyne- containing amino acid residues, e.g., p-ethynylphenylalanine, homopropargylglycine, p-(prop-2-ynyl)-tyrosine; alkene-containing amino acid residues e.g., homoallylglycine; aryl halide- containing amino acid residues e.g. p-iodophenylalanine, p-bromophenylalanine; and 1,2-aminothiol containing amino acid residues.

[173] Non-canonical amino acid residues (e.g., unnatural amino acid residues) can be incorporated into an antiGIPR antibody by amino acid substitution or insertion. Non-canonical amino acid residues can be incorporated into the antibody by chemical peptide synthesis rather than by synthesis in biological systems, such as recombinantly expressing cells, or alternatively the skilled artisan can employ known techniques of protein engineering that use recombinantly expressing cells (see, e.g., Link et al., Current Opinion in Biotechnology, 14(6):603-609 (2003); U.S. Patent No. 7,045,337 to Schultz).

[174] Any of the exposed amino acid residues on the anti-GIPR antibody can be potentially useful conjugation sites. Such sites may naturally contain cysteine or another reactive amino acid for siteselective coupling. Other sites can be mutated to a cysteine or another reactive amino acid for site-selective coupling. In some embodiments, the conjugation site is located within the light chain constant region (CL), heavy chain constant region 1 (CH1), CH2 or CH3 region of the anti-GIPR antibody.

[175] In one embodiment, the anti-GIPR antibody comprises a cysteine amino acid at one or more conjugation site(s). In one embodiment, the one or more conjugation site(s) is located within the CL, CH1, CH2 or CH3 region of the anti-GIPR antibody. In one embodiment, the one or more conjugation site(s) are at positions independently selected from the group consisting of 88 (e.g., D88) of the light chain, 384 (e.g., E384) of the heavy chain, and 487 (e.g., T487) of the heavy chain, according to AHo numbering. For sake of clarity position 88 of the light chain according to Aho number corresponds to position 70 according to Kabat Numbering. Position 88 of the light chain according to AHo number corresponds to position 70 in the reference light chain antibody sequence of SEQ ID NO: 455 (light chain of anti-GIPR antibody 5G12.006). Position 88 of the light chain according to AHo number corresponds to position 70 in the reference light chain antibody sequence of SEQ ID NO: 388 (light chain of anti-GIPR antibody 2G10.006).

[176] Position 384 of the heavy chain according to AHo numbering is another suitable conjugation site within the anti-GIPR antibody. Position 384 of the heavy chain according to AHo numbering corresponds to position 272 according to EU Numbering. Position 384 of the heavy chain according to AHo numbering corresponds to position 276 in the reference heavy chain antibody sequence of SEQ ID NO: 612 (heavy chain of anti-GIPR antibody 5G12.006) and to position 275 in the reference heavy chain antibody sequence of SEQ ID NO: 545 (heavy chain of anti-GIPR antibody 2G10.006).

[177] Position 487 of the heavy chain according to AHo numbering is another suitable conjugation site within the anti-GIPR antibody. Position 487 of the antibody heavy chain according to AHo numbering corresponds to position 359 according to EU numbering. Position 487 according to AHo numbering also corresponds to position 363 in the reference heavy chain antibody sequence of SEQ ID NO: 612 (heavy chain of anti-GIPR antibody 5G12.006) and position 362 in the reference heavy chain antibody sequence of SEQ ID NO: 545 (heavy chain of anti-GIPR antibody 2G10.006).

[178] Exemplary antibodies that bind and antagonize GIPR, including human GIPR (hGIPR), for inclusion in the conjugate molecules as described herein are provided infra and disclosed in U.S. Patent No. 10,294,303, which is hereby incorporated by reference in its entirety.

[179] In one embodiment, the antagonist anti-GIPR antibody of the conjugate molecule binds to the extracellular portion of human GIPR. In one embodiment, antagonist anti-GIPR antibody inhibits binding of GIP to the extracellular portion of human GIPR. In one embodiment, the human GIPR has the amino acid sequence of SEQ ID NO: 1572.

[180] In one embodiment, the antagonist anti-GIPR antibody of the conjugate molecule binds to the Nterminal extracellular domain of human GIPR. In one embodiment, the antagonist anti-GIPR antibody inhibits binding of GIP to the Nterminal extracellular domain of human GIPR. In one embodiment, the human GIPR has the amino acid sequence of SEQ ID NO: 1572.

[181] In one embodiment, the antagonist anti-GIPR antibody of the conjugate molecule binds to one or more amino acids at positions 1-139 of human GIPR. In one embodiment, the antagonist anti-GIPR antibody inhibits binding of GIP to the amino acids at positions 1-139 of human GIPR. In one embodiment, the human GIPR has the amino acid sequence of SEQ ID NO: 1572.

[182] In one embodiment, the antagonist anti-GIPR antibody of the conjugate molecule of the present disclosure prevents or reduces binding of GIP to GIPR, where the level of prevention or reduction can be measured, for example, by a GIPR binding assay (e.g., a radioactive- or fluorescence-labeled GIP ligand binding study). A GIPR binding assay can be an assay using FMAT or FACS that measures fluorescence-labeled GIP binding to GIPR expressing cells, and the antagonistic activity of an anti-GIPR antibody is measured by its ability to displace fluorescence-labeled GIP binding to GIPR expressing cells. Alternatively, a GIPR binding assay can measure radioactive-labeled GIP binding to GIPR expressing cells, and the antagonist activity of an anti-GIPR antibody is measured by its ability to displace radioactive labeled GIP binding to GIPR expressing cells (seee.g., Biochimica et Biophysica Acta (2001) 1547:143-155). The reduction in GIP binding can be at least 10%, 25%, 50%, 100% or more relative treatment with a non-GIPR control antibody under comparable conditions.

[183] In one embodiment, the antagonist anti-GIPR antibody of the conjugate molecule of the present disclosure prevents or reduces binding of GIP to GIPR, where the level of prevention or reduction is measured using a GIPR activity assay that measures GIP binding protein activity in a cellular setting. In one embodiment, the GIPR activity assay is a cAMP assay in GIPR expressing cells, in which GIP induces cAMP signal, and the antagonist activity of an anti-GIPR antibody is measured in the presence / absence of GIP ligand, in which IC50 / EC50 and degree of inhibition / activation can be obtained (see e.g., Gault et al., Biochem. Biophys. Res. Commun.(2002) 290:1420–1426). In another embodiment, the GIPR activity assay is an insulin secretion assay in pancreatic beta cells. GIP induces glucose-dependent insulin secretion, and the antagonist activity of an anti-GIPR antibody is measured in the presence / absence of GIP ligand and the IC50 / EC50 and degree of GIP inhibition can be obtained (see e.g., Gault et al., Biochem. Biophys. Res. Commun. (2002) 290:1420–1426).

[184] The prevention or reduction of GIP binding to GIPR achieved using the anti-GIPR antibody-GLP-1 conjugate molecule of the present disclosure results in one or more of the following pharmacodynamic effects following in vivo administration: an increase in glucose tolerance; an increase in insulin sensitivity; a decrease in body weight or a reduction in body weight gain; a decrease in fat mass or a decrease in inflammation in fat tissue; a decrease in circulating cholesterol levels; a decrease in circulating triglyceride levels; a decrease in liver steatosis or reduction of the liver triglyceride level; a decrease one or more liver enzymes, e.g., aspartate aminotransferase (AST), alanine aminotransferase (ALT), and / or alkaline phosphatase (ALP) levels. Methods for assaying and determining the preceding characteristics are known in the art and disclosed in U.S. Patent No. 10,294,303, which is hereby incorporated by reference in its entirety.

[185] In one embodiment, the antagonist anti-GIPR antibodies disclosed herein are characterized by their binding affinity for GIPR. In one embodiment, the anti-GIPR antibodies disclosed herein that are suitable for conjugation to a GLP-1 receptor agonist disclosed herein binds human GIPR with an equilibrium dissociation constant (KD) of ≤200 nM, a KD of ≤150 nM, a KD of ≤100 nM, a KD of ≤50 nM, a KD of ≤10 nM, a KD of ≤5 nM, a KD of ≤2 nM, or a KD of ≤1 nM, e.g., as measured via a surface plasma resonance or kinetic exclusion assay technique. In one embodiment, the anti-GIPR antibody has a KD for human GIPR of 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, 9 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 35 nM, 40 nM, 45 nM, 50 nM, 55 nM, 60 nM, 65 nM, 70 nM, 75 nM, 80 nM, 85 nM, 90 nM, 95 nM, 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260 nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460 nM, 470 nM, 480 nM, 490 nM, or 500 nM.

[186] In one embodiment, the antagonist anti-GIPR antibodies disclosed herein have a slow dissociation rate or off-rate. For example, in one embodiment, the antagonist anti-GIPR antibody has a kd (off-rate) of 1x 10-2 s-1 , or 1x 10-3 s-1 , or 1x 10-4 s-1 , or 1x 10-5 s-1 .

[187] In one embodiment, the antagonist anti-GIPR antibody is a monoclonal antibody, a recombinant antibody, a human antibody, or a multi-specific antibody. In one embodiment, the anti-GIPR antibody is a monoclonal antibody. In one embodiment, the anti-GIPR antibody is a recombinant antibody. In one embodiment, the anti-GIPR antibody is a human antibody.

[188] As defined herein, the antagonist anti-GIPR antibody is of the IgG isotype. In one embodiment, the antagonist anti-GIPR antibody is of the IgG1-, IgG2- IgG3- or IgG4-subclass. In one embodiment, the antibody is of the IgG1-, IgG2-, or IgG4- subclass. In one embodiment, the antibody is of the IgG1- or IgG2- subclass. In one embodiment, the antibody is of the IgG1-subclass.

[189] Non-limiting examples of anti-GIPR antibodies of the IgG1 subclass are summarized in Table 3. In one embodiment, the anti-GIPR antibody is an antibody with the CDR, variable domain, and light and heavy chain sequences as specified in one of the rows of Table 3.

[190] SEQ ID NOs have been assigned to variable light chain, variable heavy chain, light chain, heavy chain, CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequences of the exemplary antagonist anti-GIPR antibodies provided in Tables 3-11. These antibodies can be identified by SEQ ID NO, but also by construct name (e.g., 2C2.005) or identifier number (e.g., iPS:336175). The antiGIPR antibodies identified in Tables 3-11 below can be grouped into families based on construct name. For example, the “4B1 family” includes the constructs 4B1, 4B1.010, 4B1.011, 4B1.012, 4B1.013, 4B1.014, 4B1.015, and 4B1.016.

[191] The various light chain and heavy chain variable regions provided herein are depicted in Tables 4 and 5, respectively. Each of these variable regions may be attached to a heavy or light chain constant regions to form a complete antibody heavy and light chain, respectively. Furthermore, each of the so generated heavy and light chain sequences may be combined to form a complete antibody structure.   Table 3. Anti-GIPR Antibody Amino Acid SequencesIdentifierConstructVLVHLCHCCDRL1CDRL2CDRL3CDRH1CDRH2CDRH3iPS:3361752C2.0051158315472629786943110012571414iPS:3359144B12159316473630787944110112581415iPS:3359386H13160317474631788945110212591416iPS:3359412F114161318475632789946110312601417iPS:3359705C25162319476633790947110412611418iPS:33597813H126163320477634791948110512621419iPS:33598611C17164321478635792949110612631420iPS:33599412H118165322479636793950110712641421iPS:33602418E39166323480637794951110812651422iPS:3360412G10_LC110167324481638795952110912661423iPS:3360774H9.00411168325482639796953111012671424iPS:3360886A5.00412169326483640797954111112681425iPS:33609917H11.00413170327484641798955111212691426iPS:35962117H11.004.00114171328485642799956111312701427iPS:3597814H9.004.00115172329486643800957111412711428iPS:3609294H9.004.00216173330487644801958111512721429iPS:3609364H9.004.00317174331488645802959111612731430iPS:3609434H9.004.00418175332489646803960111712741431iPS:3609494H9.004.00519176333490647804961111812751432iPS:3597614H9.004.00620177334491648805962111912761433iPS:3609554B1.01021178335492649806963112012771434iPS:3609624B1.01122179336493650807964112112781435iPS:3609684B1.01223180337494651808965112212791436iPS:3609744B1.01324181338495652809966112312801437iPS:3609784B1.01425182339496653810967112412811438iPS:3597854B1.01526183340497654811968112512821439iPS:3609824B1.01627184341498655812969112612831440iPS:33592218F228185342499656813970112712841441iPS:36098618F2.00229186343500657814971112812851442iPS:36099518F2.00330187344501658815972112912861443iPS:36099918F2.00431188345502659816973113012871444iPS:36100518F2.00532189346503660817974113112881445iPS:36100918F2.00633190347504661818975113212891446iPS:36101318F2.00734191348505662819976113312901447iPS:36101718F2.00835192349506663820977113412911448iPS:36102118F2.00936193350507664821978113512921449iPS:36102818F2.01037194351508665822979113612931450iPS:36053518F2.01138195352509666823980113712941451iPS:36103518F2.01239196353510667824981113812951452iPS:3599402F11.00240197354511668825982113912961453iPS:3610392F11.00341198355512669826983114012971454iPS:3610432F11.00442199356513670827984114112981455iPS:3610492F11.00543200357514671828985114212991456iPS:3610552F11.00644201358515672829986114313001457iPS:3610592F11.00745202359516673830987114413011458iPS:3610632F11.00846203360517674831988114513021459iPS:3599492F11.00947204361518675832989114613031460iPS:3599562F11.01048205362519676833990114713041461iPS:3598656H1.00249206363520677834991114813051462iPS:3598696H1.00350207364521678835992114913061463iPS:3598736H1.00451208365522679836993115013071464iPS:3598776H1.00552209366523680837994115113081465iPS:3610676H1.00653210367524681838995115213091466iPS:3610716H1.00754211368525682839996115313101467iPS:3610756H1.00855212369526683840997115413111468iPS:3610796A5.004.00156213370527684841998115513121469iPS:3610856A5.004.00257214371528685842999115613131470iPS:3610916A5.004.003582153725296868431000115713141471iPS:3610956A5.004.004592163735306878441001115813151472iPS:3611016A5.004.005602173745316888451002115913161473iPS:3611056A5.004.006612183755326898461003116013171474iPS:3611096A5.004.007622193765336908471004116113181475iPS:3611136A5.004.008632203775346918481005116213191476iPS:3611206A5.004.009642213785356928491006116313201477iPS:3598966A5.004.010652223795366938501007116413211478iPS:3598906A5.004.011662233805376948511008116513221479iPS:3595672A11.002672243815386958521009116613231480iPS:3359652A11.003682253825396968531010116713241481iPS:3611582A11.004692263835406978541011116813251482iPS:3611652A11.005702273845416988551012116913261483iPS:3611722G10_LC1.003712283855426998561013117013271484iPS:3611782G10_LC1.004722293865437008571014117113281485iPS:3611852G10_LC1.005732303875447018581015117213291486iPS:3611922G10_LC1.006742313885457028591016117313301487iPS:3596092G10_LC1.007752323895467038601017117413311488iPS:3596152G10_LC1.008762333905477048611018117513321489iPS:3611962G10_LC1.009772343915487058621019117613331490iPS:3612022G10_LC1.010782353925497068631020117713341491iPS:35964418E3.002792363935507078641021117813351492iPS:36120618E3.003802373945517088651022117913361493iPS:35962818E3.004812383955527098661023118013371494iPS:35963718E3.005822393965537108671024118113381495iPS:36121018E3.006832403975547118681025118213391496iPS:36121418E3.007842413985557128691026118313401497iPS:36121818E3.008852423995567138701027118413411498iPS:3612225C2.006862434005577148711028118513421499iPS:3612295C2.007872444015587158721029118613431500iPS:3612365C2.008882454025597168731030118713441501iPS:3596855C2.009892464035607178741031118813451502iPS:3612405C2.010902474045617188751032118913461503iPS:3612475C2.011912484055627198761033119013471504iPS:3612545C2.012922494065637208771034119113481505iPS:3612615C2.013932504075647218781035119213491506iPS:3612685C2.014942514085657228791036119313501507iPS:3596695C2.015952524095667238801037119413511508iPS:3596785C2.016962534105677248811038119513521509iPS:36127511C1.002972544115687258821039119613531510iPS:36128211C1.003982554125697268831040119713541511iPS:36128911C1.004992564135707278841041119813551512iPS:35971211C1.0051002574145717288851042119913561513iPS:36129311C1.0061012584155727298861043120013571514iPS:36129711C1.0071022594165737308871044120113581515iPS:36130111C1.0081032604175747318881045120213591516iPS:35970311C1.0091042614185757328891046120313601517iPS:36130511C1.0101052624195767338901047120413611518iPS:36131213H12.0021062634205777348911048120513621519iPS:35974413H12.0031072644215787358921049120613631520iPS:36131913H12.0041082654225797368931050120713641521iPS:35973713H12.0051092664235807378941051120813651522iPS:36132613H12.0061102674245817388951052120913661523iPS:36133012H11.0021112684255827398961053121013671524iPS:36133712H11.0031122694265837408971054121113681525iPS:36134412H11.0041132704275847418981055121213691526iPS:36135112H11.0051142714285857428991056121313701527iPS:36135812H11.0061152724295867439001057121413711528iPS:36136512H11.0071162734305877449011058121513721529iPS:36137212H11.0081172744315887459021059121613731530iPS:36137912H11.0091182754325897469031060121713741531iPS:36138312H11.0101192764335907479041061121813751532iPS:36138712H11.0111202774345917489051062121913761533iPS:36139112H11.0121212784355927499061063122013771534iPS:36139512H11.0131222794365937509071064122113781535iPS:36140212H11.0141232804375947519081065122213791536iPS:3614062C2.005.0011242814385957529091066122313801537iPS:3614122C2.005.0021252824395967539101067122413811538iPS:3614182C2.005.0031262834405977549111068122513821539iPS:3614242C2.005.0041272844415987559121069122613831540iPS:3614302C2.005.0051282854425997569131070122713841541iPS:3614362C2.005.0061292864436007579141071122813851542iPS:3614422C2.005.0071302874446017589151072122913861543iPS:3614482C2.005.0081312884456027599161073123013871544iPS:3614542C2.005.0091322894466037609171074123113881545iPS:3614602C2.005.0101332904476047619181075123213891546iPS:3614662C2.005.0111342914486057629191076123313901547iPS:3614722C2.005.0121352924496067639201077123413911548iPS:3614782C2.005.0131362934506077649211078123513921549iPS:3614852C2.005.0141372944516087659221079123613931550iPS:36184518F2.0131382954526097669231080123713941551iPS:3618516H1.0091392964536107679241081123813951552iPS:3618552C2.005.0151402974546117689251082123913961553iPS:3360675G12.0061412984556127699261083124013971554iPS:33616917B11.0021422994566137709271084124113981555iPS:3611275G12.006.0011433004576147719281085124213991556iPS:3611365G12.006.0021443014586157729291086124314001557iPS:3611405G12.006.0031453024596167739301087124414011558iPS:3599195G12.006.0041463034606177749311088124514021559iPS:3611445G12.006.0051473044616187759321089124614031560iPS:3611515G12.006.0061483054626197769331090124714041561iPS:36149117B11.002.0011493064636207779341091124814051562iPS:36149917B11.002.0021503074646217789351092124914061563iPS:36150317B11.002.0031513084656227799361093125014071564iPS:36150717B11.002.0041523094666237809371094125114081565iPS:36151417B11.002.0051533104676247819381095125214091566iPS:36058217B11.002.0061543114686257829391096125314101567iPS:36151817B11.002.0071553124696267839401097125414111568iPS:36057017B11.002.0081563134706277849411098125514121569iPS:3620515G12.005.0011573144716287859421099125614131570 Table 4. Variable Light (VL) Region Amino Acid Sequences of Exemplary Anti-GIPR AntibodiesIdentifierConstructVLSEQ ID NO:iPS:3361752C2.005QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNGPVFGGGTKLTVLG1iPS:3359144B1DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR2iPS:3359386H1DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR3iPS:3359412F11DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKR4iPS:3359705C2DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR5iPS:33597813H12DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR6iPS:33598611C1DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR7iPS:33599412H11DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR8iPS:33602418E3EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR9iPS:3360412G10_LC1EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKR10iPS:3360774H9.004DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGPGTKVDVKR11iPS:3360886A5.004DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKR12iPS:33609917H11.004DIQMTQSPSSVSASVGDRVTITCRASQGLIIWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPPTFGQGTKVEIKR13iPS:35962117H11.004.001DIQMTQSPSSVSASVGDRVTITCRASQGLIIWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPPTFGQGTKVEIKR14iPS:3597814H9.004.001DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKR15iPS:3609294H9.004.002DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKR16iPS:3609364H9.004.003DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKR17iPS:3609434H9.004.004DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGPGTKVDVKR18iPS:3609494H9.004.005DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKR19iPS:3597614H9.004.006DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKR20iPS:3609554B1.010DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR21iPS:3609624B1.011DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR22iPS:3609684B1.012DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR23iPS:3609744B1.013DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR24iPS:3609784B1.014DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR25iPS:3597854B1.015DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR26iPS:3609824B1.016DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR27iPS:33592218F2DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR28iPS:36098618F2.002DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR29iPS:36099518F2.003DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR30iPS:36099918F2.004DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR31iPS:36100518F2.005DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR32iPS:36100918F2.006DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR33iPS:36101318F2.007DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR34iPS:36101718F2.008DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR35iPS:36102118F2.009DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR36iPS:36102818F2.010DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR37iPS:36053518F2.011DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR38iPS:36103518F2.012DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR39iPS:3599402F11.002DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKR40iPS:3610392F11.003DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKR41iPS:3610432F11.004DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKR42iPS:3610492F11.005DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKR43iPS:3610552F11.006DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKR44iPS:3610592F11.007DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKR45iPS:3610632F11.008DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKR46iPS:3599492F11.009DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKR47iPS:3599562F11.010DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKR48iPS:3598656H1.002DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR49iPS:3598696H1.003DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR50iPS:3598736H1.004DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR51iPS:3598776H1.005DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR52iPS:3610676H1.006DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR53iPS:3610716H1.007DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR54iPS:3610756H1.008DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKR55iPS:3610796A5.004.001DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKR56iPS:3610856A5.004.002DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKR57iPS:3610916A5.004.003DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKR58iPS:3610956A5.004.004DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKR59iPS:3611016A5.004.005DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKR60iPS:3611056A5.004.006DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKR61iPS:3611096A5.004.007DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKR62iPS:3611136A5.004.008DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKR63iPS:3611206A5.004.009DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKR64iPS:3598966A5.004.010DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGQGTKVDIKR65iPS:3598906A5.004.011DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGQGTKVDIKR66iPS:3595672A11.002EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKR67iPS:3359652A11.003EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKR68iPS:3611582A11.004EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKR69iPS:3611652A11.005EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKR70iPS:3611722G10_LC1.003EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKR71iPS:3611782G10_LC1.004EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKR72iPS:3611852G10_LC1.005EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKR73iPS:3611922G10_LC1.006EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKR74iPS:3596092G10_LC1.007EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNFPLTFGGGTKVEIKR75iPS:3596152G10_LC1.008EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNYPLTFGGGTKVEIKR76iPS:3611962G10_LC1.009EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNWPLTFGGGTKVEIKR77iPS:3612022G10_LC1.010EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNWPLTFGGGTKVEIKR78iPS:35964418E3.002EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR79iPS:36120618E3.003EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR80iPS:35962818E3.004EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR81iPS:35963718E3.005EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR82iPS:36121018E3.006EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR83iPS:36121418E3.007EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR84iPS:36121818E3.008EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKR85iPS:3612225C2.006DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR86iPS:3612295C2.007DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR87iPS:3612365C2.008DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR88iPS:3596855C2.009DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR89iPS:3612405C2.010DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR90iPS:3612475C2.011DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR91iPS:3612545C2.012DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR92iPS:3612615C2.013DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR93iPS:3612685C2.014DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR94iPS:3596695C2.015DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR95iPS:3596785C2.016DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR96iPS:36127511C1.002DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR97iPS:36128211C1.003DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR98iPS:36128911C1.004DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR99iPS:35971211C1.005DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR100iPS:36129311C1.006DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR101iPS:36129711C1.007DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR102iPS:36130111C1.008DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR103iPS:35970311C1.009DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPKLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR104iPS:36130511C1.010DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR105iPS:36131213H12.002DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR106iPS:35974413H12.003DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR107iPS:36131913H12.004DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR108iPS:35973713H12.005DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR109iPS:36132613H12.006DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKR110iPS:36133012H11.002DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR111iPS:36133712H11.003DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR112iPS:36134412H11.004DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR113iPS:36135112H11.005DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR114iPS:36135812H11.006DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR115iPS:36136512H11.007DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR116iPS:36137212H11.008DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR117iPS:36137912H11.009DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR118iPS:36138312H11.010DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR119iPS:36138712H11.011DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR120iPS:36139112H11.012DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR121iPS:36139512H11.013DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPKLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR122iPS:36140212H11.014DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPKLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKR123iPS:3614062C2.005.001QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLSGPVFGGGTKLTVLG124iPS:3614122C2.005.002QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLQGPVFGGGTKLTVLG125iPS:3614182C2.005.003QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLSGPVFGGGTKLTVLG126iPS:3614242C2.005.004QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLQGPVFGGGTKLTVLG127iPS:3614302C2.005.005QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNGPVFGGGTKLTVLG128iPS:3614362C2.005.006QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNGPVFGGGTKLTVLG129iPS:3614422C2.005.007QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLNGPVFGGGTKLTVLG130iPS:3614482C2.005.008QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLQGPVFGGGTKLTVLG131iPS:3614542C2.005.009QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLSGPVFGGGTKLTVLG132iPS:3614602C2.005.010QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNAPVFGGGTKLTVLG133iPS:3614662C2.005.011QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLNGPVFGGGTKLTVLG134iPS:3614722C2.005.012QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLNAPVFGGGTKLTVLG135iPS:3614782C2.005.013QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLNAPVFGGGTKLTVLG136iPS:3614852C2.005.014QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLSGPVFGGGTKLTVLG137iPS:36184518F2.013DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR138iPS:3618516H1.009DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKR139iPS:3618552C2.005.015QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLSGPVFGGGTKLTVLG140iPS:3360675G12.006DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEITR141iPS:33616917B11.002QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYEQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG142iPS:3611275G12.006.001DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKR143iPS:3611365G12.006.002DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKR144iPS:3611405G12.006.003DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEITR145iPS:3599195G12.006.004DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKR146iPS:3611445G12.006.005DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKR147iPS:3611515G12.006.006DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKR148iPS:36149117B11.002.001QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG149iPS:36149917B11.002.002QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG150iPS:36150317B11.002.003QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYEQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG151iPS:36150717B11.002.004QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTFESSLSAVVFGGGTKLTVLG152iPS:36151417B11.002.005QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG153iPS:36058217B11.002.006QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG154iPS:36151817B11.002.007QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG155iPS:36057017B11.002.008QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTFESSLSAVVFGGGTKLTVLG156iPS:3620515G12.005.001DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLLSFGQGTKLEIKR157 Table 5. Variable Heavy (VH) Region Amino Acid Sequences of Exemplary Anti-GIPR AntibodiesIdentifierConstructVHSEQ ID NO:iPS:3361752C2.005QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS158iPS:3359144B1QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADSVKGRFTISRDNSKNTLYLHMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS159iPS:3359386H1QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS160iPS:3359412F11QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS161iPS:3359705C2QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS162iPS:33597813H12QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRFTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS163iPS:33598611C1QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSS164iPS:33599412H11QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSS165iPS:33602418E3QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS166iPS:3360412G10_LC1QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS167iPS:3360774H9.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS168iPS:3360886A5.004QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDGNNKYYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSS169iPS:33609917H11.004QVQLQESGPGLVKPSETLSLTCTVSQGSISSYYWSWIRQPAGKGLEWIGRIYTSGSTNYNPSLKSRVTMSIDTSKNQFSLKLNSVTAADTAVYYCARDVAVAGFDYWGQGTLVTVSS170iPS:35962117H11.004.001QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPAGKGLEWIGRIYTSGSTNYNPSLKSRVTMSIDTSKNQFSLKLNSVTAADTAVYYCARDVAVAGFDYWGQGTLVTVSS171iPS:3597814H9.004.001QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS172iPS:3609294H9.004.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS173iPS:3609364H9.004.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS174iPS:3609434H9.004.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS175iPS:3609494H9.004.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS176iPS:3597614H9.004.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSS177iPS:3609554B1.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS178iPS:3609624B1.011QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS179iPS:3609684B1.012QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS180iPS:3609744B1.013QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADSVKGRFTISRDNSKNTLYLHMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS181iPS:3609784B1.014QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADAVKGRFTISRDNSKNTLYLHMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS182iPS:3597854B1.015QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDRTIFGVVLGDYWGQGTLVTVSS183iPS:3609824B1.016QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS184iPS:33592218F2QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADSVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS185iPS:36098618F2.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS186iPS:36099518F2.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS187iPS:36099918F2.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS188iPS:36100518F2.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS189iPS:36100918F2.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS190iPS:36101318F2.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS191iPS:36101718F2.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS192iPS:36102118F2.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS193iPS:36102818F2.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADSVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS194iPS:36053518F2.011QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLGDYWGQGTLVTVSS195iPS:36103518F2.012QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVVLGDYWGQGTLVTVSS196iPS:3599402F11.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS197iPS:3610392F11.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS198iPS:3610432F11.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS199iPS:3610492F11.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS200iPS:3610552F11.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS201iPS:3610592F11.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS202iPS:3610632F11.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS203iPS:3599492F11.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS204iPS:3599562F11.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSS205iPS:3598656H1.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS206iPS:3598696H1.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSS207iPS:3598736H1.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS208iPS:3598776H1.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSS209iPS:3610676H1.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS210iPS:3610716H1.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS211iPS:3610756H1.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSS212iPS:3610796A5.004.001QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS213iPS:3610856A5.004.002QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS214iPS:3610916A5.004.003QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSS215iPS:3610956A5.004.004QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS216iPS:3611016A5.004.005QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSS217iPS:3611056A5.004.006QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSS218iPS:3611096A5.004.007QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS219iPS:3611136A5.004.008QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDGNNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS220iPS:3611206A5.004.009QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS221iPS:3598966A5.004.010QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSS222iPS:3598906A5.004.011QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSS223iPS:3595672A11.002QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYEDAVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSS224iPS:3359652A11.003QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYEDSVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSS225iPS:3611582A11.004QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYEDAVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSS226iPS:3611652A11.005QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYEDSVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSS227iPS:3611722G10_LC1.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS228iPS:3611782G10_LC1.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS229iPS:3611852G10_LC1.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDGSDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS230iPS:3611922G10_LC1.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS231iPS:3596092G10_LC1.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS232iPS:3596152G10_LC1.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS233iPS:3611962G10_LC1.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS234iPS:3612022G10_LC1.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS235iPS:35964418E3.002QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS236iPS:36120618E3.003QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS237iPS:35962818E3.004QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS238iPS:35963718E3.005QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS239iPS:36121018E3.006QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS240iPS:36121418E3.007QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS241iPS:36121818E3.008QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSS242iPS:3612225C2.006QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS243iPS:3612295C2.007QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS244iPS:3612365C2.008QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS245iPS:3596855C2.009QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS246iPS:3612405C2.010QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS247iPS:3612475C2.011QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS248iPS:3612545C2.012QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS249iPS:3612615C2.013QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS250iPS:3612685C2.014QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS251iPS:3596695C2.015QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRVTMTRDTSISTAYMELNSLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS252iPS:3596785C2.016QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELNSLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS253iPS:36127511C1.002QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSS254iPS:36128211C1.003QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSS255iPS:36128911C1.004QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSS256iPS:35971211C1.005QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSS257iPS:36129311C1.006QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSS258iPS:36129711C1.007QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSS259iPS:36130111C1.008QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSS260iPS:35970311C1.009QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSSLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSS261iPS:36130511C1.010QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSS262iPS:36131213H12.002QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS263iPS:35974413H12.003QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRFTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS264iPS:36131913H12.004QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS265iPS:35973713H12.005QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS266iPS:36132613H12.006QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSS267iPS:36133012H11.002QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS268iPS:36133712H11.003QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS269iPS:36134412H11.004QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSS270iPS:36135112H11.005QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS271iPS:36135812H11.006QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS272iPS:36136512H11.007QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSS273iPS:36137212H11.008QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSS274iPS:36137912H11.009QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS275iPS:36138312H11.010QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS276iPS:36138712H11.011QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS277iPS:36139112H11.012QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS278iPS:36139512H11.013QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSSLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS279iPS:36140212H11.014QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSSLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSS280iPS:3614062C2.005.001QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS281iPS:3614122C2.005.002QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS282iPS:3614182C2.005.003QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS283iPS:3614242C2.005.004QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS284iPS:3614302C2.005.005QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS285iPS:3614362C2.005.006QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS286iPS:3614422C2.005.007QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS287iPS:3614482C2.005.008QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS288iPS:3614542C2.005.009QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS289iPS:3614602C2.005.010QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS290iPS:3614662C2.005.011QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS291iPS:3614722C2.005.012QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS292iPS:3614782C2.005.013QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARGGDYVFGTYRPHYYYGMDVWGQGTTVTVSS293iPS:3614852C2.005.014QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVFGTYRPHYYYGMDVWGQGTTVTVSS294iPS:36184518F2.013QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLGDYWGQGTLVTVSS295iPS:3618516H1.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSS296iPS:3618552C2.005.015QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSS297iPS:3360675G12.006QVQLVESGGGVVQPGRSLRLSCTASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDGSNKFHADSVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTKVTVSS298iPS:33616917B11.002QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSQDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS299iPS:3611275G12.006.001QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDASNKFHADAVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTKVTVSS300iPS:3611365G12.006.002QVQLVESGGGVVQPGRSLRLSCTASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDASNKFHADAVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTKVTVSS301iPS:3611405G12.006.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDASNKFHADAVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTKVTVSS302iPS:3599195G12.006.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDASNKFHADAVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTLVTVSS303iPS:3611445G12.006.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDASNKFHADSVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTKVTVSS304iPS:3611515G12.006.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDGSNKFHADAVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTKVTVSS305iPS:36149117B11.002.001QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGGTGYAQKFQGRVTMTRDTSISTAYMELSSLRSQDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS306iPS:36149917B11.002.002QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSQDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS307iPS:36150317B11.002.003QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGGTGYAQKFQGRVTMTRDTSISTAYMELSSLRSQDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS308iPS:36150717B11.002.004QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGGTGYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS309iPS:36151417B11.002.005QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGGTGYAQKFQGRVTMTRDTSISTAYMELSSLRSQDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS310iPS:36058217B11.002.006QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARGGDYVWGSYRPYYYYYGMDVWGQGTTVTVSS311iPS:36151817B11.002.007QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGGTGYAQKFQGRVTMTRDTSISTAYMELSSLRSQDTAVYYCARGGDYVFGSYRPYYYYYGMDVWGQGTTVTVSS312iPS:36057017B11.002.008QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGGTGYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARGGDYVFGSYRPYYYYYGMDVWGQGTTVTVSS313iPS:3620515G12.005.001QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDASNKFHADAVKGRFTISRDNSKNTLYLQMNSLRAEDSAMYFCARGKVAGMPEAFEIWGQGTLVTVSS314Table 6. CDRL1, CDRL2, and CDRL3 Amino Acid Sequences of Exemplary Anti-GIPR AntibodiesIdentifierConstructCDRL1CDRL2CDRL3iPS:3361752C2.005SGSSSNIGSNTVNSEQ ID NO: 629TNNQRPSSEQ ID NO: 786ATFDDSLNGPVSEQ ID NO: 943iPS:3359144B1RASQDIRDYLGSEQ ID NO: 630GASSLQSSEQ ID NO: 787LQHNNYPFTSEQ ID NO: 944iPS:3359386H1RASQDIRDYLGSEQ ID NO: 631GASSLQSSEQ ID NO: 788LQHNNYPFTSEQ ID NO: 945iPS:3359412F11QASQDISNYLNSEQ ID NO: 632DASNLETSEQ ID NO: 789QQYDILLTSEQ ID NO: 946iPS:3359705C2KSSQSVLSSSNNKNYIASEQ ID NO: 633WASTRESSEQ ID NO: 790QQYYSTPWTSEQ ID NO: 947iPS:33597813H12KSSQSVLSSSNNKNYIASEQ ID NO: 634WASTRESSEQ ID NO: 791QQYYSTPWTSEQ ID NO: 948iPS:33598611C1KSSQSVLSSSNNKNYLASEQ ID NO: 635WTSTRDSSEQ ID NO: 792QQYYRTPWTSEQ ID NO: 949iPS:33599412H11KSSQSVLSSSNNKNYLASEQ ID NO: 636WTSTRDSSEQ ID NO: 793QQYYRTPWTSEQ ID NO: 950iPS:33602418E3RASQSISYSYLASEQ ID NO: 637GASSRATSEQ ID NO: 794QQYGSSPLTSEQ ID NO: 951iPS:3360412G10_LC1RASQSVSSNLASEQ ID NO: 638GAATRATSEQ ID NO: 795QQYNNWPLTSEQ ID NO: 952iPS:3360774H9.004RASQGIRNELGSEQ ID NO: 639GASSLQSSEQ ID NO: 796LQHNSYPFTSEQ ID NO: 953iPS:3360886A5.004QASQDITNYLNSEQ ID NO: 640DASNLEPSEQ ID NO: 797QQYDDLFTSEQ ID NO: 954iPS:33609917H11.004RASQGLIIWLASEQ ID NO: 641AASSLQSSEQ ID NO: 798QQTNSFPPTSEQ ID NO: 955iPS:35962117H11.004.001RASQGLIIWLASEQ ID NO: 642AASSLQSSEQ ID NO: 799QQTNSFPPTSEQ ID NO: 956iPS:3597814H9.004.001RASQGIRNELGSEQ ID NO: 643GASSLQSSEQ ID NO: 800LQHNSYPFTSEQ ID NO: 957iPS:3609294H9.004.002RASQGIRNELGSEQ ID NO: 644GASSLQSSEQ ID NO: 801LQHNSYPFTSEQ ID NO: 958iPS:3609364H9.004.003RASQGIRNELGSEQ ID NO: 645GASSLQSSEQ ID NO: 802LQHNSYPFTSEQ ID NO: 959iPS:3609434H9.004.004RASQGIRNELGSEQ ID NO: 646GASSLQSSEQ ID NO: 803LQHNSYPFTSEQ ID NO: 960iPS:3609494H9.004.005RASQGIRNELGSEQ ID NO: 647GASSLQSSEQ ID NO: 804LQHNSYPFTSEQ ID NO: 961iPS:3597614H9.004.006RASQGIRNELGSEQ ID NO: 648GASSLQSSEQ ID NO: 805LQHNSYPFTSEQ ID NO: 962iPS:3609554B1.010RASQDIRDYLGSEQ ID NO: 649GASSLQSSEQ ID NO: 806LQHNNYPFTSEQ ID NO: 963iPS:3609624B1.011RASQDIRDYLGSEQ ID NO: 650GASSLQSSEQ ID NO: 807LQHNNYPFTSEQ ID NO: 964iPS:3609684B1.012RASQDIRDYLGSEQ ID NO: 651GASSLQSSEQ ID NO: 808LQHNNYPFTSEQ ID NO: 965iPS:3609744B1.013RASQDIRDYLGSEQ ID NO: 652GASSLQSSEQ ID NO: 809LQHNNYPFTSEQ ID NO: 966iPS:3609784B1.014RASQDIRDYLGSEQ ID NO: 653GASSLQSSEQ ID NO: 810LQHNNYPFTSEQ ID NO: 967iPS:3597854B1.015RASQDIRDYLGSEQ ID NO: 654GASSLQSSEQ ID NO: 811LQHNNYPFTSEQ ID NO: 968iPS:3609824B1.016RASQDIRDYLGSEQ ID NO: 655GASSLQSSEQ ID NO: 812LQHNNYPFTSEQ ID NO: 969iPS:33592218F2RASQDLRNYLGSEQ ID NO: 656GASSLQSSEQ ID NO: 813LQHNNYPFTSEQ ID NO: 970iPS:36098618F2.002RASQDLRNYLGSEQ ID NO: 657GASSLQSSEQ ID NO: 814LQHNNYPFTSEQ ID NO: 971iPS:36099518F2.003RASQDLRNYLGSEQ ID NO: 658GASSLQSSEQ ID NO: 815LQHNNYPFTSEQ ID NO: 972iPS:36099918F2.004RASQDLRNYLGSEQ ID NO: 659GASSLQSSEQ ID NO: 816LQHNNYPFTSEQ ID NO: 973iPS:36100518F2.005RASQDLRNYLGSEQ ID NO: 660GASSLQSSEQ ID NO: 817LQHNNYPFTSEQ ID NO: 974iPS:36100918F2.006RASQDLRNYLGSEQ ID NO: 661GASSLQSSEQ ID NO: 818LQHNNYPFTSEQ ID NO: 975iPS:36101318F2.007RASQDLRNYLGSEQ ID NO: 662GASSLQSSEQ ID NO: 819LQHNNYPFTSEQ ID NO: 976iPS:36101718F2.008RASQDLRNYLGSEQ ID NO: 663GASSLQSSEQ ID NO: 820LQHNNYPFTSEQ ID NO: 977iPS:36102118F2.009RASQDLRNYLGSEQ ID NO: 664GASSLQSSEQ ID NO: 821LQHNNYPFTSEQ ID NO: 978iPS:36102818F2.010RASQDLRNYLGSEQ ID NO: 665GASSLQSSEQ ID NO: 822LQHNNYPFTSEQ ID NO: 979iPS:36053518F2.011RASQDLRNYLGSEQ ID NO: 666GASSLQSSEQ ID NO: 823LQHNNYPFTSEQ ID NO: 980iPS:36103518F2.012RASQDLRNYLGSEQ ID NO: 667GASSLQSSEQ ID NO: 824LQHNNYPFTSEQ ID NO: 981iPS:3599402F11.002QASQDISNYLNSEQ ID NO: 668DASNLETSEQ ID NO: 825QQYDILLTSEQ ID NO: 982iPS:3610392F11.003QASQDISNYLNSEQ ID NO: 669DASNLETSEQ ID NO: 826QQYDILLTSEQ ID NO: 983iPS:3610432F11.004QASQDISNYLNSEQ ID NO: 670DASNLETSEQ ID NO: 827QQYDILLTSEQ ID NO: 984iPS:3610492F11.005QASQDISNYLNSEQ ID NO: 671DASNLETSEQ ID NO: 828QQYDILLTSEQ ID NO: 985iPS:3610552F11.006QASQDISNYLNSEQ ID NO: 672DASNLETSEQ ID NO: 829QQYDILLTSEQ ID NO: 986iPS:3610592F11.007QASQDISNYLNSEQ ID NO: 673DASNLETSEQ ID NO: 830QQYDILLTSEQ ID NO: 987iPS:3610632F11.008QASQDISNYLNSEQ ID NO: 674DASNLETSEQ ID NO: 831QQYDILLTSEQ ID NO: 988iPS:3599492F11.009QASQDISNYLNSEQ ID NO: 675DASNLETSEQ ID NO: 832QQYDILLTSEQ ID NO: 989iPS:3599562F11.010QASQDISNYLNSEQ ID NO: 676DASNLETSEQ ID NO: 833QQYDILLTSEQ ID NO: 990iPS:3598656H1.002RASQDIRDYLGSEQ ID NO: 677GASSLQSSEQ ID NO: 834LQHNNYPFTSEQ ID NO: 991iPS:3598696H1.003RASQDIRDYLGSEQ ID NO: 678GASSLQSSEQ ID NO: 835LQHNNYPFTSEQ ID NO: 992iPS:3598736H1.004RASQDIRDYLGSEQ ID NO: 679GASSLQSSEQ ID NO: 836LQHNNYPFTSEQ ID NO: 993iPS:3598776H1.005RASQDIRDYLGSEQ ID NO: 680GASSLQSSEQ ID NO: 837LQHNNYPFTSEQ ID NO: 994iPS:3610676H1.006RASQDIRDYLGSEQ ID NO: 681GASSLQSSEQ ID NO: 838LQHNNYPFTSEQ ID NO: 995iPS:3610716H1.007RASQDIRDYLGSEQ ID NO: 682GASSLQSSEQ ID NO: 839LQHNNYPFTSEQ ID NO: 996iPS:3610756H1.008RASQDIRDYLGSEQ ID NO: 683GASSLQSSEQ ID NO: 840LQHNNYPFTSEQ ID NO: 997iPS:3610796A5.004.001QASQDITNYLNSEQ ID NO: 684DASNLEPSEQ ID NO: 841QQYDDLFTSEQ ID NO: 998iPS:3610856A5.004.002QASQDITNYLNSEQ ID NO: 685DASNLEPSEQ ID NO: 842QQYDDLFTSEQ ID NO: 999iPS:3610916A5.004.003QASQDITNYLNSEQ ID NO: 686DASNLEPSEQ ID NO: 843QQYDDLFTSEQ ID NO: 1000iPS:3610956A5.004.004QASQDITNYLNSEQ ID NO: 687DASNLEPSEQ ID NO: 844QQYDDLFTSEQ ID NO: 1001iPS:3611016A5.004.005QASQDITNYLNSEQ ID NO: 688DASNLEPSEQ ID NO: 845QQYDDLFTSEQ ID NO: 1002iPS:3611056A5.004.006QASQDITNYLNSEQ ID NO: 689DASNLEPSEQ ID NO: 846QQYDDLFTSEQ ID NO: 1003iPS:3611096A5.004.007QASQDITNYLNSEQ ID NO: 690DASNLEPSEQ ID NO: 847QQYDDLFTSEQ ID NO: 1004iPS:3611136A5.004.008QASQDITNYLNSEQ ID NO: 691DASNLEPSEQ ID NO: 848QQYDDLFTSEQ ID NO: 1005iPS:3611206A5.004.009QASQDITNYLNSEQ ID NO: 692DASNLEPSEQ ID NO: 849QQYDDLFTSEQ ID NO: 1006iPS:3598966A5.004.010QASQDITNYLNSEQ ID NO: 693DASNLEPSEQ ID NO: 850QQYDDLFTSEQ ID NO: 1007iPS:3598906A5.004.011QASQDITNYLNSEQ ID NO: 694DASNLEPSEQ ID NO: 851QQYDDLFTSEQ ID NO: 1008iPS:3595672A11.002RASQIFTSTYLASEQ ID NO: 695GASSRATSEQ ID NO: 852QQYGSSPRSEQ ID NO: 1009iPS:3359652A11.003RASQIFTSTYLASEQ ID NO: 696GASSRATSEQ ID NO: 853QQYGSSPRSEQ ID NO: 1010iPS:3611582A11.004RASQIFTSTYLASEQ ID NO: 697GASSRATSEQ ID NO: 854QQYGSSPRSEQ ID NO: 1011iPS:3611652A11.005RASQIFTSTYLASEQ ID NO: 698GASSRATSEQ ID NO: 855QQYGSSPRSEQ ID NO: 1012iPS:3611722G10_LC1.003RASQSVSSNLASEQ ID NO: 699GAATRATSEQ ID NO: 856QQYNNWPLTSEQ ID NO: 1013iPS:3611782G10_LC1.004RASQSVSSNLASEQ ID NO: 700GAATRATSEQ ID NO: 857QQYNNWPLTSEQ ID NO: 1014iPS:3611852G10_LC1.005RASQSVSSNLASEQ ID NO: 701GAATRATSEQ ID NO: 858QQYNNWPLTSEQ ID NO: 1015iPS:3611922G10_LC1.006RASQSVSSNLASEQ ID NO: 702GAATRATSEQ ID NO: 859QQYNNWPLTSEQ ID NO: 1016iPS:3596092G10_LC1.007RASQSVSSNLASEQ ID NO: 703GAATRATSEQ ID NO: 860QQYNNFPLTSEQ ID NO: 1017iPS:3596152G10_LC1.008RASQSVSSNLASEQ ID NO: 704GAATRATSEQ ID NO: 861QQYNNYPLTSEQ ID NO: 1018iPS:3611962G10_LC1.009RASQSVSSNLASEQ ID NO: 705GAATRATSEQ ID NO: 862QQYNNWPLTSEQ ID NO: 1019iPS:3612022G10_LC1.010RASQSVSSNLASEQ ID NO: 706GAATRATSEQ ID NO: 863QQYNNWPLTSEQ ID NO: 1020iPS:35964418E3.002RASQSISYSYLASEQ ID NO: 707GASSRATSEQ ID NO: 864QQYGSSPLTSEQ ID NO: 1021iPS:36120618E3.003RASQSISYSYLASEQ ID NO: 708GASSRATSEQ ID NO: 865QQYGSSPLTSEQ ID NO: 1022iPS:35962818E3.004RASQSISYSYLASEQ ID NO: 709GASSRATSEQ ID NO: 866QQYGSSPLTSEQ ID NO: 1023iPS:35963718E3.005RASQSISYSYLASEQ ID NO: 710GASSRATSEQ ID NO: 867QQYGSSPLTSEQ ID NO: 1024iPS:36121018E3.006RASQSISYSYLASEQ ID NO: 711GASSRATSEQ ID NO: 868QQYGSSPLTSEQ ID NO: 1025iPS:36121418E3.007RASQSISYSYLASEQ ID NO: 712GASSRATSEQ ID NO: 869QQYGSSPLTSEQ ID NO: 1026iPS:36121818E3.008RASQSISYSYLASEQ ID NO: 713GASSRATSEQ ID NO: 870QQYGSSPLTSEQ ID NO: 1027iPS:3612225C2.006KSSQSVLSSSNNKNYIASEQ ID NO: 714WASTRESSEQ ID NO: 871QQYYSTPWTSEQ ID NO: 1028iPS:3612295C2.007KSSQSVLSSSNNKNYIASEQ ID NO: 715WASTRESSEQ ID NO: 872QQYYSTPWTSEQ ID NO: 1029iPS:3612365C2.008KSSQSVLSSSNNKNYIASEQ ID NO: 716WASTRESSEQ ID NO: 873QQYYSTPWTSEQ ID NO: 1030iPS:3596855C2.009KSSQSVLSSSNNKNYIASEQ ID NO: 717WASTRESSEQ ID NO: 874QQYYSTPWTSEQ ID NO: 1031iPS:3612405C2.010KSSQSVLSSSNNKNYIASEQ ID NO: 718WASTRESSEQ ID NO: 875QQYYSTPWTSEQ ID NO: 1032iPS:3612475C2.011KSSQSVLSSSNNKNYIASEQ ID NO: 719WASTRESSEQ ID NO: 876QQYYSTPWTSEQ ID NO: 1033iPS:3612545C2.012KSSQSVLSSSNNKNYIASEQ ID NO: 720WASTRESSEQ ID NO: 877QQYYSTPWTSEQ ID NO: 1034iPS:3612615C2.013KSSQSVLSSSNNKNYIASEQ ID NO: 721WASTRESSEQ ID NO: 878QQYYSTPWTSEQ ID NO: 1035iPS:3612685C2.014KSSQSVLSSSNNKNYIASEQ ID NO: 722WASTRESSEQ ID NO: 879QQYYSTPWTSEQ ID NO: 1036iPS:3596695C2.015KSSQSVLSSSNNKNYIASEQ ID NO: 723WASTRESSEQ ID NO: 880QQYYSTPWTSEQ ID NO: 1037iPS:3596785C2.016KSSQSVLSSSNNKNYIASEQ ID NO: 724WASTRESSEQ ID NO: 881QQYYSTPWTSEQ ID NO: 1038iPS:36127511C1.002KSSQSVLSSSNNKNYLASEQ ID NO: 725WTSTRESSEQ ID NO: 882QQYYRTPWTSEQ ID NO: 1039iPS:36128211C1.003KSSQSVLSSSNNKNYLASEQ ID NO: 726WTSTRESSEQ ID NO: 883QQYYRTPWTSEQ ID NO: 1040iPS:36128911C1.004KSSQSVLSSSNNKNYLASEQ ID NO: 727WTSTRDSSEQ ID NO: 884QQYYRTPWTSEQ ID NO: 1041iPS:35971211C1.005KSSQSVLSSSNNKNYLASEQ ID NO: 728WTSTRESSEQ ID NO: 885QQYYRTPWTSEQ ID NO: 1042iPS:36129311C1.006KSSQSVLSSSNNKNYLASEQ ID NO: 729WTSTRESSEQ ID NO: 886QQYYRTPWTSEQ ID NO: 1043iPS:36129711C1.007KSSQSVLSSSNNKNYLASEQ ID NO: 730WTSTRDSSEQ ID NO: 887QQYYRTPWTSEQ ID NO: 1044iPS:36130111C1.008KSSQSVLSSSNNKNYLASEQ ID NO: 731WTSTRDSSEQ ID NO: 888QQYYRTPWTSEQ ID NO: 1045iPS:35970311C1.009KSSQSVLSSSNNKNYLASEQ ID NO: 732WTSTRESSEQ ID NO: 889QQYYRTPWTSEQ ID NO: 1046iPS:36130511C1.010KSSQSVLSSSNNKNYLASEQ ID NO: 733WTSTRESSEQ ID NO: 890QQYYRTPWTSEQ ID NO: 1047iPS:36131213H12.002KSSQSVLSSSNNKNYIASEQ ID NO: 734WASTRESSEQ ID NO: 891QQYYSTPWTSEQ ID NO: 1048iPS:35974413H12.003KSSQSVLSSSNNKNYIASEQ ID NO: 735WASTRESSEQ ID NO: 892QQYYSTPWTSEQ ID NO: 1049iPS:36131913H12.004KSSQSVLSSSNNKNYIASEQ ID NO: 736WASTRESSEQ ID NO: 893QQYYSTPWTSEQ ID NO: 1050iPS:35973713H12.005KSSQSVLSSSNNKNYIASEQ ID NO: 737WASTRESSEQ ID NO: 894QQYYSTPWTSEQ ID NO: 1051iPS:36132613H12.006KSSQSVLSSSNNKNYIASEQ ID NO: 738WASTRESSEQ ID NO: 895QQYYSTPWTSEQ ID NO: 1052iPS:36133012H11.002KSSQSVLSSSNNKNYLASEQ ID NO: 739WTSTRDSSEQ ID NO: 896QQYYRTPWTSEQ ID NO: 1053iPS:36133712H11.003KSSQSVLSSSNNKNYLASEQ ID NO: 740WTSTRDSSEQ ID NO: 897QQYYRTPWTSEQ ID NO: 1054iPS:36134412H11.004KSSQSVLSSSNNKNYLASEQ ID NO: 741WTSTRDSSEQ ID NO: 898QQYYRTPWTSEQ ID NO: 1055iPS:36135112H11.005KSSQSVLSSSNNKNYLASEQ ID NO: 742WTSTRDSSEQ ID NO: 899QQYYRTPWTSEQ ID NO: 1056iPS:36135812H11.006KSSQSVLSSSNNKNYLASEQ ID NO: 743WTSTRDSSEQ ID NO: 900QQYYRTPWTSEQ ID NO: 1057iPS:36136512H11.007KSSQSVLSSSNNKNYLASEQ ID NO: 744WTSTRDSSEQ ID NO: 901QQYYRTPWTSEQ ID NO: 1058iPS:36137212H11.008KSSQSVLSSSNNKNYLASEQ ID NO: 745WTSTRDSSEQ ID NO: 902QQYYRTPWTSEQ ID NO: 1059iPS:36137912H11.009KSSQSVLSSSNNKNYLASEQ ID NO: 746WTSTRESSEQ ID NO: 903QQYYRTPWTSEQ ID NO: 1060iPS:36138312H11.010KSSQSVLSSSNNKNYLASEQ ID NO: 747WTSTRESSEQ ID NO: 904QQYYRTPWTSEQ ID NO: 1061iPS:36138712H11.011KSSQSVLSSSNNKNYLASEQ ID NO: 748WTSTRESSEQ ID NO: 905QQYYRTPWTSEQ ID NO: 1062iPS:36139112H11.012KSSQSVLSSSNNKNYLASEQ ID NO: 749WTSTRESSEQ ID NO: 906QQYYRTPWTSEQ ID NO: 1063iPS:36139512H11.013KSSQSVLSSSNNKNYLASEQ ID NO: 750WTSTRDSSEQ ID NO: 907QQYYRTPWTSEQ ID NO: 1064iPS:36140212H11.014KSSQSVLSSSNNKNYLASEQ ID NO: 751WTSTRESSEQ ID NO: 908QQYYRTPWTSEQ ID NO: 1065iPS:3614062C2.005.001SGSSSNIGSQTVNSEQ ID NO: 752TNNQRPSSEQ ID NO: 909ATFDESLSGPVSEQ ID NO: 1066iPS:3614122C2.005.002SGSSSNIGSQTVNSEQ ID NO: 753TNNQRPSSEQ ID NO: 910ATFDESLQGPVSEQ ID NO: 1067iPS:3614182C2.005.003SGSSSNIGSNYVNSEQ ID NO: 754TNNQRPSSEQ ID NO: 911ATFDESLSGPVSEQ ID NO: 1068iPS:3614242C2.005.004SGSSSNIGSNYVNSEQ ID NO: 755TNNQRPSSEQ ID NO: 912ATFDESLQGPVSEQ ID NO: 1069iPS:3614302C2.005.005SGSSSNIGSQTVNSEQ ID NO: 756TNNQRPSSEQ ID NO: 913ATFDDSLNGPVSEQ ID NO: 1070iPS:3614362C2.005.006SGSSSNIGSNYVNSEQ ID NO: 757TNNQRPSSEQ ID NO: 914ATFDDSLNGPVSEQ ID NO: 1071iPS:3614422C2.005.007SGSSSNIGSNTVNSEQ ID NO: 758TNNQRPSSEQ ID NO: 915ATFDESLNGPVSEQ ID NO: 1072iPS:3614482C2.005.008SGSSSNIGSNTVNSEQ ID NO: 759TNNQRPSSEQ ID NO: 916ATFDDSLQGPVSEQ ID NO: 1073iPS:3614542C2.005.009SGSSSNIGSNTVNSEQ ID NO: 760TNNQRPSSEQ ID NO: 917ATFDDSLSGPVSEQ ID NO: 1074iPS:3614602C2.005.010SGSSSNIGSNTVNSEQ ID NO: 761TNNQRPSSEQ ID NO: 918ATFDDSLNAPVSEQ ID NO: 1075iPS:3614662C2.005.011SGSSSNIGSNTVNSEQ ID NO: 762TNNQRPSSEQ ID NO: 919ATFDSSLNGPVSEQ ID NO: 1076iPS:3614722C2.005.012SGSSSNIGSNYVNSEQ ID NO: 763TNNQRPSSEQ ID NO: 920ATFDSSLNAPVSEQ ID NO: 1077iPS:3614782C2.005.013SGSSSNIGSNYVNSEQ ID NO: 764TNNQRPSSEQ ID NO: 921ATFDSSLNAPVSEQ ID NO: 1078iPS:3614852C2.005.014SGSSSNIGSQTVNSEQ ID NO: 765TNNQRPSSEQ ID NO: 922ATFDESLSGPVSEQ ID NO: 1079iPS:36184518F2.013RASQDLRNYLGSEQ ID NO: 766GASSLQSSEQ ID NO: 923LQHNNYPFTSEQ ID NO: 1080iPS:3618516H1.009RASQDIRDYLGSEQ ID NO: 767GASSLQSSEQ ID NO: 924LQHNNYPFTSEQ ID NO: 1081iPS:3618552C2.005.015SGSSSNIGSNTVNSEQ ID NO: 768TNNQRPSSEQ ID NO: 925ATFDSSLSGPVSEQ ID NO: 1082iPS:3360675G12.006RASQTISRFLNSEQ ID NO: 769VASSLQSSEQ ID NO: 926QQSYSTLISSEQ ID NO: 1083iPS:33616917B11.002SGSSSNIGNNYVSSEQ ID NO: 770DNNKRPSSEQ ID NO: 927GTWDSSLSAVVSEQ ID NO: 1084iPS:3611275G12.006.001RASQTISRFLNSEQ ID NO: 771VASSLQSSEQ ID NO: 928QQSYSTLISSEQ ID NO: 1085iPS:3611365G12.006.002RASQTISRFLNSEQ ID NO: 772VASSLQSSEQ ID NO: 929QQSYSTLISSEQ ID NO: 1086iPS:3611405G12.006.003RASQTISRFLNSEQ ID NO: 773VASSLQSSEQ ID NO: 930QQSYSTLISSEQ ID NO: 1087iPS:3599195G12.006.004RASQTISRFLNSEQ ID NO: 774VASSLQSSEQ ID NO: 931QQSYSTLISSEQ ID NO: 1088iPS:3611445G12.006.005RASQTISRFLNSEQ ID NO: 775VASSLQSSEQ ID NO: 932QQSYSTLISSEQ ID NO: 1089iPS:3611515G12.006.006RASQTISRFLNSEQ ID NO: 776VASSLQSSEQ ID NO: 933QQSYSTLISSEQ ID NO: 1090iPS:36149117B11.002.001SGSSSNIGNNYVSSEQ ID NO: 777DNNKRPSSEQ ID NO: 934GTWDSSLSAVVSEQ ID NO: 1091iPS:36149917B11.002.002SGSSSNIGNNYVSSEQ ID NO: 778DNNKRPSSEQ ID NO: 935GTWDSSLSAVVSEQ ID NO: 1092iPS:36150317B11.002.003SGSSSNIGNNYVSSEQ ID NO: 779DNNKRPSSEQ ID NO: 936GTWDSSLSAVVSEQ ID NO: 1093iPS:36150717B11.002.004SGSSSNIGNNYVSSEQ ID NO: 780DNNKRPSSEQ ID NO: 937GTFESSLSAVVSEQ ID NO: 1094iPS:36151417B11.002.005SGSSSNIGNNYVSSEQ ID NO: 781DNNKRPSSEQ ID NO: 938GTWDSSLSAVVSEQ ID NO: 1095iPS:36058217B11.002.006SGSSSNIGNNYVSSEQ ID NO: 782DNNKRPSSEQ ID NO: 939GTWDSSLSAVVSEQ ID NO: 1096iPS:36151817B11.002.007SGSSSNIGNNYVSSEQ ID NO: 783DNNKRPSSEQ ID NO: 940GTWDSSLSAVVSEQ ID NO: 1097iPS:36057017B11.002.008SGSSSNIGNNYVSSEQ ID NO: 784DNNKRPSSEQ ID NO: 941GTFESSLSAVVSEQ ID NO: 1098iPS:3620515G12.005.001RASQTISRFLNSEQ ID NO: 785VASSLQSSEQ ID NO: 942QQSYSTLLSSEQ ID NO: 1099 Table 7. CDRH1, CDRH2, and CDRH3 Amino Acid Sequences of Exemplary Anti-GIPR AntibodiesIdentifierConstructCDRH1CDRH2CDRH3iPS:3361752C2.005GYYMHSEQ ID NO: 1100WINPNSGGTNYAQKFQGSEQ ID NO: 1257GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1414iPS:3359144B1NFGMHSEQ ID NO: 1101VIWYDGSNENYADSVKGSEQ ID NO: 1258DGTIFGVVLGDYSEQ ID NO: 1415iPS:3359386H1YFGMHSEQ ID NO: 1102VIWYDGSNKYYADSVKGSEQ ID NO: 1259DGTIFGVLLGDYSEQ ID NO: 1416iPS:3359412F11SYGMHSEQ ID NO: 1103VIWYDGSNKYYADSVKGSEQ ID NO: 1260DRTIFGVVLDYSEQ ID NO: 1417iPS:3359705C2GYYIHSEQ ID NO: 1104WINPDSGGTDYSQRFQGSEQ ID NO: 1261EATIFGMVIVPFDYSEQ ID NO: 1418iPS:33597813H12GYYIHSEQ ID NO: 1105WINPDSGGTDYSQRFQGSEQ ID NO: 1262EATIFGMVIVPFDYSEQ ID NO: 1419iPS:33598611C1GYYIHSEQ ID NO: 1106WISPNSGDTSYAQKFQDSEQ ID NO: 1263EATIFGMLIVPFDYSEQ ID NO: 1420iPS:33599412H11GYYIHSEQ ID NO: 1107WISPNNGDTNYAQKFQDSEQ ID NO: 1264EATIFGMLIVPFDYSEQ ID NO: 1421iPS:33602418E3SGGYYWSSEQ ID NO: 1108YIYYSGSTYYNPSLKSSEQ ID NO: 1265DRITIFGVVMGGGMDVSEQ ID NO: 1422iPS:3360412G10_LC1NYGMHSEQ ID NO: 1109AIWFDGSDKYYADSVKGSEQ ID NO: 1266DQAIFGVVPDYSEQ ID NO: 1423iPS:3360774H9.004YFGMHSEQ ID NO: 1110VIWYDGSNKYYADSVKGSEQ ID NO: 1267DGTIFGVLLGDYSEQ ID NO: 1424iPS:3360886A5.004SYGMHSEQ ID NO: 1111AIWYDGNNKYYADSVKGSEQ ID NO: 1268DRTIFGVVLEYSEQ ID NO: 1425iPS:33609917H11.004SYYWSSEQ ID NO: 1112RIYTSGSTNYNPSLKSSEQ ID NO: 1269DVAVAGFDYSEQ ID NO: 1426iPS:35962117H11.004.001SYYWSSEQ ID NO: 1113RIYTSGSTNYNPSLKSSEQ ID NO: 1270DVAVAGFDYSEQ ID NO: 1427iPS:3597814H9.004.001YFGMHSEQ ID NO: 1114VIWYDASNKYYADAVKGSEQ ID NO: 1271DGTIFGVLLGDYSEQ ID NO: 1428iPS:3609294H9.004.002YFGMHSEQ ID NO: 1115VIWYDASNKYYADSVKGSEQ ID NO: 1272DGTIFGVLLGDYSEQ ID NO: 1429iPS:3609364H9.004.003YFGMHSEQ ID NO: 1116VIWYDGSNKYYADAVKGSEQ ID NO: 1273DGTIFGVLLGDYSEQ ID NO: 1430iPS:3609434H9.004.004YFGMHSEQ ID NO: 1117VIWYDASNKYYADAVKGSEQ ID NO: 1274DGTIFGVLLGDYSEQ ID NO: 1431iPS:3609494H9.004.005YFGMHSEQ ID NO: 1118VIWYDASNKYYADAVKGSEQ ID NO: 1275DGTIFGVLLGDYSEQ ID NO: 1432iPS:3597614H9.004.006YFGMHSEQ ID NO: 1119VIWYDASNKYYADAVKGSEQ ID NO: 1276DRTIFGVLLGDYSEQ ID NO: 1433iPS:3609554B1.010NFGMHSEQ ID NO: 1120VIWYDASNENYADAVKGSEQ ID NO: 1277DGTIFGVVLGDYSEQ ID NO: 1434iPS:3609624B1.011NFGMHSEQ ID NO: 1121VIWYDASNENYADAVKGSEQ ID NO: 1278DGTIFGVVLGDYSEQ ID NO: 1435iPS:3609684B1.012NFGMHSEQ ID NO: 1122VIWYDASNENYADAVKGSEQ ID NO: 1279DGTIFGVVLGDYSEQ ID NO: 1436iPS:3609744B1.013NFGMHSEQ ID NO: 1123VIWYDASNENYADSVKGSEQ ID NO: 1280DGTIFGVVLGDYSEQ ID NO: 1437iPS:3609784B1.014NFGMHSEQ ID NO: 1124VIWYDGSNENYADAVKGSEQ ID NO: 1281DGTIFGVVLGDYSEQ ID NO: 1438iPS:3597854B1.015NFGMHSEQ ID NO: 1125VIWYDASNENYADAVKGSEQ ID NO: 1282DRTIFGVVLGDYSEQ ID NO: 1439iPS:3609824B1.016NFGMHSEQ ID NO: 1126VIWYDASNENYADAVKGSEQ ID NO: 1283DGTIFGVVLGDYSEQ ID NO: 1440iPS:33592218F2NFGMHSEQ ID NO: 1127VIWYDGSNENYADSVKGSEQ ID NO: 1284DGTIFGVVLGDYSEQ ID NO: 1441iPS:36098618F2.002NFGMHSEQ ID NO: 1128VIWYDASNENYADAVKGSEQ ID NO: 1285DGTIFGVVLGDYSEQ ID NO: 1442iPS:36099518F2.003NFGMHSEQ ID NO: 1129VIWYDASNENYADAVKGSEQ ID NO: 1286DGTIFGVVLGDYSEQ ID NO: 1443iPS:36099918F2.004NFGMHSEQ ID NO: 1130VIWYDASNENYADAVKGSEQ ID NO: 1287DGTIFGVVLGDYSEQ ID NO: 1444iPS:36100518F2.005NFGMHSEQ ID NO: 1131VIWYDASNENYADAVKGSEQ ID NO: 1288DGTIFGVVLGDYSEQ ID NO: 1445iPS:36100918F2.006NFGMHSEQ ID NO: 1132VIWYDASNENYADAVKGSEQ ID NO: 1289DGTIFGVVLGDYSEQ ID NO: 1446iPS:36101318F2.007NFGMHSEQ ID NO: 1133VIWYDASNENYADAVKGSEQ ID NO: 1290DGTIFGVVLGDYSEQ ID NO: 1447iPS:36101718F2.008NFGMHSEQ ID NO: 1134VIWYDASNENYADAVKGSEQ ID NO: 1291DGTIFGVVLGDYSEQ ID NO: 1448iPS:36102118F2.009NFGMHSEQ ID NO: 1135VIWYDGSNENYADAVKGSEQ ID NO: 1292DGTIFGVVLGDYSEQ ID NO: 1449iPS:36102818F2.010NFGMHSEQ ID NO: 1136VIWYDASNENYADSVKGSEQ ID NO: 1293DGTIFGVVLGDYSEQ ID NO: 1450iPS:36053518F2.011NFGMHSEQ ID NO: 1137VIWYDASNENYADAVKGSEQ ID NO: 1294DRTIFGVVLGDYSEQ ID NO: 1451iPS:36103518F2.012NFGMHSEQ ID NO: 1138VIWYDASNENYADAVKGSEQ ID NO: 1295DGTIFGVVLGDYSEQ ID NO: 1452iPS:3599402F11.002SYGMHSEQ ID NO: 1139VIWYDASNKYYADAVKGSEQ ID NO: 1296DRTIFGVVLDYSEQ ID NO: 1453iPS:3610392F11.003SYGMHSEQ ID NO: 1140VIWYDASNKYYADAVKGSEQ ID NO: 1297DRTIFGVVLDYSEQ ID NO: 1454iPS:3610432F11.004SYGMHSEQ ID NO: 1141VIWYDASNKYYADAVKGSEQ ID NO: 1298DRTIFGVVLDYSEQ ID NO: 1455iPS:3610492F11.005SYGMHSEQ ID NO: 1142VIWYDASNKYYADAVKGSEQ ID NO: 1299DRTIFGVVLDYSEQ ID NO: 1456iPS:3610552F11.006SYGMHSEQ ID NO: 1143VIWYDASNKYYADAVKGSEQ ID NO: 1300DRTIFGVVLDYSEQ ID NO: 1457iPS:3610592F11.007SYGMHSEQ ID NO: 1144VIWYDASNKYYADAVKGSEQ ID NO: 1301DRTIFGVVLDYSEQ ID NO: 1458iPS:3610632F11.008SYGMHSEQ ID NO: 1145VIWYDASNKYYADAVKGSEQ ID NO: 1302DRTIFGVVLDYSEQ ID NO: 1459iPS:3599492F11.009SYGMHSEQ ID NO: 1146VIWYDASNKYYADSVKGSEQ ID NO: 1303DRTIFGVVLDYSEQ ID NO: 1460iPS:3599562F11.010SYGMHSEQ ID NO: 1147VIWYDGSNKYYADAVKGSEQ ID NO: 1304DRTIFGVVLDYSEQ ID NO: 1461iPS:3598656H1.002YFGMHSEQ ID NO: 1148VIWYDASNKYYADAVKGSEQ ID NO: 1305DGTIFGVLLGDYSEQ ID NO: 1462iPS:3598696H1.003YFGMHSEQ ID NO: 1149VIWYDASNKYYADAVKGSEQ ID NO: 1306DRTIFGVLLGDYSEQ ID NO: 1463iPS:3598736H1.004YFGMHSEQ ID NO: 1150VIWYDASNKYYADAVKGSEQ ID NO: 1307DGTIFGVLLGDYSEQ ID NO: 1464iPS:3598776H1.005YFGMHSEQ ID NO: 1151VIWYDASNKYYADAVKGSEQ ID NO: 1308DRTIFGVLLGDYSEQ ID NO: 1465iPS:3610676H1.006YFGMHSEQ ID NO: 1152VIWYDGSNKYYADSVKGSEQ ID NO: 1309DGTIFGVLLGDYSEQ ID NO: 1466iPS:3610716H1.007YFGMHSEQ ID NO: 1153VIWYDASNKYYADSVKGSEQ ID NO: 1310DGTIFGVLLGDYSEQ ID NO: 1467iPS:3610756H1.008YFGMHSEQ ID NO: 1154VIWYDGSNKYYADAVKGSEQ ID NO: 1311DGTIFGVLLGDYSEQ ID NO: 1468iPS:3610796A5.004.001SYGMHSEQ ID NO: 1155AIWYDANNKYYADAVKGSEQ ID NO: 1312DRTIFGVVLEYSEQ ID NO: 1469iPS:3610856A5.004.002SYGMHSEQ ID NO: 1156AIWYDANNKYYADAVKGSEQ ID NO: 1313DRTIFGVVLEYSEQ ID NO: 1470iPS:3610916A5.004.003SYGMHSEQ ID NO: 1157AIWYDANNKYYADAVKGSEQ ID NO: 1314DRTIFGVVLEYSEQ ID NO: 1471iPS:3610956A5.004.004SYGMHSEQ ID NO: 1158AIWYDANNKYYADAVKGSEQ ID NO: 1315DRTIFGVVLEYSEQ ID NO: 1472iPS:3611016A5.004.005SYGMHSEQ ID NO: 1159AIWYDANNKYYADAVKGSEQ ID NO: 1316DRTIFGVVLEYSEQ ID NO: 1473iPS:3611056A5.004.006SYGMHSEQ ID NO: 1160AIWYDANNKYYADAVKGSEQ ID NO: 1317DRTIFGVVLEYSEQ ID NO: 1474iPS:3611096A5.004.007SYGMHSEQ ID NO: 1161AIWYDANNKYYADAVKGSEQ ID NO: 1318DRTIFGVVLEYSEQ ID NO: 1475iPS:3611136A5.004.008SYGMHSEQ ID NO: 1162AIWYDGNNKYYADAVKGSEQ ID NO: 1319DRTIFGVVLEYSEQ ID NO: 1476iPS:3611206A5.004.009SYGMHSEQ ID NO: 1163AIWYDANNKYYADSVKGSEQ ID NO: 1320DRTIFGVVLEYSEQ ID NO: 1477iPS:3598966A5.004.010SYGMHSEQ ID NO: 1164AIWYDANNKYYADAVKGSEQ ID NO: 1321DRTIFGVVLEYSEQ ID NO: 1478iPS:3598906A5.004.011SYGMHSEQ ID NO: 1165AIWYDANNKYYADAVKGSEQ ID NO: 1322DRTIFGVVLEYSEQ ID NO: 1479iPS:3595672A11.002SYGMHSEQ ID NO: 1166VIWYDASNKYYEDAVKGSEQ ID NO: 1323GITIFGHGFEYSEQ ID NO: 1480iPS:3359652A11.003SYGMHSEQ ID NO: 1167VIWYDGSNKYYEDSVKGSEQ ID NO: 1324GITIFGHGFEYSEQ ID NO: 1481iPS:3611582A11.004SYGMHSEQ ID NO: 1168VIWYDGSNKYYEDAVKGSEQ ID NO: 1325GITIFGHGFEYSEQ ID NO: 1482iPS:3611652A11.005SYGMHSEQ ID NO: 1169VIWYDASNKYYEDSVKGSEQ ID NO: 1326GITIFGHGFEYSEQ ID NO: 1483iPS:3611722G10_LC1.003NYGMHSEQ ID NO: 1170AIWFDASDKYYADAVKGSEQ ID NO: 1327DQAIFGVVPDYSEQ ID NO: 1484iPS:3611782G10_LC1.004NYGMHSEQ ID NO: 1171AIWFDASDKYYADSVKGSEQ ID NO: 1328DQAIFGVVPDYSEQ ID NO: 1485iPS:3611852G10_LC1.005NYGMHSEQ ID NO: 1172AIWFDGSDKYYADAVKGSEQ ID NO: 1329DQAIFGVVPDYSEQ ID NO: 1486iPS:3611922G10_LC1.006NYGMHSEQ ID NO: 1173AIWFDASDKYYADAVKGSEQ ID NO: 1330DQAIFGVVPDYSEQ ID NO: 1487iPS:3596092G10_LC1.007NYGMHSEQ ID NO: 1174AIWFDASDKYYADAVKGSEQ ID NO: 1331DQAIFGVVPDYSEQ ID NO: 1488iPS:3596152G10_LC1.008NYGMHSEQ ID NO: 1175AIWFDASDKYYADAVKGSEQ ID NO: 1332DQAIFGVVPDYSEQ ID NO: 1489iPS:3611962G10_LC1.009NYGMHSEQ ID NO: 1176AIWFDASDKYYADAVKGSEQ ID NO: 1333DQAIFGVVPDYSEQ ID NO: 1490iPS:3612022G10_LC1.010NYGMHSEQ ID NO: 1177AIWFDASDKYYADAVKGSEQ ID NO: 1334DQAIFGVVPDYSEQ ID NO: 1491iPS:35964418E3.002SGGYYWSSEQ ID NO: 1178YIYYSGSTYYNPSLKSSEQ ID NO: 1335DRITIFGVVMGGGMDVSEQ ID NO: 1492iPS:36120618E3.003SGGYYWSSEQ ID NO: 1179YIYYSGSTYYNPSLKSSEQ ID NO: 1336DRITIFGVVMGGGMDVSEQ ID NO: 1493iPS:35962818E3.004SGGYYWSSEQ ID NO: 1180YIYYSGSTYYNPSLKSSEQ ID NO: 1337DRITIFGVVMGGGMDVSEQ ID NO: 1494iPS:35963718E3.005SGGYYWSSEQ ID NO: 1181YIYYSGSTYYNPSLKSSEQ ID NO: 1338DRITIFGVVMGGGMDVSEQ ID NO: 1495iPS:36121018E3.006SGGYYWSSEQ ID NO: 1182YIYYSGSTYYNPSLKSSEQ ID NO: 1339DRITIFGVVMGGGMDVSEQ ID NO: 1496iPS:36121418E3.007SGGYYWSSEQ ID NO: 1183YIYYSGSTYYNPSLKSSEQ ID NO: 1340DRITIFGVVMGGGMDVSEQ ID NO: 1497iPS:36121818E3.008SGGYYWSSEQ ID NO: 1184YIYYSGSTYYNPSLKSSEQ ID NO: 1341DRITIFGVVMGGGMDVSEQ ID NO: 1498iPS:3612225C2.006GYYIHSEQ ID NO: 1185WINPESGGTDYSQRFQGSEQ ID NO: 1342EATIFGMVIVPFDYSEQ ID NO: 1499iPS:3612295C2.007GYYIHSEQ ID NO: 1186WINPESGGTDYSQRFQGSEQ ID NO: 1343EATIFGMVIVPFDYSEQ ID NO: 1500iPS:3612365C2.008GYYIHSEQ ID NO: 1187WINPDAGGTDYSQRFQGSEQ ID NO: 1344EATIFGMVIVPFDYSEQ ID NO: 1501iPS:3596855C2.009GYYIHSEQ ID NO: 1188WINPDAGGTDYSQRFQGSEQ ID NO: 1345EATIFGMVIVPFDYSEQ ID NO: 1502iPS:3612405C2.010GYYIHSEQ ID NO: 1189WINPDSGGTDYSQRFQGSEQ ID NO: 1346EATIFGMVIVPFDYSEQ ID NO: 1503iPS:3612475C2.011GYYIHSEQ ID NO: 1190WINPDSGGTDYSQRFQGSEQ ID NO: 1347EATIFGMVIVPFDYSEQ ID NO: 1504iPS:3612545C2.012GYYIHSEQ ID NO: 1191WINPDSGGTDYSQRFQGSEQ ID NO: 1348EATIFGMVIVPFDYSEQ ID NO: 1505iPS:3612615C2.013GYYIHSEQ ID NO: 1192WINPDAGGTDYSQRFQGSEQ ID NO: 1349EATIFGMVIVPFDYSEQ ID NO: 1506iPS:3612685C2.014GYYIHSEQ ID NO: 1193WINPDAGGTDYSQRFQGSEQ ID NO: 1350EATIFGMVIVPFDYSEQ ID NO: 1507iPS:3596695C2.015GYYIHSEQ ID NO: 1194WINPDAGGTDYSQRFQGSEQ ID NO: 1351EATIFGMVIVPFDYSEQ ID NO: 1508iPS:3596785C2.016GYYIHSEQ ID NO: 1195WINPESGGTDYSQRFQGSEQ ID NO: 1352EATIFGMVIVPFDYSEQ ID NO: 1509iPS:36127511C1.002GYYIHSEQ ID NO: 1196WISPNSGETSYAQKFQDSEQ ID NO: 1353EATIFGMLIVPFDYSEQ ID NO: 1510iPS:36128211C1.003GYYIHSEQ ID NO: 1197WISPNSGDTSYAQKFQDSEQ ID NO: 1354EATIFGMLIVPFDYSEQ ID NO: 1511iPS:36128911C1.004GYYIHSEQ ID NO: 1198WISPNSGETSYAQKFQDSEQ ID NO: 1355EATIFGMLIVPFDYSEQ ID NO: 1512iPS:35971211C1.005GYYIHSEQ ID NO: 1199WISPNSGETSYAQKFQDSEQ ID NO: 1356EATIFGMLIVPFDYSEQ ID NO: 1513iPS:36129311C1.006GYYIHSEQ ID NO: 1200WISPNSGDTSYAQKFQDSEQ ID NO: 1357EATIFGMLIVPFDYSEQ ID NO: 1514iPS:36129711C1.007GYYIHSEQ ID NO: 1201WISPNSGETSYAQKFQDSEQ ID NO: 1358EATIFGMLIVPFDYSEQ ID NO: 1515iPS:36130111C1.008GYYIHSEQ ID NO: 1202WISPNSGDTSYAQKFQDSEQ ID NO: 1359EATIFGMLIVPFDYSEQ ID NO: 1516iPS:35970311C1.009GYYIHSEQ ID NO: 1203WISPNSGETSYAQKFQDSEQ ID NO: 1360EATIFGMLIVPFDYSEQ ID NO: 1517iPS:36130511C1.010GYYIHSEQ ID NO: 1204WISPNSGETSYAQKFQDSEQ ID NO: 1361EATIFGMLIVPFDYSEQ ID NO: 1518iPS:36131213H12.002GYYIHSEQ ID NO: 1205WINPESGGTDYSQRFQGSEQ ID NO: 1362EATIFGMVIVPFDYSEQ ID NO: 1519iPS:35974413H12.003GYYIHSEQ ID NO: 1206WINPESGGTDYSQRFQGSEQ ID NO: 1363EATIFGMVIVPFDYSEQ ID NO: 1520iPS:36131913H12.004GYYIHSEQ ID NO: 1207WINPDSGGTDYSQRFQGSEQ ID NO: 1364EATIFGMVIVPFDYSEQ ID NO: 1521iPS:35973713H12.005GYYIHSEQ ID NO: 1208WINPESGGTDYSQRFQGSEQ ID NO: 1365EATIFGMVIVPFDYSEQ ID NO: 1522iPS:36132613H12.006GYYIHSEQ ID NO: 1209WINPESGGTDYSQRFQGSEQ ID NO: 1366EATIFGMVIVPFDYSEQ ID NO: 1523iPS:36133012H11.002GYYIHSEQ ID NO: 1210WISPNQGETNYAQKFQDSEQ ID NO: 1367EATIFGMLIVPFDYSEQ ID NO: 1524iPS:36133712H11.003GYYIHSEQ ID NO: 1211WISPNQGDTNYAQKFQDSEQ ID NO: 1368EATIFGMLIVPFDYSEQ ID NO: 1525iPS:36134412H11.004GYYIHSEQ ID NO: 1212WISPNQGETNYAQKFQDSEQ ID NO: 1369EATIFGMLIVPFDYSEQ ID NO: 1526iPS:36135112H11.005GYYIHSEQ ID NO: 1213WISPNNGETNYAQKFQDSEQ ID NO: 1370EATIFGMLIVPFDYSEQ ID NO: 1527iPS:36135812H11.006GYYIHSEQ ID NO: 1214WISPNNGDTNYAQKFQDSEQ ID NO: 1371EATIFGMLIVPFDYSEQ ID NO: 1528iPS:36136512H11.007GYYIHSEQ ID NO: 1215WISPNQGDTNYAQKFQDSEQ ID NO: 1372EATIFGMLIVPFDYSEQ ID NO: 1529iPS:36137212H11.008GYYIHSEQ ID NO: 1216WISPNNGETNYAQKFQDSEQ ID NO: 1373EATIFGMLIVPFDYSEQ ID NO: 1530iPS:36137912H11.009GYYIHSEQ ID NO: 1217WISPNQGETNYAQKFQDSEQ ID NO: 1374EATIFGMLIVPFDYSEQ ID NO: 1531iPS:36138312H11.010GYYIHSEQ ID NO: 1218WISPNNGDTNYAQKFQDSEQ ID NO: 1375EATIFGMLIVPFDYSEQ ID NO: 1532iPS:36138712H11.011GYYIHSEQ ID NO: 1219WISPNQGDTNYAQKFQDSEQ ID NO: 1376EATIFGMLIVPFDYSEQ ID NO: 1533iPS:36139112H11.012GYYIHSEQ ID NO: 1220WISPNNGETNYAQKFQDSEQ ID NO: 1377EATIFGMLIVPFDYSEQ ID NO: 1534iPS:36139512H11.013GYYIHSEQ ID NO: 1221WISPNQGETNYAQKFQDSEQ ID NO: 1378EATIFGMLIVPFDYSEQ ID NO: 1535iPS:36140212H11.014GYYIHSEQ ID NO: 1222WISPNQGETNYAQKFQDSEQ ID NO: 1379EATIFGMLIVPFDYSEQ ID NO: 1536iPS:3614062C2.005.001GYYMHSEQ ID NO: 1223WINPNSGGTNYAQKFQGSEQ ID NO: 1380GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1537iPS:3614122C2.005.002GYYMHSEQ ID NO: 1224WINPNSGGTNYAQKFQGSEQ ID NO: 1381GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1538iPS:3614182C2.005.003GYYMHSEQ ID NO: 1225WINPNSGGTNYAQKFQGSEQ ID NO: 1382GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1539iPS:3614242C2.005.004GYYMHSEQ ID NO: 1226WINPNSGGTNYAQKFQGSEQ ID NO: 1383GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1540iPS:3614302C2.005.005GYYMHSEQ ID NO: 1227WINPNSGGTNYAQKFQGSEQ ID NO: 1384GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1541iPS:3614362C2.005.006GYYMHSEQ ID NO: 1228WINPNSGGTNYAQKFQGSEQ ID NO: 1385GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1542iPS:3614422C2.005.007GYYMHSEQ ID NO: 1229WINPNSGGTNYAQKFQGSEQ ID NO: 1386GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1543iPS:3614482C2.005.008GYYMHSEQ ID NO: 1230WINPNSGGTNYAQKFQGSEQ ID NO: 1387GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1544iPS:3614542C2.005.009GYYMHSEQ ID NO: 1231WINPNSGGTNYAQKFQGSEQ ID NO: 1388GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1545iPS:3614602C2.005.010GYYMHSEQ ID NO: 1232WINPNSGGTNYAQKFQGSEQ ID NO: 1389GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1546iPS:3614662C2.005.011GYYMHSEQ ID NO: 1233WINPNSGGTNYAQKFQGSEQ ID NO: 1390GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1547iPS:3614722C2.005.012GYYMHSEQ ID NO: 1234WINPNSGGTNYAQKFQGSEQ ID NO: 1391GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1548iPS:3614782C2.005.013GYYMHSEQ ID NO: 1235WINPNSGGTNYAQKFQGSEQ ID NO: 1392GGDYVFGTYRPHYYYGMDVSEQ ID NO: 1549iPS:3614852C2.005.014GYYMHSEQ ID NO: 1236WINPNSGGTNYAQKFQGSEQ ID NO: 1393GGDYVFGTYRPHYYYGMDVSEQ ID NO: 1550iPS:36184518F2.013NFGMHSEQ ID NO: 1237VIWYDASNENYADAVKGSEQ ID NO: 1394DRTIFGVVLGDYSEQ ID NO: 1551iPS:3618516H1.009YFGMHSEQ ID NO: 1238VIWYDASNKYYADAVKGSEQ ID NO: 1395DRTIFGVLLGDYSEQ ID NO: 1552iPS:3618552C2.005.015GYYMHSEQ ID NO: 1239WINPNSGGTNYAQKFQGSEQ ID NO: 1396GGDYVWGTYRPHYYYGMDVSEQ ID NO: 1553iPS:3360675G12.006SYGIHSEQ ID NO: 1240VIWYDGSNKFHADSVKGSEQ ID NO: 1397GKVAGMPEAFEISEQ ID NO: 1554iPS:33616917B11.002SYDINSEQ ID NO: 1241WMNPNSGNTGYAQKFQGSEQ ID NO: 1398GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1555iPS:3611275G12.006.001SYGIHSEQ ID NO: 1242VIWYDASNKFHADAVKGSEQ ID NO: 1399GKVAGMPEAFEISEQ ID NO: 1556iPS:3611365G12.006.002SYGIHSEQ ID NO: 1243VIWYDASNKFHADAVKGSEQ ID NO: 1400GKVAGMPEAFEISEQ ID NO: 1557iPS:3611405G12.006.003SYGIHSEQ ID NO: 1244VIWYDASNKFHADAVKGSEQ ID NO: 1401GKVAGMPEAFEISEQ ID NO: 1558iPS:3599195G12.006.004SYGIHSEQ ID NO: 1245VIWYDASNKFHADAVKGSEQ ID NO: 1402GKVAGMPEAFEISEQ ID NO: 1559iPS:3611445G12.006.005SYGIHSEQ ID NO: 1246VIWYDASNKFHADSVKGSEQ ID NO: 1403GKVAGMPEAFEISEQ ID NO: 1560iPS:3611515G12.006.006SYGIHSEQ ID NO: 1247VIWYDGSNKFHADAVKGSEQ ID NO: 1404GKVAGMPEAFEISEQ ID NO: 1561iPS:36149117B11.002.001SYDINSEQ ID NO: 1248WMNPNSGGTGYAQKFQGSEQ ID NO: 1405GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1562iPS:36149917B11.002.002SYDINSEQ ID NO: 1249WMNPNSGNTGYAQKFQGSEQ ID NO: 1406GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1563iPS:36150317B11.002.003SYDINSEQ ID NO: 1250WMNPNSGGTGYAQKFQGSEQ ID NO: 1407GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1564iPS:36150717B11.002.004SYDINSEQ ID NO: 1251WMNPNSGGTGYAQKFQGSEQ ID NO: 1408GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1565iPS:36151417B11.002.005SYDINSEQ ID NO: 1252WMNPNSGGTGYAQKFQGSEQ ID NO: 1409GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1566iPS:36058217B11.002.006SYDINSEQ ID NO: 1253WMNPNSGNTGYAQKFQGSEQ ID NO: 1410GGDYVWGSYRPYYYYYGMDVSEQ ID NO: 1567iPS:36151817B11.002.007SYDINSEQ ID NO: 1254WMNPNSGGTGYAQKFQGSEQ ID NO: 1411GGDYVFGSYRPYYYYYGMDVSEQ ID NO: 1568iPS:36057017B11.002.008SYDINSEQ ID NO: 1255WMNPNSGGTGYAQKFQGSEQ ID NO: 1412GGDYVFGSYRPYYYYYGMDVSEQ ID NO: 1569iPS:3620515G12.005.001SYGIHSEQ ID NO: 1256VIWYDASNKFHADAVKGSEQ ID NO: 1413GKVAGMPEAFEISEQ ID NO: 1570 Table 8. Light Chain (LC) Amino Acid Sequences of Exemplary Anti-GIPR AntibodiesIdentifierConstructLCSEQ ID NO:iPS:3361752C2.005QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS315iPS:3359144B1DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC316iPS:3359386H1DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC317iPS:3359412F11DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC318iPS:3359705C2DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC319iPS:33597813H12DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC320iPS:33598611C1DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC321iPS:33599412H11DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC322iPS:33602418E3EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC323iPS:3360412G10_LC1EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC324iPS:3360774H9.004DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGPGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC325iPS:3360886A5.004DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC326iPS:33609917H11.004DIQMTQSPSSVSASVGDRVTITCRASQGLIIWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC327iPS:35962117H11.004.001DIQMTQSPSSVSASVGDRVTITCRASQGLIIWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC328iPS:3597814H9.004.001DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC329iPS:3609294H9.004.002DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC330iPS:3609364H9.004.003DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC331iPS:3609434H9.004.004DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGPGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC332iPS:3609494H9.004.005DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC333iPS:3597614H9.004.006DIQMTQSPSSLSASVGDRVTITCRASQGIRNELGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFVTYYCLQHNSYPFTFGQGTKVDVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC334iPS:3609554B1.010DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC335iPS:3609624B1.011DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC336iPS:3609684B1.012DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC337iPS:3609744B1.013DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC338iPS:3609784B1.014DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC339iPS:3597854B1.015DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC340iPS:3609824B1.016DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC341iPS:33592218F2DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC342iPS:36098618F2.002DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC343iPS:36099518F2.003DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC344iPS:36099918F2.004DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC345iPS:36100518F2.005DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC346iPS:36100918F2.006DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC347iPS:36101318F2.007DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC348iPS:36101718F2.008DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYHQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC349iPS:36102118F2.009DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC350iPS:36102818F2.010DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC351iPS:36053518F2.011DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC352iPS:36103518F2.012DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC353iPS:3599402F11.002DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC354iPS:3610392F11.003DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC355iPS:3610432F11.004DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC356iPS:3610492F11.005DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC357iPS:3610552F11.006DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC358iPS:3610592F11.007DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC359iPS:3610632F11.008DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC360iPS:3599492F11.009DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC361iPS:3599562F11.010DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQYDILLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC362iPS:3598656H1.002DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC363iPS:3598696H1.003DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC364iPS:3598736H1.004DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC365iPS:3598776H1.005DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC366iPS:3610676H1.006DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC367iPS:3610716H1.007DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC368iPS:3610756H1.008DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC369iPS:3610796A5.004.001DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC370iPS:3610856A5.004.002DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC371iPS:3610916A5.004.003DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC372iPS:3610956A5.004.004DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC373iPS:3611016A5.004.005DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC374iPS:3611056A5.004.006DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC375iPS:3611096A5.004.007DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC376iPS:3611136A5.004.008DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC377iPS:3611206A5.004.009DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC378iPS:3598966A5.004.010DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC379iPS:3598906A5.004.011DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLEPGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDDLFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC380iPS:3595672A11.002EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC381iPS:3359652A11.003EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC382iPS:3611582A11.004EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC383iPS:3611652A11.005EIVLTQSPGTLSLSPGERATLSCRASQIFTSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC384iPS:3611722G10_LC1.003EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC385iPS:3611782G10_LC1.004EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC386iPS:3611852G10_LC1.005EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC387iPS:3611922G10_LC1.006EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC388iPS:3596092G10_LC1.007EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC389iPS:3596152G10_LC1.008EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC390iPS:3611962G10_LC1.009EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC391iPS:3612022G10_LC1.010EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARFSGSGSGTEFTLTISSLEPEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC392iPS:35964418E3.002EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC393iPS:36120618E3.003EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC394iPS:35962818E3.004EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC395iPS:35963718E3.005EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC396iPS:36121018E3.006EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC397iPS:36121418E3.007EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC398iPS:36121818E3.008EIVLTQSPGTLSLSPGERATLSCRASQSISYSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRQEPDDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC399iPS:3612225C2.006DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC400iPS:3612295C2.007DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC401iPS:3612365C2.008DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC402iPS:3596855C2.009DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC403iPS:3612405C2.010DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC404iPS:3612475C2.011DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC405iPS:3612545C2.012DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC406iPS:3612615C2.013DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC407iPS:3612685C2.014DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQQPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC408iPS:3596695C2.015DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC409iPS:3596785C2.016DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC410iPS:36127511C1.002DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC411iPS:36128211C1.003DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC412iPS:36128911C1.004DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC413iPS:35971211C1.005DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC414iPS:36129311C1.006DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC415iPS:36129711C1.007DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC416iPS:36130111C1.008DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC417iPS:35970311C1.009DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPKLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC418iPS:36130511C1.010DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC419iPS:36131213H12.002DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC420iPS:35974413H12.003DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC421iPS:36131913H12.004DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGHPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC422iPS:35973713H12.005DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC423iPS:36132613H12.006DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVFYCQQYYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC424iPS:36133012H11.002DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC425iPS:36133712H11.003DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC426iPS:36134412H11.004DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC427iPS:36135112H11.005DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC428iPS:36135812H11.006DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC429iPS:36136512H11.007DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC430iPS:36137212H11.008DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC431iPS:36137912H11.009DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC432iPS:36138312H11.010DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC433iPS:36138712H11.011DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC434iPS:36139112H11.012DIVMTQSPDSLSVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPNLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC435iPS:36139512H11.013DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPKLLIYWTSTRDSGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC436iPS:36140212H11.014DIVMTQSPDSLAVSLGERATINCKSSQSVLSSSNNKNYLAWYQQKPGQPPKLLIYWTSTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYRTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC437iPS:3614062C2.005.001QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLSGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS438iPS:3614122C2.005.002QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLQGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS439iPS:3614182C2.005.003QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLSGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS440iPS:3614242C2.005.004QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLQGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS441iPS:3614302C2.005.005QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS442iPS:3614362C2.005.006QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS443iPS:3614422C2.005.007QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLNGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS444iPS:3614482C2.005.008QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLQGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS445iPS:3614542C2.005.009QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLSGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS446iPS:3614602C2.005.010QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDDSLNAPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS447iPS:3614662C2.005.011QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLNGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS448iPS:3614722C2.005.012QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLNAPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS449iPS:3614782C2.005.013QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLNAPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS450iPS:3614852C2.005.014QSVLTQPPSASGTPGQRVTISCSGSSSNIGSQTVNWYQHLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDESLSGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS451iPS:36184518F2.013DIQMTQSPSSLSASIGDRVTITCRASQDLRNYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC452iPS:3618516H1.009DIQMTQSPSSLSASIGDRVTITCRASQDIRDYLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPFTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC453iPS:3618552C2.005.015QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCATFDSSLSGPVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS454iPS:3360675G12.006DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEITRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC455iPS:33616917B11.002QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYEQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS456iPS:3611275G12.006.001DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC457iPS:3611365G12.006.002DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC458iPS:3611405G12.006.003DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEITRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC459iPS:3599195G12.006.004DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC460iPS:3611445G12.006.005DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC461iPS:3611515G12.006.006DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLISFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC462iPS:36149117B11.002.001QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS463iPS:36149917B11.002.002QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS464iPS:36150317B11.002.003QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYEQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS465iPS:36150717B11.002.004QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTFESSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS466iPS:36151417B11.002.005QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS467iPS:36058217B11.002.006QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS468iPS:36151817B11.002.007QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS469iPS:36057017B11.002.008QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTFESSLSAVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS470iPS:3620515G12.005.001DIQLTQSPSSLSASVGDRVTITCRASQTISRFLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLLSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC471 Table 9. Heavy Chain (HC) Amino Acid Sequences of Exemplary Anti-GIPR AntibodiesIdentifierConstructHCSEQ ID NO:iPS:3361752C2.005QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK472iPS:3359144B1QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADSVKGRFTISRDNSKNTLYLHMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK473iPS:3359386H1QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK474iPS:3359412F11QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK475iPS:3359705C2QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK476iPS:33597813H12QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRFTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK477iPS:33598611C1QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK478iPS:33599412H11QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK479iPS:33602418E3QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK480iPS:3360412G10_LC1QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK481iPS:3360774H9.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK482iPS:3360886A5.004QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDGNNKYYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK483iPS:33609917H11.004QVQLQESGPGLVKPSETLSLTCTVSQGSISSYYWSWIRQPAGKGLEWIGRIYTSGSTNYNPSLKSRVTMSIDTSKNQFSLKLNSVTAADTAVYYCARDVAVAGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK484iPS:35962117H11.004.001QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPAGKGLEWIGRIYTSGSTNYNPSLKSRVTMSIDTSKNQFSLKLNSVTAADTAVYYCARDVAVAGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK485iPS:3597814H9.004.001QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK486iPS:3609294H9.004.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK487iPS:3609364H9.004.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK488iPS:3609434H9.004.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK489iPS:3609494H9.004.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK490iPS:3597614H9.004.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK491iPS:3609554B1.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK492iPS:3609624B1.011QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK493iPS:3609684B1.012QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK494iPS:3609744B1.013QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADSVKGRFTISRDNSKNTLYLHMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK495iPS:3609784B1.014QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADAVKGRFTISRDNSKNTLYLHMNSLRVADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK496iPS:3597854B1.015QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDRTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK497iPS:3609824B1.016QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK498iPS:33592218F2QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADSVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK499iPS:36098618F2.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK500iPS:36099518F2.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK501iPS:36099918F2.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK502iPS:36100518F2.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK503iPS:36100918F2.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK504iPS:36101318F2.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLHMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK505iPS:36101718F2.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK506iPS:36102118F2.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNENYADAVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK507iPS:36102818F2.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADSVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK508iPS:36053518F2.011QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK509iPS:36103518F2.012QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDASNENYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVVLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK510iPS:3599402F11.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK511iPS:3610392F11.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK512iPS:3610432F11.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK513iPS:3610492F11.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK514iPS:3610552F11.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK515iPS:3610592F11.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK516iPS:3610632F11.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK517iPS:3599492F11.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK518iPS:3599562F11.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK519iPS:3598656H1.002QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK520iPS:3598696H1.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK521iPS:3598736H1.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK522iPS:3598776H1.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK523iPS:3610676H1.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK524iPS:3610716H1.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDASNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK525iPS:3610756H1.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSYFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTIFGVLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK526iPS:3610796A5.004.001QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK527iPS:3610856A5.004.002QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK528iPS:3610916A5.004.003QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK529iPS:3610956A5.004.004QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK530iPS:3611016A5.004.005QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK531iPS:3611056A5.004.006QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK532iPS:3611096A5.004.007QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK533iPS:3611136A5.004.008QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDGNNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK534iPS:3611206A5.004.009QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK535iPS:3598966A5.004.010QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK536iPS:3598906A5.004.011QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQPPGKGLEWVAAIWYDANNKYYADAVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRTIFGVVLEYLGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK537iPS:3595672A11.002QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYEDAVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK538iPS:3359652A11.003QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYEDSVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK539iPS:3611582A11.004QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYEDAVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK540iPS:3611652A11.005QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDASNKYYEDSVKGRFTISRDNSKNTLFLQVNSLRAEDTAVYYCARGITIFGHGFEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK541iPS:3611722G10_LC1.003QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK542iPS:3611782G10_LC1.004QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK543iPS:3611852G10_LC1.005QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDGSDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK544iPS:3611922G10_LC1.006QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK545iPS:3596092G10_LC1.007QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK546iPS:3596152G10_LC1.008QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK547iPS:3611962G10_LC1.009QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK548iPS:3612022G10_LC1.010QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK549iPS:35964418E3.002QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK550iPS:36120618E3.003QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK551iPS:35962818E3.004QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK552iPS:35963718E3.005QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK553iPS:36121018E3.006QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK554iPS:36121418E3.007QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK555iPS:36121818E3.008QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRITIFGVVMGGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK556iPS:3612225C2.006QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK557iPS:3612295C2.007QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK558iPS:3612365C2.008QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK559iPS:3596855C2.009QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK560iPS:3612405C2.010QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK561iPS:3612475C2.011QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK562iPS:3612545C2.012QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK563iPS:3612615C2.013QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRFTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK564iPS:3612685C2.014QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK565iPS:3596695C2.015QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDAGGTDYSQRFQGRVTMTRDTSISTAYMELNSLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK566iPS:3596785C2.016QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELNSLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK567iPS:36127511C1.002QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK568iPS:36128211C1.003QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK569iPS:36128911C1.004QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK570iPS:35971211C1.005QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK571iPS:36129311C1.006QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK572iPS:36129711C1.007QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK573iPS:36130111C1.008QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLVWMGWISPNSGDTSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK574iPS:35970311C1.009QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSSLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK575iPS:36130511C1.010QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNSGETSYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYFCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK576iPS:36131213H12.002QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK577iPS:35974413H12.003QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRFTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK578iPS:36131913H12.004QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPDSGGTDYSQRFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK579iPS:35973713H12.005QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK580iPS:36132613H12.006QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPESGGTDYSQRFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMVIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK581iPS:36133012H11.002QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK582iPS:36133712H11.003QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK583iPS:36134412H11.004QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK584iPS:36135112H11.005QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK585iPS:36135812H11.006QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK586iPS:36136512H11.007QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK587iPS:36137212H11.008QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCTREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK588iPS:36137912H11.009QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK589iPS:36138312H11.010QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK590iPS:36138712H11.011QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGDTNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK591iPS:36139112H11.012QVPLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNNGETNYAQKFQDRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK592iPS:36139512H11.013QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSSLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK593iPS:36140212H11.014QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWISPNQGETNYAQKFQDRVTMTRDTSISTAYMELSSLRSDDTAVYYCAREATIFGMLIVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK594iPS:3614062C2.005.001QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK595iPS:3614122C2.005.002QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK596iPS:3614182C2.005.003QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK597iPS:3614242C2.005.004QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK598iPS:3614302C2.005.005QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK599iPS:3614362C2.005.006QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK600iPS:3614422C2.005.007QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK601iPS:3614482C2.005.008QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK602iPS:3614542C2.005.009QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK603iPS:3614602C2.005.010QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK604iPS:3614662C2.005.011QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK605iPS:3614722C2.005.012QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGDYVWGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK606iPS:3614782C2.005.013QMQVVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARGGDYVFGTYRPHYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGS...

Claims

1. A human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide comprising the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereinX17 is Q, K, E, or R; X20 is K, R, Q, or homoarginine (hArg); X24 is A, E, Q, D, d-Ala, G, N, K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), T, S, or Y; X27 is V, K, Aib, N, S, T, Y, Q, or R; and X28 is K, E, R, Q, D, N, G, S, or T; and wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1574 (H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG).

2. The GLP-1 receptor agonist polypeptide of claim 1, wherein the GLP-1 receptor agonist polypeptide comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1576), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R.

3. The GLP-1 receptor agonist polypeptide of claim 1, wherein the GLP-1 receptor agonist polypeptide comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAREFIX24WLX27X28GGG (SEQ ID NO: 1577) wherein X17 is Q or K; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R.

4. The GLP-1 receptor agonist polypeptide of claim 1, wherein the GLP-1 receptor agonist polypeptide comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLKX28GGG (SEQ ID NO: 1578), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; and X28 is K, E, or R.

5. The GLP-1 receptor agonist polypeptide of claim 1, where the GLP-1 receptor agonist polypeptide comprises the amino acid sequence of any one of SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1582, or SEQ ID NO: 1583.

6. A human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide, wherein: the polypeptide comprises 31 amino acids and comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1580; and wherein the polypeptide comprises an α-amino-isobutyric acid (Aib) at position 2; a tyrosine at position 10; a glutamic acid at positions 16, 24, and 28; an arginine at position 20; a lysine at positions 17 and 27; and a glycine at position 31.

7. A human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide, wherein: the GLP-1 receptor agonist polypeptide comprises 31 amino acids and comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1579; and wherein the GLP-1 receptor agonist polypeptide comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 27; and a glycine at position 30.

8. A human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide, wherein: the GLP-1 receptor agonist polypeptide comprises 31 amino acids and comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1581; and wherein the GLP-1 receptor agonist polypeptide comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at position 20; a lysine at positions 17, 27; and a glycine at position 30.

9. A human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide, wherein: the GLP-1 receptor agonist polypeptide comprises 31 amino acids and comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1583; and wherein the GLP-1 receptor agonist polypeptide comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 28; an arginine at position 20; a lysine at positions 17, 27; a glutamine at position 24; and a glycine at position 30.

10. A human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide, wherein: the GLP-1 receptor agonist polypeptide comprises 31 amino acids and comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1582; and wherein the GLP-1 receptor agonist polypeptide comprises an Aib at position 2; a tyrosine at position 10; a glutamic acid at positions 16 and 24; an arginine at positions 20 and 28; a lysine at positions 27; and a glycine at position 30.  11. A molecule comprising: a first human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide comprising the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereinX17 is Q, K, E, or R; X20 is K, R, Q, or homoarginine (hArg); X24 is A, E, Q, D, d-Ala, G, N, K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), T, S, or Y; X27 is V, K, Aib, N, S, T, Y, Q, or R; and X28 is K, E, R, Q, D, N, G, S, or T, and wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1574; and a half-life extending moiety.

12. The molecule of claim 11, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1576), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R.

13. The molecule of claim 11, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAR20EFIX24WLX27X28GGG (SEQ ID NO: 1577) wherein X17 is Q or K; X24 is A, E, or Q; X27 is V or K; and X28 is K, E, or R.

14. The molecule of claim 11, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLK27X28GGG (SEQ ID NO: 1578), wherein X17 is Q or K; X20 is K or R; X24 is A, E, or Q; and X28 is K, E, or R.

15. The molecule of claim 11, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of any one of SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1582, or SEQ ID NO: 1583.

16. The molecule of any one of claims 11–15, wherein the half-life extending moiety is an antibody.

17. A conjugate molecule comprising: a first human glucagon-like peptide 1 (GLP-1) receptor agonist polypeptide comprising the amino acid sequence of H[Aib]EGTFTSDYSSYLEEX17AAX20EFIX24WLX27X28GGG (SEQ ID NO: 1575), whereinX17 is Q, K, E, or R; X20 is K, R, Q, or homoarginine (hArg); X24 is A, E, Q, D, d-Ala, G, N, K, (1S,2S)-2-Aminocyclopentanecarboxylic acid (ACPC), (3S,4R)-4-Amino-3-pyrrolidinecarboxylic acid (APCA), T, S, or Y; X27 is V, K, Aib, N, S, T, Y, Q, or R; and X28 is K, E, R, Q, D, N, G, S, or T, and wherein the GLP-1 receptor agonist polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1574; and an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) human antibody.

18. The conjugate molecule of claim 17, wherein the anti-GIPR antibody antagonizes human GIPR.

19. The conjugate molecule of claim 17, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1575.

20. The conjugate molecule of claim 17, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1576.

21. The conjugate molecule of claim 17, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1577.

22. The conjugate molecule of claim 17, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1578.

23. The conjugate molecule of claim 17, wherein the first GLP-1 receptor agonist polypeptide comprises the amino acid sequence of any one of SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1582, or SEQ ID NO: 1583.

24. The conjugate molecule of claim 17 or claim 18, wherein the anti-GIPR antibody comprises a first cysteine conjugation site within a light chain or heavy chain of the antibody, and wherein the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody.

25. The conjugate molecule of claim 24, wherein the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to the first cysteine conjugation site of the anti-GIPR antibody via a first linker moiety.

26. The conjugate molecule of claim 25, wherein the first linker moiety is a peptide linker and the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 1585–1593.

27. The conjugate molecule of claim 25, wherein the first linker moiety is a PEG linker.

28. The conjugate molecule of any one of claims 24 to 27, wherein the first cysteine conjugation site of the anti-GIPR antibody is at position 88 of the light chain, position 384 of the heavy chain, or position 487 of the heavy chain according to AHo numbering.

29. The conjugate molecule of anyone of claims 17 to 28, wherein the molecule further comprises: a second GLP-1 receptor agonist polypeptide, wherein the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to a second cysteine conjugation site of the anti-GIPR antibody.

30. The conjugate molecule of claim 29, wherein the second GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1575.

31. The conjugate molecule of claim 29, wherein the second GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1576.

32. The conjugate molecule of claim 29 wherein the second GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1577.

33. The conjugate molecule of claim 29, wherein the second GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1578.

34. The conjugate molecule of claim 29, wherein the second GLP-1 receptor agonist polypeptide comprises the amino acid sequence of any one of SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1582, or SEQ ID NO: 1583.

35. The conjugate molecule of claim 29, wherein the second GLP-1 receptor agonist polypeptide comprises the same amino acid sequence as the first GLP-1 receptor agonist polypeptide.

36. The conjugate molecule of any one of claims 29 to 35, wherein the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus, to the second cysteine conjugation site of the anti-GIPR antibody via a second linker moiety.

37. The conjugate molecule of claim 36, wherein the second linker moiety is a peptide linker and the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 1585–1593.

38. The conjugate molecule of claim 36, wherein the second linker moiety is a PEG linker.

39. The conjugate molecule of claim 29, wherein the first and second conjugation sites of the anti-GIPR antibody are at position 88 of each light chain, position 384 of each heavy chain, or position 487 of each heavy chain according to AHo numbering.

40. The conjugate molecule of any one of embodiments 17 to 39, wherein the anti-GIPR antibody comprises a light chain complementarity determining region 1 (CDRL1), a CDRL2, a CDRL3, a heavy chain complementarity determining region 1 (CDRH1), a CDRH2, and a CDRH3, wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise the amino acid sequences selected from:i. SEQ ID NO: 629, SEQ ID NO: 786, SEQ ID NO: 943, SEQ ID NO: 1100, SEQ ID NO: 1257, and SEQ ID NO: 1414, respectively; ii. SEQ ID NO: 630, SEQ ID NO: 787, SEQ ID NO: 944, SEQ ID NO: 1101, SEQ ID NO: 1258, and SEQ ID NO: 1415, respectively; iii. SEQ ID NO: 631, SEQ ID NO: 788, SEQ ID NO: 945, SEQ ID NO: 1102, SEQ ID NO: 1259, and SEQ ID NO: 1416, respectively; iv. SEQ ID NO: 632, SEQ ID NO: 789, SEQ ID NO: 946, SEQ ID NO: 1103, SEQ ID NO: 1260, and SEQ ID NO: 1417, respectively; v. SEQ ID NO: 633, SEQ ID NO: 790, SEQ ID NO: 947, SEQ ID NO: 1104, SEQ ID NO: 1261, and SEQ ID NO: 1418, respectively; vi. SEQ ID NO: 634, SEQ ID NO: 791, SEQ ID NO: 948, SEQ ID NO: 1105, SEQ ID NO: 1262, and SEQ ID NO: 1419, respectively; vii. SEQ ID NO: 635, SEQ ID NO: 792, SEQ ID NO: 949, SEQ ID NO: 1106, SEQ ID NO: 1263, and SEQ ID NO: 1420, respectively; viii. SEQ ID NO: 636, SEQ ID NO: 793, SEQ ID NO: 950, SEQ ID NO: 1107, SEQ ID NO: 1264, and SEQ ID NO: 1421, respectively; ix. SEQ ID NO: 637, SEQ ID NO: 794, SEQ ID NO: 951, SEQ ID NO: 1108, SEQ ID NO: 1265, and SEQ ID NO: 1422, respectively; x. SEQ ID NO: 638, SEQ ID NO: 795, SEQ ID NO: 952, SEQ ID NO: 1109, SEQ ID NO: 1266, and SEQ ID NO: 1423, respectively; xi. SEQ ID NO: 639, SEQ ID NO: 796, SEQ ID NO: 953, SEQ ID NO: 1110, SEQ ID NO: 1267, and SEQ ID NO: 1424, respectively; xii. SEQ ID NO: 640, SEQ ID NO: 797, SEQ ID NO: 954, SEQ ID NO: 1111, SEQ ID NO: 1268, and SEQ ID NO: 1425, respectively; xiii. SEQ ID NO: 641, SEQ ID NO: 798, SEQ ID NO: 955, SEQ ID NO: 1112, SEQ ID NO: 1269, and SEQ ID NO: 1426, respectively; xiv. SEQ ID NO: 642, SEQ ID NO: 799, SEQ ID NO: 956, SEQ ID NO: 1113, SEQ ID NO: 1270, and SEQ ID NO: 1427, respectively; xv. SEQ ID NO: 643, SEQ ID NO: 800, SEQ ID NO: 957, SEQ ID NO: 1114, SEQ ID NO: 1271, and SEQ ID NO: 1428, respectively; xvi. SEQ ID NO: 644, SEQ ID NO: 801, SEQ ID NO: 958, SEQ ID NO: 1115, SEQ ID NO: 1272, and SEQ ID NO: 1429, respectively; xvii. SEQ ID NO: 645, SEQ ID NO: 802, SEQ ID NO: 959, SEQ ID NO: 1116, SEQ ID NO: 1273, and SEQ ID NO: 1430, respectively; xviii. SEQ ID NO: 646, SEQ ID NO: 803, SEQ ID NO: 960, SEQ ID NO: 1117, SEQ ID NO: 1274, and SEQ ID NO: 1431, respectively; xix. SEQ ID NO: 647, SEQ ID NO: 804, SEQ ID NO: 961, SEQ ID NO: 1118, SEQ ID NO: 1275, and SEQ ID NO: 1432, respectively; xx. SEQ ID NO: 648, SEQ ID NO: 805, SEQ ID NO: 962, SEQ ID NO: 1119, SEQ ID NO: 1276, and SEQ ID NO: 1433, respectively; xxi. SEQ ID NO: 649, SEQ ID NO: 806, SEQ ID NO: 963, SEQ ID NO: 1120, SEQ ID NO: 1277, and SEQ ID NO: 1434, respectively; xxii. SEQ ID NO: 650, SEQ ID NO: 807, SEQ ID NO: 964, SEQ ID NO: 1121, SEQ ID NO: 1278, and SEQ ID NO: 1435, respectively; xxiii. SEQ ID NO: 651, SEQ ID NO: 808, SEQ ID NO: 965, SEQ ID NO: 1122, SEQ ID NO: 1279, and SEQ ID NO: 1436, respectively; xxiv. SEQ ID NO: 652, SEQ ID NO: 809, SEQ ID NO: 966, SEQ ID NO: 1123, SEQ ID NO: 1280, and SEQ ID NO: 1437, respectively; xxv. SEQ ID NO: 653, SEQ ID NO: 810, SEQ ID NO: 967, SEQ ID NO: 1124, SEQ ID NO: 1281, and SEQ ID NO: 1438, respectively; xxvi. SEQ ID NO: 654, SEQ ID NO: 811, SEQ ID NO: 968, SEQ ID NO: 1125, SEQ ID NO: 1282, and SEQ ID NO: 1439, respectively; xxvii. SEQ ID NO: 655, SEQ ID NO: 812, SEQ ID NO: 969, SEQ ID NO: 1126, SEQ ID NO: 1283, and SEQ ID NO: 1440, respectively; xxviii. SEQ ID NO: 656, SEQ ID NO: 813, SEQ ID NO: 970, SEQ ID NO: 1127, SEQ ID NO: 1284, and SEQ ID NO: 1441, respectively; xxix. SEQ ID NO: 657, SEQ ID NO: 814, SEQ ID NO: 971, SEQ ID NO: 1128, SEQ ID NO: 1285, and SEQ ID NO: 1442, respectively; xxx. SEQ ID NO: 658, SEQ ID NO: 815, SEQ ID NO: 972, SEQ ID NO: 1129, SEQ ID NO: 1286, and SEQ ID NO: 1443, respectively; xxxi. SEQ ID NO: 659, SEQ ID NO: 816, SEQ ID NO: 973, SEQ ID NO: 1130, SEQ ID NO: 1287, and SEQ ID NO: 1444, respectively; xxxii. SEQ ID NO: 660, SEQ ID NO: 817, SEQ ID NO: 974, SEQ ID NO: 1131, SEQ ID NO: 1288, and SEQ ID NO: 1445, respectively; xxxiii. SEQ ID NO: 661, SEQ ID NO: 818, SEQ ID NO: 975, SEQ ID NO: 1132, SEQ ID NO: 1289, and SEQ ID NO: 1446, respectively; xxxiv. SEQ ID NO: 662, SEQ ID NO: 819, SEQ ID NO: 976, SEQ ID NO: 1133, SEQ ID NO: 1290, and SEQ ID NO: 1447, respectively; xxxv. SEQ ID NO: 663, SEQ ID NO: 820, SEQ ID NO: 977, SEQ ID NO: 1134, SEQ ID NO: 1291, and SEQ ID NO: 1448, respectively; xxxvi. SEQ ID NO: 664, SEQ ID NO: 821, SEQ ID NO: 978, SEQ ID NO: 1135, SEQ ID NO: 1292, and SEQ ID NO: 1449, respectively; xxxvii. SEQ ID NO: 665, SEQ ID NO: 822, SEQ ID NO: 979, SEQ ID NO: 1136, SEQ ID NO: 1293, and SEQ ID NO: 1450, respectively; xxxviii. SEQ ID NO: 666, SEQ ID NO: 823, SEQ ID NO: 980, SEQ ID NO: 1137, SEQ ID NO: 1294, and SEQ ID NO: 1451, respectively; xxxix. SEQ ID NO: 667, SEQ ID NO: 824, SEQ ID NO: 981, SEQ ID NO: 1138, SEQ ID NO: 1295, and SEQ ID NO: 1452, respectively; xl. SEQ ID NO: 668, SEQ ID NO: 825, SEQ ID NO: 982, SEQ ID NO: 1139, SEQ ID NO: 1296, and SEQ ID NO: 1453, respectively; xli. SEQ ID NO: 669, SEQ ID NO: 826, SEQ ID NO: 983, SEQ ID NO: 1140, SEQ ID NO: 1297, and SEQ ID NO: 1454, respectively; xlii. SEQ ID NO: 670, SEQ ID NO: 827, SEQ ID NO: 984, SEQ ID NO: 1141, SEQ ID NO: 1298, and SEQ ID NO: 1455, respectively; xliii. SEQ ID NO: 671, SEQ ID NO: 828, SEQ ID NO: 985, SEQ ID NO: 1142, SEQ ID NO: 1299, and SEQ ID NO: 1456, respectively; xliv. SEQ ID NO: 672, SEQ ID NO: 829, SEQ ID NO: 986, SEQ ID NO: 1143, SEQ ID NO: 1300, and SEQ ID NO: 1457, respectively; xlv. SEQ ID NO: 673, SEQ ID NO: 830, SEQ ID NO: 987, SEQ ID NO: 1144, SEQ ID NO: 1301, and SEQ ID NO: 1458, respectively; xlvi. SEQ ID NO: 674, SEQ ID NO: 831, SEQ ID NO: 988, SEQ ID NO: 1145, SEQ ID NO: 1302, and SEQ ID NO: 1459, respectively; xlvii. SEQ ID NO: 675, SEQ ID NO: 832, SEQ ID NO: 989, SEQ ID NO: 1146, SEQ ID NO: 1303, and SEQ ID NO: 1460, respectively; xlviii. SEQ ID NO: 676, SEQ ID NO: 833, SEQ ID NO: 990, SEQ ID NO: 1147, SEQ ID NO: 1304, and SEQ ID NO: 1461, respectively; xlix. SEQ ID NO: 677, SEQ ID NO: 834, SEQ ID NO: 991, SEQ ID NO: 1148, SEQ ID NO: 1305, and SEQ ID NO: 1462, respectively; l. SEQ ID NO: 678, SEQ ID NO: 835, SEQ ID NO: 992, SEQ ID NO: 1149, SEQ ID NO: 1306, and SEQ ID NO: 1463, respectively; li. SEQ ID NO: 679, SEQ ID NO: 836, SEQ ID NO: 993, SEQ ID NO: 1150, SEQ ID NO: 1307, and SEQ ID NO: 1464, respectively; lii. SEQ ID NO: 680, SEQ ID NO: 837, SEQ ID NO: 994, SEQ ID NO: 1151, SEQ ID NO: 1308, and SEQ ID NO: 1465, respectively; liii. SEQ ID NO: 681, SEQ ID NO: 838, SEQ ID NO: 995, SEQ ID NO: 1152, SEQ ID NO: 1309, and SEQ ID NO: 1466, respectively; liv. SEQ ID NO: 682, SEQ ID NO: 839, SEQ ID NO: 996, SEQ ID NO: 1153, SEQ ID NO: 1310, and SEQ ID NO: 1467, respectively; lv. SEQ ID NO: 683, SEQ ID NO: 840, SEQ ID NO: 997, SEQ ID NO: 1154, SEQ ID NO: 1311, and SEQ ID NO: 1468, respectively; lvi. SEQ ID NO: 684, SEQ ID NO: 841, SEQ ID NO: 998, SEQ ID NO: 1155, SEQ ID NO: 1312, and SEQ ID NO: 1469, respectively; lvii. SEQ ID NO: 685, SEQ ID NO: 842, SEQ ID NO: 999, SEQ ID NO: 1156, SEQ ID NO: 1313, and SEQ ID NO: 1470, respectively; lviii. SEQ ID NO: 686, SEQ ID NO: 843, SEQ ID NO: 1000, SEQ ID NO: 1157, SEQ ID NO: 1314, and SEQ ID NO: 1471, respectively; lix. SEQ ID NO: 687, SEQ ID NO: 844, SEQ ID NO: 1001, SEQ ID NO: 1158, SEQ ID NO: 1315, and SEQ ID NO: 1472, respectively; lx. SEQ ID NO: 688, SEQ ID NO: 845, SEQ ID NO: 1002, SEQ ID NO: 1159, SEQ ID NO: 1316, and SEQ ID NO: 1473, respectively; lxi. SEQ ID NO: 689, SEQ ID NO: 846, SEQ ID NO: 1003, SEQ ID NO: 1160, SEQ ID NO: 1317, and SEQ ID NO: 1474, respectively; lxii. SEQ ID NO: 690, SEQ ID NO: 847, SEQ ID NO: 1004, SEQ ID NO: 1161, SEQ ID NO: 1318, and SEQ ID NO: 1475, respectively; lxiii. SEQ ID NO: 691, SEQ ID NO: 848, SEQ ID NO: 1005, SEQ ID NO: 1162, SEQ ID NO: 1319, and SEQ ID NO: 1476, respectively; lxiv. SEQ ID NO: 692, SEQ ID NO: 849, SEQ ID NO: 1006, SEQ ID NO: 1163, SEQ ID NO: 1320, and SEQ ID NO: 1477, respectively; lxv. SEQ ID NO: 693, SEQ ID NO: 850, SEQ ID NO: 1007, SEQ ID NO: 1164, SEQ ID NO: 1321, and SEQ ID NO: 1478, respectively; lxvi. SEQ ID NO: 694, SEQ ID NO: 851, SEQ ID NO: 1008, SEQ ID NO: 1165, SEQ ID NO: 1322, and SEQ ID NO: 1479, respectively; lxvii. SEQ ID NO: 695, SEQ ID NO: 852, SEQ ID NO: 1009, SEQ ID NO: 1166, SEQ ID NO: 1323, and SEQ ID NO: 1480, respectively; lxviii. SEQ ID NO: 696, SEQ ID NO: 853, SEQ ID NO: 1010, SEQ ID NO: 1167, SEQ ID NO: 1324, and SEQ ID NO: 1481, respectively; lxix. SEQ ID NO: 697, SEQ ID NO: 854, SEQ ID NO: 1011, SEQ ID NO: 1168, SEQ ID NO: 1325, and SEQ ID NO: 1482, respectively; lxx. SEQ ID NO: 698, SEQ ID NO: 855, SEQ ID NO: 1012, SEQ ID NO: 1169, SEQ ID NO: 1326, and SEQ ID NO: 1483, respectively; lxxi. SEQ ID NO: 699, SEQ ID NO: 856, SEQ ID NO: 1013, SEQ ID NO: 1170, SEQ ID NO: 1327, and SEQ ID NO: 1484, respectively; lxxii. SEQ ID NO: 700, SEQ ID NO: 857, SEQ ID NO: 1014, SEQ ID NO: 1171, SEQ ID NO: 1328, and SEQ ID NO: 1485, respectively; lxxiii. SEQ ID NO: 701, SEQ ID NO: 858, SEQ ID NO: 1015, SEQ ID NO: 1172, SEQ ID NO: 1329, and SEQ ID NO: 1486, respectively; lxxiv. SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; lxxv. SEQ ID NO: 703, SEQ ID NO: 860, SEQ ID NO: 1017, SEQ ID NO: 1174, SEQ ID NO: 1331, and SEQ ID NO: 1488, respectively; lxxvi. SEQ ID NO: 704, SEQ ID NO: 861, SEQ ID NO: 1018, SEQ ID NO: 1175, SEQ ID NO: 1332, and SEQ ID NO: 1489, respectively; lxxvii. SEQ ID NO: 705, SEQ ID NO: 862, SEQ ID NO: 1019, SEQ ID NO: 1176, SEQ ID NO: 1333, and SEQ ID NO: 1490, respectively; lxxviii. SEQ ID NO: 706, SEQ ID NO: 863, SEQ ID NO: 1020, SEQ ID NO: 1177, SEQ ID NO: 1334, and SEQ ID NO: 1491, respectively; lxxix. SEQ ID NO: 707, SEQ ID NO: 864, SEQ ID NO: 1021, SEQ ID NO: 1178, SEQ ID NO: 1335, and SEQ ID NO: 1492, respectively; lxxx. SEQ ID NO: 708, SEQ ID NO: 865, SEQ ID NO: 1022, SEQ ID NO: 1179, SEQ ID NO: 1336, and SEQ ID NO: 1493, respectively; lxxxi. SEQ ID NO: 709, SEQ ID NO: 866, SEQ ID NO: 1023, SEQ ID NO: 1180, SEQ ID NO: 1337, and SEQ ID NO: 1494, respectively; lxxxii. SEQ ID NO: 710, SEQ ID NO: 867, SEQ ID NO: 1024, SEQ ID NO: 1181, SEQ ID NO: 1338, and SEQ ID NO: 1495, respectively; lxxxiii. SEQ ID NO: 711, SEQ ID NO: 868, SEQ ID NO: 1025, SEQ ID NO: 1182, SEQ ID NO: 1339, and SEQ ID NO: 1496, respectively; lxxxiv. SEQ ID NO: 712, SEQ ID NO: 869, SEQ ID NO: 1026, SEQ ID NO: 1183, SEQ ID NO: 1340, and SEQ ID NO: 1497, respectively; lxxxv. SEQ ID NO: 713, SEQ ID NO: 870, SEQ ID NO: 1027, SEQ ID NO: 1184, SEQ ID NO: 1341, and SEQ ID NO: 1498, respectively; lxxxvi. SEQ ID NO: 714, SEQ ID NO: 871, SEQ ID NO: 1028, SEQ ID NO: 1185, SEQ ID NO: 1342, and SEQ ID NO: 1499, respectively; lxxxvii. SEQ ID NO: 715, SEQ ID NO: 872, SEQ ID NO: 1029, SEQ ID NO: 1186, SEQ ID NO: 1343, and SEQ ID NO: 1500, respectively; lxxxviii. SEQ ID NO: 716, SEQ ID NO: 873, SEQ ID NO: 1030, SEQ ID NO: 1187, SEQ ID NO: 1344, and SEQ ID NO: 1501, respectively; lxxxix. SEQ ID NO: 717, SEQ ID NO: 874, SEQ ID NO: 1031, SEQ ID NO: 1188, SEQ ID NO: 1345, and SEQ ID NO: 1502, respectively; xc. SEQ ID NO: 718, SEQ ID NO: 875, SEQ ID NO: 1032, SEQ ID NO: 1189, SEQ ID NO: 1346, and SEQ ID NO: 1503, respectively; xci. SEQ ID NO: 719, SEQ ID NO: 876, SEQ ID NO: 1033, SEQ ID NO: 1190, SEQ ID NO: 1347, and SEQ ID NO: 1504, respectively; xcii. SEQ ID NO: 720, SEQ ID NO: 877, SEQ ID NO: 1034, SEQ ID NO: 1191, SEQ ID NO: 1348, and SEQ ID NO: 1505, respectively; xciii. SEQ ID NO: 721, SEQ ID NO: 878, SEQ ID NO: 1035, SEQ ID NO: 1192, SEQ ID NO: 1349, and SEQ ID NO: 1506, respectively; xciv. SEQ ID NO: 722, SEQ ID NO: 879, SEQ ID NO: 1036, SEQ ID NO: 1193, SEQ ID NO: 1350, and SEQ ID NO: 1507, respectively; xcv. SEQ ID NO: 723, SEQ ID NO: 880, SEQ ID NO: 1037, SEQ ID NO: 1194, SEQ ID NO: 1351, and SEQ ID NO: 1508, respectively; xcvi. SEQ ID NO: 724, SEQ ID NO: 881, SEQ ID NO: 1038, SEQ ID NO: 1195, SEQ ID NO: 1352, and SEQ ID NO: 1509, respectively; xcvii. SEQ ID NO: 725, SEQ ID NO: 882, SEQ ID NO: 1039, SEQ ID NO: 1196, SEQ ID NO: 1353, and SEQ ID NO: 1510, respectively; xcviii. SEQ ID NO: 726, SEQ ID NO: 883, SEQ ID NO: 1040, SEQ ID NO: 1197, SEQ ID NO: 1354, and SEQ ID NO: 1511, respectively; xcix. SEQ ID NO: 727, SEQ ID NO: 884, SEQ ID NO: 1041, SEQ ID NO: 1198, SEQ ID NO: 1355, and SEQ ID NO: 1512, respectively; c. SEQ ID NO: 728, SEQ ID NO: 885, SEQ ID NO: 1042, SEQ ID NO: 1199, SEQ ID NO: 1356, and SEQ ID NO: 1513, respectively; ci. SEQ ID NO: 729, SEQ ID NO: 886, SEQ ID NO: 1043, SEQ ID NO: 1200, SEQ ID NO: 1357, and SEQ ID NO: 1514, respectively; cii. SEQ ID NO: 730, SEQ ID NO: 887, SEQ ID NO: 1044, SEQ ID NO: 1201, SEQ ID NO: 1358, and SEQ ID NO: 1515, respectively; ciii. SEQ ID NO: 731, SEQ ID NO: 888, SEQ ID NO: 1045, SEQ ID NO: 1202, SEQ ID NO: 1359, and SEQ ID NO: 1516, respectively; civ. SEQ ID NO: 732, SEQ ID NO: 889, SEQ ID NO: 1046, SEQ ID NO: 1203, SEQ ID NO: 1360, and SEQ ID NO: 1517, respectively; cv. SEQ ID NO: 733, SEQ ID NO: 890, SEQ ID NO: 1047, SEQ ID NO: 1204, SEQ ID NO: 1361, and SEQ ID NO: 1518, respectively; cvi. SEQ ID NO: 734, SEQ ID NO: 891, SEQ ID NO: 1048, SEQ ID NO: 1205, SEQ ID NO: 1362, and SEQ ID NO: 1519, respectively; cvii. SEQ ID NO: 735, SEQ ID NO: 892, SEQ ID NO: 1049, SEQ ID NO: 1206, SEQ ID NO: 1363, and SEQ ID NO: 1520, respectively; cviii. SEQ ID NO: 736, SEQ ID NO: 893, SEQ ID NO: 1050, SEQ ID NO: 1207, SEQ ID NO: 1364, and SEQ ID NO: 1521, respectively; cix. SEQ ID NO: 737, SEQ ID NO: 894, SEQ ID NO: 1051, SEQ ID NO: 1208, SEQ ID NO: 1365, and SEQ ID NO: 1522, respectively; cx. SEQ ID NO: 738, SEQ ID NO: 895, SEQ ID NO: 1052, SEQ ID NO: 1209, SEQ ID NO: 1366, and SEQ ID NO: 1523, respectively; cxi. SEQ ID NO: 739, SEQ ID NO: 896, SEQ ID NO: 1053, SEQ ID NO: 1210, SEQ ID NO: 1367, and SEQ ID NO: 1524, respectively; cxii. SEQ ID NO: 740, SEQ ID NO: 897, SEQ ID NO: 1054, SEQ ID NO: 1211, SEQ ID NO: 1368, and SEQ ID NO: 1525, respectively; cxiii. SEQ ID NO: 741, SEQ ID NO: 898, SEQ ID NO: 1055, SEQ ID NO: 1212, SEQ ID NO: 1369, and SEQ ID NO: 1526, respectively; cxiv. SEQ ID NO: 742, SEQ ID NO: 899, SEQ ID NO: 1056, SEQ ID NO: 1213, SEQ ID NO: 1370, and SEQ ID NO: 1527, respectively; cxv. SEQ ID NO: 743, SEQ ID NO: 900, SEQ ID NO: 1057, SEQ ID NO: 1214, SEQ ID NO: 1371, and SEQ ID NO: 1528, respectively; cxvi. SEQ ID NO: 744, SEQ ID NO: 901, SEQ ID NO: 1058, SEQ ID NO: 1215, SEQ ID NO: 1372, and SEQ ID NO: 1529, respectively; cxvii. SEQ ID NO: 745, SEQ ID NO: 902, SEQ ID NO: 1059, SEQ ID NO: 1216, SEQ ID NO: 1373, and SEQ ID NO: 1530, respectively; cxviii. SEQ ID NO: 746, SEQ ID NO: 903, SEQ ID NO: 1060, SEQ ID NO: 1217, SEQ ID NO: 1374, and SEQ ID NO: 1531, respectively; cxix. SEQ ID NO: 747, SEQ ID NO: 904, SEQ ID NO: 1061, SEQ ID NO: 1218, SEQ ID NO: 1375, and SEQ ID NO: 1532, respectively; cxx. SEQ ID NO: 748, SEQ ID NO: 905, SEQ ID NO: 1062, SEQ ID NO: 1219, SEQ ID NO: 1376, and SEQ ID NO: 1533, respectively; cxxi. SEQ ID NO: 749, SEQ ID NO: 906, SEQ ID NO: 1063, SEQ ID NO: 1220, SEQ ID NO: 1377, and SEQ ID NO: 1534, respectively; cxxii. SEQ ID NO: 750, SEQ ID NO: 907, SEQ ID NO: 1064, SEQ ID NO: 1221, SEQ ID NO: 1378, and SEQ ID NO: 1535, respectively; cxxiii. SEQ ID NO: 751, SEQ ID NO: 908, SEQ ID NO: 1065, SEQ ID NO: 1222, SEQ ID NO: 1379, and SEQ ID NO: 1536, respectively; cxxiv. SEQ ID NO: 752, SEQ ID NO: 909, SEQ ID NO: 1066, SEQ ID NO: 1223, SEQ ID NO: 1380, and SEQ ID NO: 1537, respectively; cxxv. SEQ ID NO: 753, SEQ ID NO: 910, SEQ ID NO: 1067, SEQ ID NO: 1224, SEQ ID NO: 1381, and SEQ ID NO: 1538, respectively; cxxvi. SEQ ID NO: 754, SEQ ID NO: 911, SEQ ID NO: 1068, SEQ ID NO: 1225, SEQ ID NO: 1382, and SEQ ID NO: 1539, respectively; cxxvii. SEQ ID NO: 755, SEQ ID NO: 912, SEQ ID NO: 1069, SEQ ID NO: 1226, SEQ ID NO: 1383, and SEQ ID NO: 1540, respectively; cxxviii. SEQ ID NO: 756, SEQ ID NO: 913, SEQ ID NO: 1070, SEQ ID NO: 1227, SEQ ID NO: 1384, and SEQ ID NO: 1541, respectively; cxxix. SEQ ID NO: 757, SEQ ID NO: 914, SEQ ID NO: 1071, SEQ ID NO: 1228, SEQ ID NO: 1385, and SEQ ID NO: 1542, respectively; cxxx. SEQ ID NO: 758, SEQ ID NO: 915, SEQ ID NO: 1072, SEQ ID NO: 1229, SEQ ID NO: 1386, and SEQ ID NO: 1543, respectively; cxxxi. SEQ ID NO: 759, SEQ ID NO: 916, SEQ ID NO: 1073, SEQ ID NO: 1230, SEQ ID NO: 1387, and SEQ ID NO: 1544, respectively; cxxxii. SEQ ID NO: 760, SEQ ID NO: 917, SEQ ID NO: 1074, SEQ ID NO: 1231, SEQ ID NO: 1388, and SEQ ID NO: 1545, respectively; cxxxiii. SEQ ID NO: 761, SEQ ID NO: 918, SEQ ID NO: 1075, SEQ ID NO: 1232, SEQ ID NO: 1389, and SEQ ID NO: 1546, respectively; cxxxiv. SEQ ID NO: 762, SEQ ID NO: 919, SEQ ID NO: 1076, SEQ ID NO: 1233, SEQ ID NO: 1390, and SEQ ID NO: 1547, respectively; cxxxv. SEQ ID NO: 763, SEQ ID NO: 920, SEQ ID NO: 1077, SEQ ID NO: 1234, SEQ ID NO: 1391, and SEQ ID NO: 1548, respectively; cxxxvi. SEQ ID NO: 764, SEQ ID NO: 921, SEQ ID NO: 1078, SEQ ID NO: 1235, SEQ ID NO: 1392, and SEQ ID NO: 1549, respectively; cxxxvii. SEQ ID NO: 765, SEQ ID NO: 922, SEQ ID NO: 1079, SEQ ID NO: 1236, SEQ ID NO: 1393, and SEQ ID NO: 1550, respectively; cxxxviii. SEQ ID NO: 766, SEQ ID NO: 923, SEQ ID NO: 1080, SEQ ID NO: 1237, SEQ ID NO: 1394, and SEQ ID NO: 1551, respectively; cxxxix. SEQ ID NO: 767, SEQ ID NO: 924, SEQ ID NO: 1081, SEQ ID NO: 1238, SEQ ID NO: 1395, and SEQ ID NO: 1552, respectively; cxl. SEQ ID NO: 768, SEQ ID NO: 925, SEQ ID NO: 1082, SEQ ID NO: 1239, SEQ ID NO: 1396, and SEQ ID NO: 1553, respectively; cxli. SEQ ID NO: 769, SEQ ID NO: 926, SEQ ID NO: 1083, SEQ ID NO: 1240, SEQ ID NO: 1397, and SEQ ID NO: 1554, respectively; cxlii. SEQ ID NO: 770, SEQ ID NO: 927, SEQ ID NO: 1084, SEQ ID NO: 1241, SEQ ID NO: 1398, and SEQ ID NO: 1555, respectively; cxliii. SEQ ID NO: 771, SEQ ID NO: 928, SEQ ID NO: 1085, SEQ ID NO: 1242, SEQ ID NO: 1399, and SEQ ID NO: 1556, respectively; cxliv. SEQ ID NO: 772, SEQ ID NO: 929, SEQ ID NO: 1086, SEQ ID NO: 1243, SEQ ID NO: 1400, and SEQ ID NO: 1557, respectively; cxlv. SEQ ID NO: 773, SEQ ID NO: 930, SEQ ID NO: 1087, SEQ ID NO: 1244, SEQ ID NO: 1401, and SEQ ID NO: 1558, respectively; cxlvi. SEQ ID NO: 774, SEQ ID NO: 931, SEQ ID NO: 1088, SEQ ID NO: 1245, SEQ ID NO: 1402, and SEQ ID NO: 1559, respectively; cxlvii. SEQ ID NO: 775, SEQ ID NO: 932, SEQ ID NO: 1089, SEQ ID NO: 1246, SEQ ID NO: 1403, and SEQ ID NO: 1560, respectively; cxlviii. SEQ ID NO: 776, SEQ ID NO: 933, SEQ ID NO: 1090, SEQ ID NO: 1247, SEQ ID NO: 1404, and SEQ ID NO: 1561, respectively; cxlix. SEQ ID NO: 777, SEQ ID NO: 934, SEQ ID NO: 1091, SEQ ID NO: 1248, SEQ ID NO: 1405, and SEQ ID NO: 1562, respectively; cl. SEQ ID NO: 778, SEQ ID NO: 935, SEQ ID NO: 1092, SEQ ID NO: 1249, SEQ ID NO: 1406, and SEQ ID NO: 1563, respectively; cli. SEQ ID NO: 779, SEQ ID NO: 936, SEQ ID NO: 1093, SEQ ID NO: 1250, SEQ ID NO: 1407, and SEQ ID NO: 1564, respectively; clii. SEQ ID NO: 780, SEQ ID NO: 937, SEQ ID NO: 1094, SEQ ID NO: 1251, SEQ ID NO: 1408, and SEQ ID NO: 1565, respectively; cliii. SEQ ID NO: 781, SEQ ID NO: 938, SEQ ID NO: 1095, SEQ ID NO: 1252, SEQ ID NO: 1409, and SEQ ID NO: 1566, respectively; cliv. SEQ ID NO: 782, SEQ ID NO: 939, SEQ ID NO: 1096, SEQ ID NO: 1253, SEQ ID NO: 1410, and SEQ ID NO: 1567, respectively; clv. SEQ ID NO: 783, SEQ ID NO: 940, SEQ ID NO: 1097, SEQ ID NO: 1254, SEQ ID NO: 1411, and SEQ ID NO: 1568, respectively; clvi. SEQ ID NO: 784, SEQ ID NO: 941, SEQ ID NO: 1098, SEQ ID NO: 1255, SEQ ID NO: 1412, and SEQ ID NO: 1569, respectively; and clvii. SEQ ID NO: 785, SEQ ID NO: 942, SEQ ID NO: 1099, SEQ ID NO: 1256, SEQ ID NO: 1413, and SEQ ID NO: 1570, respectively.  41. The conjugate molecule of claim 40, wherein the anti-GIPR antibody comprises the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 of SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively.

42. The conjugate molecule of any one of claims 17 to 39, wherein the anti-GIPR antibody comprises a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL and the VH comprise amino acid sequences selected from:i. SEQ ID NO: 1 and SEQ ID NO: 158, respectively; ii. SEQ ID NO: 2 and SEQ ID NO: 159, respectively; iii. SEQ ID NO: 3 and SEQ ID NO: 160, respectively; iv. SEQ ID NO: 4 and SEQ ID NO: 161, respectively; v. SEQ ID NO: 5 and SEQ ID NO: 162, respectively; vi. SEQ ID NO: 6 and SEQ ID NO: 163, respectively; vii. SEQ ID NO: 7 and SEQ ID NO: 164, respectively; viii. SEQ ID NO: 8 and SEQ ID NO: 165, respectively; ix. SEQ ID NO: 9 and SEQ ID NO: 166, respectively; x. SEQ ID NO: 10 and SEQ ID NO: 167, respectively; xi. SEQ ID NO: 11 and SEQ ID NO: 168, respectively; xii. SEQ ID NO: 12 and SEQ ID NO: 169, respectively; xiii. SEQ ID NO: 13 and SEQ ID NO: 170, respectively; xiv. SEQ ID NO: 14 and SEQ ID NO: 171, respectively; xv. SEQ ID NO: 15 and SEQ ID NO: 172, respectively; xvi. SEQ ID NO: 16 and SEQ ID NO: 173, respectively; xvii. SEQ ID NO: 17 and SEQ ID NO: 174, respectively; xviii. SEQ ID NO: 18 and SEQ ID NO: 175, respectively; xix. SEQ ID NO: 19 and SEQ ID NO: 176, respectively; xx. SEQ ID NO: 20 and SEQ ID NO: 177, respectively; xxi. SEQ ID NO: 21 and SEQ ID NO: 178, respectively; xxii. SEQ ID NO: 22 and SEQ ID NO: 179, respectively; xxiii. SEQ ID NO: 23 and SEQ ID NO: 180, respectively; xxiv. SEQ ID NO: 24 and SEQ ID NO: 181, respectively; xxv. SEQ ID NO: 25 and SEQ ID NO: 182, respectively; xxvi. SEQ ID NO: 26 and SEQ ID NO: 183, respectively; xxvii. SEQ ID NO: 27 and SEQ ID NO: 184, respectively; xxviii. SEQ ID NO: 28 and SEQ ID NO: 185, respectively; xxix. SEQ ID NO: 29 and SEQ ID NO: 186, respectively; xxx. SEQ ID NO: 30 and SEQ ID NO: 187, respectively; xxxi. SEQ ID NO: 31 and SEQ ID NO: 188, respectively; xxxii. SEQ ID NO: 32 and SEQ ID NO: 189, respectively; xxxiii. SEQ ID NO: 33 and SEQ ID NO: 190, respectively; xxxiv. SEQ ID NO: 34 and SEQ ID NO: 191, respectively; xxxv. SEQ ID NO: 35 and SEQ ID NO: 192, respectively; xxxvi. SEQ ID NO: 36 and SEQ ID NO: 193, respectively; xxxvii. SEQ ID NO: 37 and SEQ ID NO: 194, respectively; xxxviii. SEQ ID NO: 38 and SEQ ID NO: 195, respectively; xxxix. SEQ ID NO: 39 and SEQ ID NO: 196, respectively; xl. SEQ ID NO: 40 and SEQ ID NO: 197, respectively; xli. SEQ ID NO: 41 and SEQ ID NO: 198, respectively; xlii. SEQ ID NO: 42 and SEQ ID NO: 199, respectively; xliii. SEQ ID NO: 43 and SEQ ID NO: 200, respectively; xliv. SEQ ID NO: 44 and SEQ ID NO: 201, respectively; xlv. SEQ ID NO: 45 and SEQ ID NO: 202, respectively; xlvi. SEQ ID NO: 46 and SEQ ID NO: 203, respectively; xlvii. SEQ ID NO: 47 and SEQ ID NO: 204, respectively; xlviii. SEQ ID NO: 48 and SEQ ID NO: 205, respectively; xlix. SEQ ID NO: 49 and SEQ ID NO: 206, respectively; l. SEQ ID NO: 50 and SEQ ID NO: 207, respectively; li. SEQ ID NO: 51 and SEQ ID NO: 208, respectively; lii. SEQ ID NO: 52 and SEQ ID NO: 209, respectively; liii. SEQ ID NO: 53 and SEQ ID NO: 210, respectively; liv. SEQ ID NO: 54 and SEQ ID NO: 211, respectively; lv. SEQ ID NO: 55 and SEQ ID NO: 212, respectively; lvi. SEQ ID NO: 56 and SEQ ID NO: 213, respectively; lvii. SEQ ID NO: 57 and SEQ ID NO: 214, respectively; lviii. SEQ ID NO: 58 and SEQ ID NO: 215, respectively; lix. SEQ ID NO: 59 and SEQ ID NO: 216, respectively; lx. SEQ ID NO: 60 and SEQ ID NO: 217, respectively; lxi. SEQ ID NO: 61 and SEQ ID NO: 218, respectively; lxii. SEQ ID NO: 62 and SEQ ID NO: 219, respectively; lxiii. SEQ ID NO: 63 and SEQ ID NO: 220, respectively; lxiv. SEQ ID NO: 64 and SEQ ID NO: 221, respectively; lxv. SEQ ID NO: 65 and SEQ ID NO: 222, respectively; lxvi. SEQ ID NO: 66 and SEQ ID NO: 223, respectively; lxvii. SEQ ID NO: 67 and SEQ ID NO: 224, respectively; lxviii. SEQ ID NO: 68 and SEQ ID NO: 225, respectively; lxix. SEQ ID NO: 69 and SEQ ID NO: 226, respectively; lxx. SEQ ID NO: 70 and SEQ ID NO: 227, respectively; lxxi. SEQ ID NO: 71 and SEQ ID NO: 228, respectively; lxxii. SEQ ID NO: 72 and SEQ ID NO: 229, respectively; lxxiii. SEQ ID NO: 73 and SEQ ID NO: 230, respectively; lxxiv. SEQ ID NO: 74 and SEQ ID NO: 231, respectively; lxxv. SEQ ID NO: 75 and SEQ ID NO: 232, respectively; lxxvi. SEQ ID NO: 76 and SEQ ID NO: 233, respectively; lxxvii. SEQ ID NO: 77 and SEQ ID NO: 234, respectively; lxxviii. SEQ ID NO: 78 and SEQ ID NO: 235, respectively; lxxix. SEQ ID NO: 79 and SEQ ID NO: 236, respectively; lxxx. SEQ ID NO: 80 and SEQ ID NO: 237, respectively; lxxxi. SEQ ID NO: 81 and SEQ ID NO: 238, respectively; lxxxii. SEQ ID NO: 82 and SEQ ID NO: 239, respectively; lxxxiii. SEQ ID NO: 83 and SEQ ID NO: 240, respectively; lxxxiv. SEQ ID NO: 84 and SEQ ID NO: 241, respectively; lxxxv. SEQ ID NO: 85 and SEQ ID NO: 242, respectively; lxxxvi. SEQ ID NO: 86 and SEQ ID NO: 243, respectively; lxxxvii. SEQ ID NO: 87 and SEQ ID NO: 244, respectively; lxxxviii. SEQ ID NO: 88 and SEQ ID NO: 245, respectively; lxxxix. SEQ ID NO: 89 and SEQ ID NO: 246, respectively; xc. SEQ ID NO: 90 and SEQ ID NO: 247, respectively; xci. SEQ ID NO: 91 and SEQ ID NO: 248, respectively; xcii. SEQ ID NO: 92 and SEQ ID NO: 249, respectively; xciii. SEQ ID NO: 93 and SEQ ID NO: 250, respectively; xciv. SEQ ID NO: 94 and SEQ ID NO: 251, respectively; xcv. SEQ ID NO: 95 and SEQ ID NO: 252, respectively; xcvi. SEQ ID NO: 96 and SEQ ID NO: 253, respectively; xcvii. SEQ ID NO: 97 and SEQ ID NO: 254, respectively; xcviii. SEQ ID NO: 98 and SEQ ID NO: 255, respectively; xcix. SEQ ID NO: 99 and SEQ ID NO: 256, respectively; c. SEQ ID NO: 100 and SEQ ID NO: 257, respectively; ci. SEQ ID NO: 101 and SEQ ID NO: 258, respectively; cii. SEQ ID NO: 102 and SEQ ID NO: 259, respectively; ciii. SEQ ID NO: 103 and SEQ ID NO: 260, respectively; civ. SEQ ID NO: 104 and SEQ ID NO: 261, respectively; cv. SEQ ID NO: 105 and SEQ ID NO: 262, respectively; cvi. SEQ ID NO: 106 and SEQ ID NO: 263, respectively; cvii. SEQ ID NO: 107 and SEQ ID NO: 264, respectively; cviii. SEQ ID NO: 108 and SEQ ID NO: 265, respectively; cix. SEQ ID NO: 109 and SEQ ID NO: 266, respectively; cx. SEQ ID NO: 110 and SEQ ID NO: 267, respectively; cxi. SEQ ID NO: 111 and SEQ ID NO: 268, respectively; cxii. SEQ ID NO: 112 and SEQ ID NO: 269, respectively; cxiii. SEQ ID NO: 113 and SEQ ID NO: 270, respectively; cxiv. SEQ ID NO: 114 and SEQ ID NO: 271, respectively; cxv. SEQ ID NO: 115 and SEQ ID NO: 272, respectively; cxvi. SEQ ID NO: 116 and SEQ ID NO: 273, respectively; cxvii. SEQ ID NO: 117 and SEQ ID NO: 274, respectively; cxviii. SEQ ID NO: 118 and SEQ ID NO: 275, respectively; cxix. SEQ ID NO: 119 and SEQ ID NO: 276, respectively; cxx. SEQ ID NO: 120 and SEQ ID NO: 277, respectively; cxxi. SEQ ID NO: 121 and SEQ ID NO: 278, respectively; cxxii. SEQ ID NO: 122 and SEQ ID NO: 279, respectively; cxxiii. SEQ ID NO: 123 and SEQ ID NO: 280, respectively; cxxiv. SEQ ID NO: 124 and SEQ ID NO: 281, respectively; cxxv. SEQ ID NO: 125 and SEQ ID NO: 282, respectively; cxxvi. SEQ ID NO: 126 and SEQ ID NO: 283, respectively; cxxvii. SEQ ID NO: 127 and SEQ ID NO: 284, respectively; cxxviii. SEQ ID NO: 128 and SEQ ID NO: 285, respectively; cxxix. SEQ ID NO: 129 and SEQ ID NO: 286, respectively; cxxx. SEQ ID NO: 130 and SEQ ID NO: 287, respectively; cxxxi. SEQ ID NO: 131 and SEQ ID NO: 288, respectively; cxxxii. SEQ ID NO: 132 and SEQ ID NO: 289, respectively; cxxxiii. SEQ ID NO: 133 and SEQ ID NO: 290, respectively; cxxxiv. SEQ ID NO: 134 and SEQ ID NO: 291, respectively; cxxxv. SEQ ID NO: 135 and SEQ ID NO: 292, respectively; cxxxvi. SEQ ID NO: 136 and SEQ ID NO: 293, respectively; cxxxvii. SEQ ID NO: 137 and SEQ ID NO: 294, respectively; cxxxviii. SEQ ID NO: 138 and SEQ ID NO: 295, respectively; cxxxix. SEQ ID NO: 139 and SEQ ID NO: 296, respectively; cxl. SEQ ID NO: 140 and SEQ ID NO: 297, respectively; cxli. SEQ ID NO: 141 and SEQ ID NO: 298, respectively; cxlii. SEQ ID NO: 142 and SEQ ID NO: 299, respectively; cxliii. SEQ ID NO: 143 and SEQ ID NO: 300, respectively; cxliv. SEQ ID NO: 144 and SEQ ID NO: 301, respectively; cxlv. SEQ ID NO: 145 and SEQ ID NO: 302, respectively; cxlvi. SEQ ID NO: 146 and SEQ ID NO: 303, respectively; cxlvii. SEQ ID NO: 147 and SEQ ID NO: 304, respectively; cxlviii. SEQ ID NO: 148 and SEQ ID NO: 305, respectively; cxlix. SEQ ID NO: 149 and SEQ ID NO: 306, respectively; cl. SEQ ID NO: 150 and SEQ ID NO: 307, respectively; cli. SEQ ID NO: 151 and SEQ ID NO: 308, respectively; clii. SEQ ID NO: 152 and SEQ ID NO: 309, respectively; cliii. SEQ ID NO: 153 and SEQ ID NO: 310, respectively; cliv. SEQ ID NO: 154 and SEQ ID NO: 311, respectively; clv. SEQ ID NO: 155 and SEQ ID NO: 312, respectively; clvi. SEQ ID NO: 156 and SEQ ID NO: 313, respectively; and clvii. SEQ ID NO: 157 and SEQ ID NO: 314, respectively.  43. The conjugate molecule of claim 42, wherein the anti-GIPR antibody comprises the VL and VH of SEQ ID NO: 74 and SEQ ID NO: 231, respectively.

44. The conjugate molecule of any one of claims 17 to 39, wherein the anti-GIPR antibody comprises a light chain and a heavy chain, wherein the light chain and heavy chain comprise amino acid sequences selected from:i. SEQ ID NO: 315 and SEQ ID NO: 472, respectively; ii. SEQ ID NO: 316 and SEQ ID NO: 473, respectively; iii. SEQ ID NO: 317 and SEQ ID NO: 474, respectively; iv. SEQ ID NO: 318 and SEQ ID NO: 475, respectively; v. SEQ ID NO: 319 and SEQ ID NO: 476, respectively; vi. SEQ ID NO: 320 and SEQ ID NO: 477, respectively; vii. SEQ ID NO: 321 and SEQ ID NO: 478, respectively; viii. SEQ ID NO: 322 and SEQ ID NO: 479, respectively; ix. SEQ ID NO: 323 and SEQ ID NO: 480, respectively; x. SEQ ID NO: 324 and SEQ ID NO: 481, respectively; xi. SEQ ID NO: 325 and SEQ ID NO: 482, respectively; xii. SEQ ID NO: 326 and SEQ ID NO: 483, respectively; xiii. SEQ ID NO: 327 and SEQ ID NO: 484, respectively; xiv. SEQ ID NO: 328 and SEQ ID NO: 485, respectively; xv. SEQ ID NO: 329 and SEQ ID NO: 486, respectively; xvi. SEQ ID NO: 330 and SEQ ID NO: 487, respectively; xvii. SEQ ID NO: 331 and SEQ ID NO: 488, respectively; xviii. SEQ ID NO: 332 and SEQ ID NO: 489, respectively; xix. SEQ ID NO: 333 and SEQ ID NO: 490, respectively; xx. SEQ ID NO: 334 and SEQ ID NO: 491, respectively; xxi. SEQ ID NO: 335 and SEQ ID NO: 492, respectively; xxii. SEQ ID NO: 336 and SEQ ID NO: 493, respectively; xxiii. SEQ ID NO: 337 and SEQ ID NO: 494, respectively; xxiv. SEQ ID NO: 338 and SEQ ID NO: 495, respectively; xxv. SEQ ID NO: 339 and SEQ ID NO: 496, respectively; xxvi. SEQ ID NO: 340 and SEQ ID NO: 497, respectively; xxvii. SEQ ID NO: 341 and SEQ ID NO: 498, respectively; xxviii. SEQ ID NO: 342 and SEQ ID NO: 499, respectively; xxix. SEQ ID NO: 343 and SEQ ID NO: 500, respectively; xxx. SEQ ID NO: 344 and SEQ ID NO: 501, respectively; xxxi. SEQ ID NO: 345 and SEQ ID NO: 502, respectively; xxxii. SEQ ID NO: 346 and SEQ ID NO: 503, respectively; xxxiii. SEQ ID NO: 347 and SEQ ID NO: 504, respectively; xxxiv. SEQ ID NO: 348 and SEQ ID NO: 505, respectively; xxxv. SEQ ID NO: 349 and SEQ ID NO: 506, respectively; xxxvi. SEQ ID NO: 350 and SEQ ID NO: 507, respectively; xxxvii. SEQ ID NO: 351 and SEQ ID NO: 508, respectively; xxxviii. SEQ ID NO: 352 and SEQ ID NO: 509, respectively; xxxix. SEQ ID NO: 353 and SEQ ID NO: 510, respectively; xl. SEQ ID NO: 354 and SEQ ID NO: 511, respectively; xli. SEQ ID NO: 355 and SEQ ID NO: 512, respectively; xlii. SEQ ID NO: 356 and SEQ ID NO: 513, respectively; xliii. SEQ ID NO: 357 and SEQ ID NO: 514, respectively; xliv. SEQ ID NO: 358 and SEQ ID NO: 515, respectively; xlv. SEQ ID NO: 359 and SEQ ID NO: 516, respectively; xlvi. SEQ ID NO: 360 and SEQ ID NO: 517, respectively; xlvii. SEQ ID NO: 361 and SEQ ID NO: 518, respectively; xlviii. SEQ ID NO: 362 and SEQ ID NO: 519, respectively; xlix. SEQ ID NO: 363 and SEQ ID NO: 520, respectively; l. SEQ ID NO: 364 and SEQ ID NO: 521, respectively; li. SEQ ID NO: 365 and SEQ ID NO: 522, respectively; lii. SEQ ID NO: 366 and SEQ ID NO: 523, respectively; liii. SEQ ID NO: 367 and SEQ ID NO: 524, respectively; liv. SEQ ID NO: 368 and SEQ ID NO: 525, respectively; lv. SEQ ID NO: 369 and SEQ ID NO: 526, respectively; lvi. SEQ ID NO: 370 and SEQ ID NO: 527, respectively; lvii. SEQ ID NO: 371 and SEQ ID NO: 528, respectively; lviii. SEQ ID NO: 372 and SEQ ID NO: 529, respectively;lix. SEQ ID NO: 373 and SEQ ID NO: 530, respectively; lx. SEQ ID NO: 374 and SEQ ID NO: 531, respectively; lxi. SEQ ID NO: 375 and SEQ ID NO: 532, respectively; lxii. SEQ ID NO: 376 and SEQ ID NO: 533, respectively; lxiii. SEQ ID NO: 377 and SEQ ID NO: 534, respectively; lxiv. SEQ ID NO: 378 and SEQ ID NO: 535, respectively; lxv. SEQ ID NO: 379 and SEQ ID NO: 536, respectively; lxvi. SEQ ID NO: 380 and SEQ ID NO: 537, respectively; lxvii. SEQ ID NO: 381 and SEQ ID NO: 538, respectively; lxviii. SEQ ID NO: 382 and SEQ ID NO: 539, respectively; lxix. SEQ ID NO: 383 and SEQ ID NO: 540, respectively; lxx. SEQ ID NO: 384 and SEQ ID NO: 541, respectively; lxxi. SEQ ID NO: 385 and SEQ ID NO: 542, respectively; lxxii. SEQ ID NO: 386 and SEQ ID NO: 543, respectively; lxxiii. SEQ ID NO: 387 and SEQ ID NO: 544, respectively; lxxiv. SEQ ID NO: 388 and SEQ ID NO: 545, respectively; lxxv. SEQ ID NO: 389 and SEQ ID NO: 546, respectively; lxxvi. SEQ ID NO: 390 and SEQ ID NO: 547, respectively; lxxvii. SEQ ID NO: 391 and SEQ ID NO: 548, respectively; lxxviii. SEQ ID NO: 392 and SEQ ID NO: 549, respectively; lxxix. SEQ ID NO: 393 and SEQ ID NO: 550, respectively; lxxx. SEQ ID NO: 394 and SEQ ID NO: 551, respectively; lxxxi. SEQ ID NO: 395 and SEQ ID NO: 552, respectively; lxxxii. SEQ ID NO: 396 and SEQ ID NO: 553, respectively; lxxxiii. SEQ ID NO: 397 and SEQ ID NO: 554, respectively; lxxxiv. SEQ ID NO: 398 and SEQ ID NO: 555, respectively; lxxxv. SEQ ID NO: 399 and SEQ ID NO: 556, respectively; lxxxvi. SEQ ID NO: 400 and SEQ ID NO: 557, respectively; lxxxvii. SEQ ID NO: 401 and SEQ ID NO: 558, respectively; lxxxviii. SEQ ID NO: 402 and SEQ ID NO: 559, respectively; lxxxix. SEQ ID NO: 403 and SEQ ID NO: 560, respectively; xc. SEQ ID NO: 404 and SEQ ID NO: 561, respectively; xci. SEQ ID NO: 405 and SEQ ID NO: 562, respectively; xcii. SEQ ID NO: 406 and SEQ ID NO: 563, respectively; xciii. SEQ ID NO: 407 and SEQ ID NO: 564, respectively; xciv. SEQ ID NO: 408 and SEQ ID NO: 565, respectively; xcv. SEQ ID NO: 409 and SEQ ID NO: 566, respectively; xcvi. SEQ ID NO: 410 and SEQ ID NO: 567, respectively; xcvii. SEQ ID NO: 411 and SEQ ID NO: 568, respectively; xcviii. SEQ ID NO: 412 and SEQ ID NO: 569, respectively; xcix. SEQ ID NO: 413 and SEQ ID NO: 570, respectively; c. SEQ ID NO: 414 and SEQ ID NO: 571, respectively; ci. SEQ ID NO: 415 and SEQ ID NO: 572, respectively; cii. SEQ ID NO: 416 and SEQ ID NO: 573, respectively; ciii. SEQ ID NO: 417 and SEQ ID NO: 574, respectively; civ. SEQ ID NO: 418 and SEQ ID NO: 575, respectively; cv. SEQ ID NO: 419 and SEQ ID NO: 576, respectively; cvi. SEQ ID NO: 420 and SEQ ID NO: 577, respectively; cvii. SEQ ID NO: 421 and SEQ ID NO: 578, respectively; cviii. SEQ ID NO: 422 and SEQ ID NO: 579, respectively; cix. SEQ ID NO: 423 and SEQ ID NO: 580, respectively; cx. SEQ ID NO: 424 and SEQ ID NO: 581, respectively; cxi. SEQ ID NO: 425 and SEQ ID NO: 582, respectively; cxii. SEQ ID NO: 426 and SEQ ID NO: 583, respectively; cxiii. SEQ ID NO: 427 and SEQ ID NO: 584, respectively; cxiv. SEQ ID NO: 428 and SEQ ID NO: 585, respectively; cxv. SEQ ID NO: 429 and SEQ ID NO: 586, respectively; cxvi. SEQ ID NO: 430 and SEQ ID NO: 587, respectively; cxvii. SEQ ID NO: 431 and SEQ ID NO: 588, respectively; cxviii. SEQ ID NO: 432 and SEQ ID NO: 589, respectively; cxix. SEQ ID NO: 433 and SEQ ID NO: 590, respectively; cxx. SEQ ID NO: 434 and SEQ ID NO: 591, respectively; cxxi. SEQ ID NO: 435 and SEQ ID NO: 592, respectively; cxxii. SEQ ID NO: 436 and SEQ ID NO: 593, respectively; cxxiii. SEQ ID NO: 437 and SEQ ID NO: 594, respectively; cxxiv. SEQ ID NO: 438 and SEQ ID NO: 595, respectively; cxxv. SEQ ID NO: 439 and SEQ ID NO: 596, respectively; cxxvi. SEQ ID NO: 440 and SEQ ID NO: 597, respectively; cxxvii. SEQ ID NO: 441 and SEQ ID NO: 598, respectively; cxxviii. SEQ ID NO: 442 and SEQ ID NO: 599, respectively; cxxix. SEQ ID NO: 443 and SEQ ID NO: 600, respectively; cxxx. SEQ ID NO: 444 and SEQ ID NO: 601, respectively; cxxxi. SEQ ID NO: 445 and SEQ ID NO: 602, respectively; cxxxii. SEQ ID NO: 446 and SEQ ID NO: 603, respectively; cxxxiii. SEQ ID NO: 447 and SEQ ID NO: 604, respectively; cxxxiv. SEQ ID NO: 448 and SEQ ID NO: 605, respectively; cxxxv. SEQ ID NO: 449 and SEQ ID NO: 606, respectively; cxxxvi. SEQ ID NO: 450 and SEQ ID NO: 607, respectively; cxxxvii. SEQ ID NO: 451 and SEQ ID NO: 608, respectively;cxxxviii. SEQ ID NO: 452 and SEQ ID NO: 609, respectively; cxxxix. SEQ ID NO: 453 and SEQ ID NO: 610, respectively; cxl. SEQ ID NO: 454 and SEQ ID NO: 611, respectively; cxli. SEQ ID NO: 455 and SEQ ID NO: 612, respectively; cxlii. SEQ ID NO: 456 and SEQ ID NO: 613, respectively; cxliii. SEQ ID NO: 457 and SEQ ID NO: 614, respectively; cxliv. SEQ ID NO: 458 and SEQ ID NO: 615, respectively; cxlv. SEQ ID NO: 459 and SEQ ID NO: 616, respectively; cxlvi. SEQ ID NO: 460 and SEQ ID NO: 617, respectively; cxlvii. SEQ ID NO: 461 and SEQ ID NO: 618, respectively; cxlviii. SEQ ID NO: 462 and SEQ ID NO: 619, respectively; cxlix. SEQ ID NO: 463 and SEQ ID NO: 620, respectively; cl. SEQ ID NO: 464 and SEQ ID NO: 621, respectively; cli. SEQ ID NO: 465 and SEQ ID NO: 622, respectively; clii. SEQ ID NO: 466 and SEQ ID NO: 623, respectively; cliii. SEQ ID NO: 467 and SEQ ID NO: 624, respectively; cliv. SEQ ID NO: 468 and SEQ ID NO: 625, respectively; clv. SEQ ID NO: 469 and SEQ ID NO: 626, respectively; clvi. SEQ ID NO: 470 and SEQ ID NO: 627, respectively; and clvii. SEQ ID NO: 471 and SEQ ID NO: 628, respectively,wherein the antibody comprises one or more cysteine amino acid substitution(s) at one or more position(s) selected from 88 of the light chain, 384 of the heavy chain, or 487 of the heavy chain, according to AHo numbering.  45. The conjugate molecule of claim 44, wherein the anti-GIPR antibody comprises the light chain and heavy chain of SEQ ID NO: 388 and SEQ ID NO: 545, respectively.

46. A conjugate molecule comprising: an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein the anti-GIPR antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1579; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1592; wherein the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering, and wherein the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering.

47. The conjugate molecule of claim 46, wherein each light chain comprises a VL of SEQ ID NO: 74, and each heavy chain comprises a VH of SEQ ID NO: 231.

48. The conjugate molecule of claim 46, wherein each light chain comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain comprises the amino acid sequence of SEQ ID NO: 1571.

49. A conjugate molecule comprising: an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein the anti-GIPR antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1580; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1591; wherein the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering, and wherein the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering.

50. The conjugate molecule of claim 49, wherein each light chain comprises a VL of SEQ ID NO: 74, and each heavy chain comprises a VH of SEQ ID NO: 231.

51. The conjugate molecule of claim 49, wherein each light chain comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain comprises the amino acid sequence of SEQ ID NO: 1571.

52. A conjugate molecule comprising: an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein the anti-GIPR antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1586; wherein the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the first heavy chain according to AHo numbering, and wherein the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 384 of the second heavy chain according to AHo numbering.

53. The conjugate molecule of claim 52, wherein each light chain comprises a VL of SEQ ID NO: 74, and each heavy chain comprises a VH of SEQ ID NO: 231.

54. The conjugate molecule of claim 52, wherein each light chain comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain comprises the amino acid sequence of SEQ ID NO: 1571.

55. A conjugate molecule comprising: an antagonist anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, wherein the anti-GIPR antibody comprises: a first and second light chain, each light chain comprising a CDRL1, a CDRL2, and a CDRL3 of SEQ ID NO: 702, SEQ ID NO: 859, and SEQ ID NO: 1016, respectively, and a first and second heavy chain, each heavy chain comprising a CDRH1, a CDRH2, and a CDRH3 of SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; a first and second GLP-1 receptor agonist polypeptide, wherein each GLP-1 receptor agonist polypeptide comprises the amino acid sequence of SEQ ID NO: 1581; and a first and second peptide linker, wherein each peptide linker comprises the amino acid sequence of SEQ ID NO: 1585; wherein the first GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the first linker, to the first heavy chain of the anti-GIPR antibody at a cysteine residue at position 275 of the first heavy chain, and wherein the second GLP-1 receptor agonist polypeptide is conjugated, at its C-terminus via the second linker, to the second heavy chain of the anti-GIPR antibody at a cysteine residue at position 275 of the second heavy chain.

56. The conjugate molecule of claim 55, wherein each light chain comprises a VL of SEQ ID NO: 74, and each heavy chain comprises a VH of SEQ ID NO: 231.

57. The conjugate molecule of claim 55, wherein each light chain comprises the amino acid sequence of SEQ ID NO: 388, and each heavy chain comprises the amino acid sequence of SEQ ID NO: 1571.

58. A pharmaceutical composition comprising: a GLP-1 receptor agonist polypeptide of any one of claims 1 to 10, the molecule of any one of claims 11 to 16, or the conjugate molecule of any one of claims 17 to 57; and a pharmaceutically acceptable excipient.  59. A method of reducing body weight and / or food intake in a subject in need thereof, the method comprising: administering the GLP-1 receptor agonist polypeptide of any one of claims 1 to 10, the molecule of any one of claims 11 to 16, the conjugate molecule of any one of claims 17 to 57, or the pharmaceutical composition of claim 58 to the subject.

60. A method of treating obesity or an obesity related condition in a subject in need thereof, the method comprising: administering, to the subject, the GLP-1 receptor agonist polypeptide of any one of claims 1 to 10, the molecule of any one of claims 11 to 16, the conjugate molecule of any one of claims 17 to 57, or the pharmaceutical composition of claim 58.

61. The method of claim 60, wherein the obesity related condition is selected from the group consisting of sleep apnea, dyslipidemia, atherosclerotic cardiovascular disease, heart failure, hypertension, chronic kidney failure, and metabolic dysfunction-associated steatohepatitis.

62. A method of treating type 2 diabetes or a type 2 diabetes related condition in a subject in need thereof, the method comprising: administering, to the subject, the GLP-1 receptor agonist polypeptide of any one of claims 1 to 10, the molecule of any one of claims 11 to 17, the conjugate molecule of any one of claims 17 to 57, or the pharmaceutical composition of claim 58.

63. The method of claim 62, wherein the typ e 2 diabetes related conditions is selected from the group consisting of hypertension, high blood sugar, diabetic kidney disease, and diabetic kidney failure.

64. The GLP-1 receptor agonist polypeptide of any one of claims 1 to 10, the molecule of any one of claims 11 to 16, or the conjugate molecule of any one of claims 17 to 57 for use as a medicament. 

Images